William G. Wierda, M.D., Ph.D.

Peer-Reviewed Articles

1. Wierda WG. Highlights in chronic lymphocytic leukemia from the 66th ASH Annual Meeting and Exposition: commentary. Clin Adv Hematol Oncol 23 Suppl 1(1):3-13, 2025. e-Pub 2025. PMID: 39907565.
2. Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica 110(1):92-102, 2025. e-Pub 2025. PMID: 39363864.
3. Ravikrishnan J, Diaz-Rohena DY, Muhowski E, Mo X, Lai TH, Misra S, Williams CD, Sanchez J, Mitchell A, Satpati S, Perry E, Kaufman T, Liu C, Lozanski A, Lozanski G, Rogers K, Kittai AS, Bhat SA, Collins MC, Davids MS, Jain N, Wierda WG, Lapalombella R, Byrd JC, Tan F, Chen Y, Chen Y, Shen Y, Anthony SP, Woyach JA, Sampath D. LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemia. Haematologica 110(1):78-91, 2025. e-Pub 2025. PMID: 39113656.
4. Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
5. Kim E, Chen SS, Sivina M, Hwang H, Huang X, Ferrajoli A, Jain N, Wierda WG, Wodarz D, Chiorazzi N, Burger JA. Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD. Blood 144(25):2678-2681, 2024. e-Pub 2024. PMID: 39441901.
6. Kismali G, Manyam G, Jain N, Ivan C, Lamothe B, Ayres ML, Iles LR, Wierda WG, Gandhi V. Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton's tyrosine kinase expression levels. Blood Cancer J 14(1):220, 2024. e-Pub 2024. PMID: 39695112.
7. Sasaki K, Garcia-Manero G, Nigo M, Jabbour E, Ravandi F, Wierda WG, Jain N, Takahashi K, Montalban-Bravo G, Daver NG, Thompson PA, Pemmaraju N, Kontoyiannis DP, Sato J, Karimaghaei S, Soltysiak KA, Raad II, Kantarjian HM, Carter BW. Artificial Intelligence Assessment of Chest Radiographs for COVID-19. Clin Lymphoma Myeloma Leuk, 2024. e-Pub 2024. PMID: 39710565.
8. Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair B, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood 144(13):1374-1386, 2024. e-Pub 2024. PMID: 38861666.
9. Aslan B, Manyam G, Iles LR, Tantawy SI, Desikan SP, Wierda WG, Gandhi V. Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv 8(17):4487-4501, 2024. e-Pub 2024. PMID: 38968154.
10. Marvin-Peek J, Jen WY, Kantarjian HM, McCue D, Haddad FG, Wierda W, Ferrajoli A, Burger J, Abusab T, Jorgensen J, Wang SA, Patel K, Loghavi S, O'Brien S, Ravandi F. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia. Leuk Lymphoma 65(9):1325-1334, 2024. e-Pub 2024. PMID: 38749022.
11. Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol 11(9):e682-e692, 2024. e-Pub 2024. PMID: 39033770.
12. Wierda WG. The approval of lisocabtagene maraleucel in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 22(6):291-293, 2024. e-Pub 2024. PMID: 39110651.
13. Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol 42(17):2071-2079, 2024. e-Pub 2024. PMID: 38552193.
14. Marvin-Peek J, Shelton V, Brassil K, Fellman B, Barr A, Chien KS, Hammond D, Swaminathan M, Jain N, Wierda W, Ferrajoli A, DiNardo C. Effect of Digital Health Coaching on Self-Efficacy and Patient-Reported Outcomes in Individuals with Acute Myeloid and Chronic Lymphocytic Leukemia: A Pilot Randomized Controlled Trial. Acta Haematol:1-10. e-Pub 2024. PMID: 38861934.
15. Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv 8(10):2342-2350, 2024. e-Pub 2024. PMID: 38537065.
16. Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, Hillmen P, Schneider C, Schetelig J, Bottcher S, Kater AP, Jiang Y, Boyer M, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, Chyla B, Wierda WG, Seymour JF. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Blood Adv 8(8):1992-2004, 2024. e-Pub 2024. PMID: 38290108.
17. Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Cortese M, Cripe L, Davis RS, Eradat H, Fakhri B, Fletcher CD, Gaballa S, Hamid MS, Hill B, Kaesberg P, Kahl B, Kamdar M, Kipps TJ, Ma S, Mosse C, Nakhoda S, Parikh S, Schorr A, Schuster S, Seshadri M, Siddiqi T, Stephens DM, Thompson M, Ujjani C, Valdez R, Wagner-Johnston N, Woyach JA, Sundar H, Dwyer M. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 22(3):175-204, 2024. e-Pub 2024. PMID: 38626800.
18. Liu P, Wang K, Li J, Ogasawara MA, Xia Z, Wierda WG, Keating MJ, Li Y, Huang P. Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations. Haematologica 109(2):479-492, 2024. e-Pub 2024. PMID: 37646669.
19. Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A Phase 1/2 Study of Mini-Hyper-CVD plus Venetoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood Adv 8(4):909-915, 2024. e-Pub 2024. PMID: 38207208.
20. Thompson PA, Bazinet A, Wierda WG, Tam CS, O'Brien SM, Saha S, Peterson CB, Plunkett W, Keating MJ. Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up. Blood 142(21):1784-1788, 2023. e-Pub 2023. PMID: 37595283.
21. Sasaki K, Morita K, Kantarjian H, Garcia-Manero G, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Wierda W, Daver N, Takahashi K, DiNardo C, Bravo GM, Issa GC, Pierce SA, Soltysiak KA, Tingen MS, Cortes JE. Geographic Disparity of Outcome in Patients with Cancer over Decades: The Surveillance, Epidemiology, and End Results. Clin Lymphoma Myeloma Leuk 23(11):e369-e378, 2023. e-Pub 2023. PMID: 37690903.
22. Parry EM, Lemvigh CK, Deng S, Dangle N, Ruthen N, Knisbacher BA, Broséus J, Hergalant S, Guièze R, Li S, Zhang W, Johnson C, Long JM, Yin S, Werner L, Anandappa A, Purroy N, Gohil S, Oliveira G, Bachireddy P, Shukla SA, Huang T, Khoury JD, Thakral B, Dickinson M, Tam C, Livak KJ, Getz G, Neuberg D, Feugier P, Kharchenko P, Wierda W, Olsen LR, Jain N, Wu CJ. ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell 41(10):1803-1816.e8, 2023. e-Pub 2023. PMID: 37738974.
23. Roccograndi LM, Lovell AR, Ferrajoli A, Thompson PA, Burger JA, Wierda WG, Jain N, Rausch CR. Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation. Leuk Lymphoma 64(9):1554-1561, 2023. e-Pub 2023. PMID: 37317991.
24. Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet 402(10402):641-654, 2023. e-Pub 2023. PMID: 37295445.
25. Shah BD, Cassaday RD, Park JH, Houot R, Oluwole OO, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff PJ, Jeyakumar D, Mao D, Adhikary S, Zhou L, Schuberth PC, Damico Khalid R, Ghobadia A. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer 11(8), 2023. e-Pub 2023. PMID: 37648261.
26. Chiu CY, Ahmed S, Thomas SK, Wang LS, Mustafayev K, Fayad LE, Wierda WG, Khawaja F, Torres HA. Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors. Clin Lymphoma Myeloma Leuk 23(8):610-615, 2023. e-Pub 2023. PMID: 37150651.
27. Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, Keating M, Wierda WG, Durand JB, Ferrajoli A. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer 129(14):2192-2200, 2023. e-Pub 2023. PMID: 37016930.
28. Mato, A, Woyach, JA, Brown, JR, Ghia, P, Patel, K, Eyre, TA, Munir, T, Lech-Maranda, E, Lamanna, N, Tam, CS, Shah, N, Coombs, CC, Ujjani, CS, Fakhri, B, Cheah, CY, Patel, MR, Alencar, AJ, Cohen, JB, Gerson, JN, Flinn, IW, Ma, S, Jagadeesh, D, Rhodes, J, Hernandez-Ilizaliturri, FJ, Zinzani, PL, Seymour, JF, Balbas, M, Nair, BC, Abada, PB, Wang, C, Ruppert, AS, Wang, D, Tsai, D, Wierda, WG, Jurczak, W. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. New England Journal of Medicine 389(1):33-44, 2023. e-Pub 2023. PMID: 37407001.
29. Mato, A, Woyach, JA, Brown, JR, Ghia, P, Patel, K, Eyre, TA, Munir, T, Lech-Maranda, E, Lamanna, N, Tam, CS, Shah, N, Coombs, CC, Ujjani, CS, Fakhri, B, Cheah, CY, Patel, MR, Alencar, AJ, Cohen, JB, Gerson, JN, Flinn, IW, Ma, S, Jagadeesh, D, Rhodes, J, Hernandez-Ilizaliturri, FJ, Zinzani, PL, Seymour, JF, Balbas, M, Nair, BC, Abada, PB, Wang, C, Ruppert, AS, Wang, D, Tsai, D, Wierda, WG, Jurczak, W. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. New England Journal of Medicine 389(1):33-44, 2023. e-Pub 2023. PMID: 37407001.
30. Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Nogueras Gonzalez G, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Adv 7(13):3284-3296, 2023. e-Pub 2023. PMID: 36884300.
31. Thompson PA, Keating MJ, Ferrajoli A, Jain N, Peterson CB, Garg N, Wang SA, Jorgensen JL, Kadia TM, Bose P, Pemmaraju N, Short NJ, Wierda WG. Venetoclax consolidation in high-risk CLL treated with ibrutinib for >/=1 year achieves a high rate of undetectable MRD. Leukemia 37(7):1444-1453, 2023. e-Pub 2023. PMID: 37138019.
32. Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
33. El Hussein S, Medeiros LJ, Gruschkus SK, Wei P, Schlette E, Fang H, Jelloul FZ, Wang W, Fiskus W, Kanagal-Shamanna R, Loghavi S, Yang H, Li S, Xu J, Tang Z, Thakral B, Jain N, Wierda WG, Patel K, Bhalla KN, Khoury JD. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant. Virchows Arch 482(6):1011-1019, 2023. e-Pub 2023. PMID: 36864257.
34. El Hussein S, Medeiros LJ, Lyapichev KA, Fang H, Jelloul FZ, Fiskus W, Chen J, Wei P, Schlette E, Xu J, Li S, Kanagal-Shamanna R, Yang H, Tang Z, Thakral B, Loghavi S, Jain N, Thompson PA, Ferrajoli A, Wierda WG, Jabbour E, Patel KP, Dabaja BS, Bhalla KN, Khoury JD. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology 55(4):514-524, 2023. e-Pub 2023. PMID: 36933995.
35. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv 7(10):1958-1966, 2023. e-Pub 2023. PMID: 36287248.
36. Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Advances 7(10):1958-1966, 2023. e-Pub 2023.
37. Chiu C, Ahmed S, Thomas SK, Wang LS, Mustafayev K, Fayad LE, Wierda WG, Khawaja F, Torres HA. Hepatitis B Virus Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors. Journal Lymphoma, Myeloma & Leukemia 23(8):610-615, 2023. e-Pub 2023.
38. Griffen TL, Hoff FW, Qiu Y, Burger J, Wierda W, Kornblau SM. Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia. Int J Mol Sci 24(6), 2023. e-Pub 2023. PMID: 36982555.
39. Hoff FW, Griffen TL, Brown BD, Horton TM, Burger J, Wierda W, Hubner SE, Qiu Y, Kornblau SM. Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group. Int J Mol Sci 24(6), 2023. e-Pub 2023. PMID: 36982537.
40. Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 98(3):493-501, 2023. e-Pub 2023. PMID: 36600670.
41. Tantawy SI, Sarkar A, Hubner S, Tan Z, Wierda WG, Eldeib A, Zhang S, Kornblau S, Gandhi V. Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies. Clin Cancer Res 29(2):446-457, 2023. e-Pub 2023. PMID: 36346691.
42. Mato, A, Woyach, JA, Brown, JR, Ghia, P, Patel, K, Eyre, TA, Munir, T, Lech-Maranda, E, Lamanna, N, Tam, CS, Shah, N, Coombs, CC, Ujjani, CS, Fakhri, B, Cheah, CY, Patel, MR, Alencar, AJ, Cohen, JB, Gerson, JN, Flinn, IW, Ma, S, Jagadeesh, D, Rhodes, J, Hernandez-Ilizaliturri, FJ, Zinzani, PL, Seymour, JF, Balbas, M, Nair, BC, Abada, PB, Wang, C, Ruppert, AS, Wang, D, Tsai, D, Wierda, WG, Jurczak, W. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. New England Journal of Medicine 389(1):33-44, 2023. e-Pub 2023. PMID: 37407001.
43. Parry EM, Leshchiner I, Guièze R, Johnson C, Tausch E, Parikh SA, Lemvigh C, Broséus J, Hergalant S, Messer C, Utro F, Levovitz C, Rhrissorrakrai K, Li L, Rosebrock D, Yin S, Deng S, Slowik K, Jacobs R, Huang T, Li S, Fell G, Redd R, Lin Z, Knisbacher BA, Livitz D, Schneider C, Ruthen N, Elagina L, Taylor-Weiner A, Persaud B, Martinez A, Fernandes SM, Purroy N, Anandappa AJ, Ma J, Hess J, Rassenti LZ, Kipps TJ, Jain N, Wierda W, Cymbalista F, Feugier P, Kay NE, Livak KJ, Danysh BP, Stewart C, Neuberg D, Davids MS, Brown JR, Parida L, Stilgenbauer S, Getz G, Wu CJ. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med 29(1):158-169, 2023. e-Pub 2023. PMID: 36624313.
44. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Dong J, Adhikary S, Zhou L, Schuberth PC, Faghmous I, Masouleh BK, Houot R. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. J Hematol Oncol 15(1):170, 2022. e-Pub 2022. PMID: 36494725.
45. Wierda WG, Kipps TJ, Al-Sawaf O, Chyla B, Biondo JML, Mun Y, Jiang Y, Seymour JF. Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. Leuk Lymphoma 63(12):2765-2784, 2022. e-Pub 2022. PMID: 35983732.
46. Benjamin, R, Jain, N, Maus, MV, Boissel, N, Graham, C, Jozwik, A, Yallop, D, Konopleva, M, Frigault, M, Teshima, T, Kato, K, Boucaud, F, Balandraud, S, Gianella-Borradori, A, Binlich, F, Marchiq, I, Dupouy, S, Almena-Carrasco, M, Pannaux, M, Fouliard, S, Brissot, E, Mohty, M, Bonganay, L, Catt, L, Chappell, J, Cheung, G, Chu, V, Cuthill, K, Devereux, S, Dunlop, A, Ellard, R, Farzeneh, F, Folarin, N, Giemza, E, Kassam, S, Kazmi, M, Kuhnl, A, Lewis, J, Liskova, M, Mason, A, Metaxa, V, Mufti, G, Munro, H, Pagliuca, A, Patten, P, Potter, V, Jabbour, EJ, Kantarjian, HM, Kebriaei, P, Wierda, WG. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM). The Lancet Haematology 9(11):e833-e843, 2022. e-Pub 2022. PMID: 36228643.
47. Barr PM, Tedeschi A, Wierda WG, Allan JN, Ghia P, Vallisa D, Jacobs R, O'Brien S, Grigg AP, Walker P, Zhou C, Ninomoto J, Krigsfeld G, Tam CS. Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts. Clin Cancer Res 28(20):4385-4391, 2022. e-Pub 2022. PMID: 35939599.
48. Rozovski U, Veletik I, Harris D, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger J, Bose P, Thompson P, Jain N, Wierda W, Verstovsek S, Keating M, Estrov Z. CLL-162 PTX3 is Constitutively Active in CLL Cells. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S271, 2022. e-Pub 2022. PMID: 36163878.
49. Haddad FG, Kantarjian H, Short NJ, Konopleva M, Jain N, Huang X, Ravandi F, Wierda W, Borthakur G, Sasaki K, Issa G, Alvarado Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. ALL-424 Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S204, 2022. e-Pub 2022. PMID: 36163747.
50. Wierda WG, Pagel JM, Davids MS, Zinzani PL, Lu Y, Liu H, Shahda S, Leow CC, Tam CS, Woyach J, Eyre TA, Mato AR. CLL-116 BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed-Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress). Clin Lymphoma Myeloma Leuk 22(Suppl 2):S267, 2022. e-Pub 2022. PMID: 36163870.
51. Coombs CC, Pagel JM, Shah NN, Lamanna N, Munir T, Lech-Maranda E, Eyre TA, Woyach JA, Wierda WG, Cheah CY, Cohen JB, Roeker LE, Patel MR, Fakhri B, Barve MA, Tam CS, Lewis D, Gerson JN, Alencar A, Ujjani C, Flinn I, Sundaram S, Ma S, Jagadeesh D, Rhodes J, Taylor J, Abdel-Wahab O, Ghia P, Schuster SJ, Wang D, Nair B, Zhu E, Tsai DE, Davids MS, Brown JR, Jurczak W, Mato AR. CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S268-S269, 2022. e-Pub 2022. PMID: 36163872.
52. Timofeeva N, Jain N, Irajizad E, Aslan B, Katayama H, Cai Y, Ayres M, Iles L, Vykoukal J, Dennison J, Hanash S, Wierda W, Gandhi V. CLL-532 Changes in Proteome of CLL (Chronic Lymphocytic Leukemia) Lymphocytes During Investigator-Initiated Trial of Ibrutinib Alone and in Combination With Venetoclax in Treatment-Naïve Patients With CLL. Clin Lymphoma Myeloma Leuk 22(Suppl 2):S283, 2022. e-Pub 2022. PMID: 36163901.
53. Thompson PA, Jiang X, Banerjee P, Basar R, Garg N, Chen K, Kaplan M, Nandivada V, Cortes AKN, Ferrajoli A, Keating MJ, Peterson CB, Andreeff M, Rezvani K, Wierda WG. A phase two study of high dose blinatumomab in Richter's syndrome. Leukemia 36(9):2228-2232, 2022. e-Pub 2022. PMID: 35941212.
54. Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N. TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. Am J Hematol 97(8):1005-1012, 2022. e-Pub 2022. PMID: 35567779.
55. Tettamanti S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, Zhang R, Banerjee P, Galletti G, McManus S, Mazza M, Nicolini F, Martinelli G, Ivan C, Veliz Rodriguez T, Barbaglio F, Scarfò L, Ponzoni M, Wierda W, Gandhi V, Keating M, Biondi A, Caligaris-Cappio F, Biagi E, Ghia P, Bertilaccio MTS. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. Leuk Lymphoma 63(7):1566-1579, 2022. e-Pub 2022. PMID: 35259043.
56. Rozovski U, Veletic I, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Verstovsek S, Keating MJ, Estrov Z. STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells. J Immunol 208(12):2847-2855, 2022. e-Pub 2022. PMID: 35595309.
57. Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Wierda WG, Ghia P. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 139(22):3278-3289, 2022. e-Pub 2022. PMID: 35196370.
58. Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. NCCN Guidelines(R) Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw 20(6):622-634, 2022. e-Pub 2022. PMID: 35714675.
59. Chen R, Chen Y, Xiong P, Zheleva D, Blake D, Keating MJ, Wierda WG, Plunkett W. Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells. Leukemia 36(6):1596-1608, 2022. e-Pub 2022. PMID: 35383271.
60. Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, Gagea M, Bertilaccio MTS, Wierda WG, Gandhi V. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J 12(5):80, 2022. e-Pub 2022. PMID: 35595730.
61. Vaca AM, Ioannou N, Sivina M, Vlachonikola E, Clise-Dwyer K, Kim E, Li D, Ma Q, Ferrajoli A, Estrov Z, Wierda WG, Patten PEM, Ramsay AG, Burger JA. Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. Leukemia 36(5):1324-1335, 2022. e-Pub 2022. PMID: 35149845.
62. Jelloul FZ, Yang R, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda W, Jain N, Thompson P, Luthra R, Medeiros LJ, Patel KP. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res 116:106827, 2022. e-Pub 2022. PMID: 35430388.
63. Allan JN, Pinilla-Ibarz J, Gladstone DE, Patel K, Sharman JP, Wierda WG, Choi MY, O'Brien SM, Shadman M, Davids MS, Pagel JM, Yimer HA, Ward R, Acton G, Taverna P, Combs DL, Fox JA, Furman RR, Brown JR. Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica 107(4):984-987, 2022. e-Pub 2022. PMID: 34937320.
64. Mukherjee A, Milton DR, Jabbour EJ, Gulbis AM, Kadia T, Jain N, Ledesma C, Burger J, Ferrajoli A, Wierda W, Medeiros LJ, Kantarjian H, Champlin R, Khouri IF. Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leuk Lymphoma 63(4):1-9, 2022. e-Pub 2022. PMID: 35225133.
65. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 139(12):1794-1806, 2022. e-Pub 2022. PMID: 34699592.
66. van Dijk AD, Griffen TL, Qiu YH, Hoff FW, Toro E, Ruiz K, Ruvolo PP, Lillard JW, ESJM DB, Burger JA, Wierda W, Kornblau SM. RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia 36(3):712-722, 2022. e-Pub 2022. PMID: 34625713.
67. Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi F. Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma 63(3):672-675, 2022. e-Pub 2022. PMID: 34668451.
68. Griffen TL, Hoff FW, Qiu Y, Lillard JW, Ferrajoli A, Thompson P, Toro E, Ruiz K, Burger J, Wierda W, Kornblau SM. Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. Blood Cancer J 12(3):43, 2022. e-Pub 2022. PMID: 35301276.
69. Galan-Cobo A, Stellrecht CM, Yilmaz E, Yang C, Qian Y, Qu X, Akhter I, Ayres ML, Fan Y, Tong P, Diao L, Ding J, Giri U, Gudikote J, Nilsson M, Wierda WG, Wang J, Skoulidis F, Minna JD, Gandhi V, Heymach JV. Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. Mol Cancer Res 20(2):280-292, 2022. e-Pub 2022. PMID: 34654720.
70. Aslan B, Hubner SE, Fox JA, Taverna P, Wierda WG, Kornblau SM, Gandhi V. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. Haematologica 107(1):292-297, 2022. e-Pub 2022. PMID: 34498444.
71. Yi X, Jain N, Iles LR, Ayres ML, Wierda WG, Gandhi V. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia. Front Oncol 12:833714, 2022. e-Pub 2022. PMID: 35273915.
72. Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol 39(34):3853-3865, 2021. e-Pub 2021. PMID: 34618601.
73. Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
74. Eyre TA, Schuh A, Wierda WG, Brown JR, Ghia P, Pagel JM, Furman RR, Cheung J, Hamdy A, Izumi R, Patel P, Wang MH, Xu Y, Byrd JC, Hillmen P. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. Lancet Haematol 8(12):e912-e921, 2021. e-Pub 2021. PMID: 34735860.
75. Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, Daver N, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia 35(11):3282-3286, 2021. e-Pub 2021. PMID: 33833386.
76. Esposito CL, Van Roosbroeck K, Santamaria G, Rotoli D, Sandomenico A, Wierda WG, Ferrajoli A, Ruvo M, Calin GA, de Franciscis V, Catuogno S. Selection of a Nuclease-Resistant RNA Aptamer Targeting CD19. Cancers (Basel) 13(20), 2021. e-Pub 2021. PMID: 34680368.
77. Davids MS, Roberts AW, Kenkre VP, Wierda WG, Kumar A, Kipps TJ, Boyer M, Salem AH, Pesko JC, Arzt JA, Mantas M, Kim SY, Seymour JF. Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clin Cancer Res 27(17):4690-4695, 2021. e-Pub 2021. PMID: 34083230.
78. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezan R, Masouleh BK, Houot R. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398(10299):491-502, 2021. e-Pub 2021. PMID: 34097852.
79. Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
80. Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 127(15):2648-2656, 2021. e-Pub 2021. PMID: 33793964.
81. Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, DiNardo CD, Kadia T, Garcia-Manero G, Ohanian M, Daver N, Konopleva M, Pemmaraju N, Ferrajoli A, Andreeff M, Jain N, Estrov Z, Jabbour EJ, Wierda WG, Pierce S, Pinsoy MR, Xiao L, Ravandi F, Cortes JE. A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica 106(8):2121-2130, 2021. e-Pub 2021. PMID: 33853292.
82. Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, O'Dwyer KM, Holmes H, Arellano ML, Ghobadi A, Pagel JM, Lin Y, Cassaday RD, Park JH, Abedi M, Castro JE, DeAngelo DJ, Malone AK, Mawad R, Schiller GJ, Rossi JM, Bot A, Shen T, Goyal L, Jain RK, Vezan R, Wierda WG. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood 138(1):11-22, 2021. e-Pub 2021. PMID: 33827116.
83. Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol 194(1):61-68, 2021. e-Pub 2021. PMID: 33973230.
84. Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG. Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood 137(24):3327-3338, 2021. e-Pub 2021. PMID: 33786588.
85. Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JA. CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia 35(6):1610-1620, 2021. e-Pub 2021. PMID: 33087831.
86. Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver N, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk 21(5):338-344, 2021. e-Pub 2021. PMID: 33597098.
87. Marques-Piubelli ML, Schlette EJ, Khoury JD, Furqan F, Vega F, Soto LMS, Wistuba II, Wierda WG, Konopleva M, Ferrajoli A, Strati P. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. Leuk Lymphoma 62(5):1129-1135, 2021. e-Pub 2021. PMID: 33327833.
88. Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet 397(10277):892-901, 2021. e-Pub 2021. PMID: 33676628.
89. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z. STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget 12(5):401-411, 2021. e-Pub 2021. PMID: 33747356.
90. Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, Burrows F, Sivina M, Burger JA, Keating MJ, Wierda WG, Plunkett W. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J 11(3):57, 2021. e-Pub 2021. PMID: 33714981.
91. Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. Am J Hematol 96(2):241-250, 2021. e-Pub 2021. PMID: 33180322.
92. Gopalakrishnan S, Wierda W, Chyla B, Menon R, Miles D, Humerickhouse R, Awni W, Salem AH, Mensing S, Freise KJ. Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia. Clin Pharmacol Ther 109(2):424-432, 2021. e-Pub 2021. PMID: 32749675.
93. Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma 62(1):224-228, 2021. e-Pub 2021. PMID: 32955970.
94. O'Brien SM, Brown JR, Byrd JC, Furman RR, Ghia P, Sharman JP, Wierda WG. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. Front Oncol 11:720704, 2021. e-Pub 2021. PMID: 34858810.
95. Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma 61(13):1-8, 2020. e-Pub 2020. PMID: 32755333.
96. Issa GC, Kantarjian HM, Xiao L, Ning J, Alvarado Y, Borthakur G, Daver N, DiNardo CD, Jabbour E, Bose P, Jain N, Kadia TM, Naqvi K, Pemmaraju N, Takahashi K, Verstovsek S, Andreeff M, Kornblau SM, Estrov Z, Ferrajoli A, Garcia-Manero G, Ohanian M, Wierda WG, Ravandi F, Cortes JE. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia 34(11):2914-2924, 2020. e-Pub 2020. PMID: 32546726.
97. Frei M, Aitken SL, Jain N, Thompson P, Wierda W, Kontoyiannis DP, DiPippo AJ. Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib. Leuk Lymphoma 61(10):1-4, 2020. e-Pub 2020. PMID: 32530347.
98. Hampel PJ, Cherng HJ, Call TG, Ding W, Khanlari M, McPhail ED, Miranda RN, Lin P, Tawbi HA, Ferrajoli A, Wierda WG, Jain N, Parikh SA. Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Adv 4(18):4508-4511, 2020. e-Pub 2020. PMID: 32946567.
99. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, Sharman JP, Wierda W, Zhao W, Heerema NA, Luan Y, Liu EA, Dean JP, O'Brien S. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clin Cancer Res 26(15):3918-3927, 2020. e-Pub 2020. PMID: 32209572.
100. Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda WG, Long JP, Bertilaccio MTS, Gandhi V. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. Clin Cancer Res 26(14):3856-3867, 2020. e-Pub 2020. PMID: 31937611.
101. Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol 95(7):734-739, 2020. e-Pub 2020. PMID: 32170867.
102. Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia 34(6):1588-1598, 2020. e-Pub 2020. PMID: 31862959.
103. Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Smedby KE, Spina V, Bruscaggin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini M, Cavalli F, Stussi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foa R, Pospisilova S, Morabito F, Stilgenbauer S, Dohner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood 135(21):1859-1869, 2020. e-Pub 2020. PMID: 32267500.
104. Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Clinical value of event-free survival in acute myeloid leukemia. Blood Adv 4(8):1690-1699, 2020. e-Pub 2020. PMID: 32330243.
105. Byrd JC, Wierda WG, Schuh A, Devereux S, Chaves JM, Brown JR, Hillmen P, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos J, Pagel JM, Woyach JA, Burke K, Covey T, Gulrajani M, Hamdy A, Izumi R, Frigault MM, Patel P, Rothbaum W, Wang MH, O'Brien S, Furman RR. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood 135(15):1204-1213, 2020. e-Pub 2020. PMID: 31876911.
106. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 395(10232):1278-1291, 2020. e-Pub 2020. PMID: 32305093.
107. Alfayez M, Thakral B, Jain P, Ravandi F, Ferrajoli A, Jain N, Pemmaraju N, Wierda W, Kadia T. First report of clinical response to venetoclax combination with pentostatin in T-cell-prolymphocytic leukemia (T-PLL). Leuk Lymphoma 61(2):445-449, 2020. e-Pub 2020. PMID: 31566032.
108. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. e-Pub 2020. PMID: 32023374.
109. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lim MS, Ma S, Malek S, Mato A, Mosse C, Shadman M, Siddiqi T, Stephens D, Sundaram S, Wagner N, Dwyer M, Sundar H. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(2):185-217, 2020. e-Pub 2020. PMID: 32023533.
110. Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol 95(2):144-150, 2020. e-Pub 2020. PMID: 31682008.
111. Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. J Geriatr Oncol 11(1):19-23, 2020. e-Pub 2020. PMID: 31005650.
112. Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris-Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS. Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunol Res 7(12):2036-2051, 2019. e-Pub 2019. PMID: 31530560.
113. Chen LS, Keating MJ, Wierda WG, Gandhi V. Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells. Leuk Lymphoma 60(12):1-4, 2019. e-Pub 2019. PMID: 31161836.
114. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z. STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol 203(11):3078-3085, 2019. e-Pub 2019. PMID: 31645416.
115. Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood 134(22):1951-1959, 2019. e-Pub 2019. PMID: 31537528.
116. Brown JR, Wierda WG. Evolving Strategies in First-Line Chronic Lymphocytic Leukemia: Is There a Role for Chemoimmunotherapy?. J Natl Compr Canc Netw 17(11.5):1408-1410, 2019. e-Pub 2019. PMID: 31766019.
117. Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC. Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica 104(11):2258-2264, 2019. e-Pub 2019. PMID: 30923097.
118. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG. Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol 187(3):307-318, 2019. e-Pub 2019. PMID: 31243771.
119. Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 134(21):1811-1820, 2019. e-Pub 2019. PMID: 31558467.
120. Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG. The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol 187(1):e1-e4, 2019. e-Pub 2019. PMID: 31344256.
121. Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell 36(4):369-384.e13, 2019. e-Pub 2019. PMID: 31543463.
122. Boddu P, Schlette E, Thakral B, Tang G, Pemmaraju N, Kadia T, Ferrajoli A, Ravandi F, Wierda W, Jain N. Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report. Hematol Oncol Stem Cell Ther 12(3):161-165, 2019. e-Pub 2019. PMID: 28830803.
123. Jain N, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply. N Engl J Med 381(8):789, 2019. e-Pub 2019. PMID: 31433937.
124. Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood 134(8):688-698, 2019. e-Pub 2019. PMID: 31292113.
125. Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, Kipps TJ, Burger JA, Stevens DA, Sharman J, Ghia P, Flinn IW, Zhou C, Ninomoto J, James DF, Tam CS. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol 186(1):184-188, 2019. e-Pub 2019. PMID: 30740654.
126. Chen R, Zhu M, Chaudhari RR, Robles O, Chen Y, Skillern W, Qin Q, Wierda WG, Zhang S, Hull KG, Romo D, Plunkett W. Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. Leukemia 33(7):1663-1674, 2019. e-Pub 2019. PMID: 30700841.
127. Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood 134(2):111-122, 2019. e-Pub 2019. PMID: 31023700.
128. Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood 133(26):2765-2775, 2019. e-Pub 2019. PMID: 30862645.
129. Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol 185(5):852-864, 2019. e-Pub 2019. PMID: 30924136.
130. Wierda WG, Byrd JC, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H, Heffner L, Zhou L, Verdugo M, Potluri J, Choi M. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. Br J Haematol 185(5):961-966, 2019. e-Pub 2019. PMID: 30478940.
131. Paul S, Jain N, Ferrajoli A, O'Brien S, Burger J, Keating M, Wierda W. A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol 185(3):606-608, 2019. e-Pub 2019. PMID: 30406944.
132. Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. e-Pub 2019. PMID: 31141631.
133. Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O'Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv 3(9):1533-1539, 2019. e-Pub 2019. PMID: 31076409.
134. Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol 109(5):545-552, 2019. e-Pub 2019. PMID: 30830579.
135. Wierda WG. Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?. Clin Adv Hematol Oncol 17(4):214-216, 2019. e-Pub 2019. PMID: 31188811.
136. Cervantes-Gomez F, Stellrecht CM, Ayres ML, Keating MJ, Wierda WG, Gandhi V. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells. Oncotarget 10(29):2793-2809, 2019. e-Pub 2019. PMID: 31073371.
137. Boddu P, Thakral B, Alhuraiji A, Pemmaraju N, Kadia T, Ohanian M, Ravandi F, Jabbour E, Wierda W, Khoury JD, Jain N. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. J Clin Pathol 72(3):251-257, 2019. e-Pub 2019. PMID: 30467242.
138. Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O'Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib versus ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 133(10):1011-1019, 2019. e-Pub 2019. PMID: 30530801.
139. Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol 6(2):e100-e109, 2019. e-Pub 2019. PMID: 30709431.
140. Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer 125(4):559-574, 2019. e-Pub 2019. PMID: 30508305.
141. Wierda WG, Byrd JC, Abramson JS, Bilgrami SF, Bociek G, Brander D, Brown J, Chanan-Khan AA, Chavez JC, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Malek S, Mato A, Mosse C, Neppalli VT, Shadman M, Siddiqi T, Stephens D, Wagner N, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. J Natl Compr Canc Netw 17(1):12-20, 2019. e-Pub 2019. PMID: 30659125.
142. Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 5(12):e618-e627, 2018. e-Pub 2018. PMID: 30501869.
143. Zulbaran-Rojas A, Lin HK, Shi Q, Williams LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F, Wierda W, Estrov Z, Borthakur G, Kadia T, Cleeland C, Cortes JE, Kantarjian H. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med 7(11):5457-5469, 2018. e-Pub 2018. PMID: 30318751.
144. Assi R, Garcia-Manero G, Ravandi F, Borthakur G, Daver NG, Jabbour E, Burger J, Estrov Z, Dinardo CD, Alvarado Y, Hendrickson S, Ferrajoli A, Wierda W, Cortes J, Kantarjian H, Kadia TM. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer 124(21):4192-4201, 2018. e-Pub 2018. PMID: 30307606.
145. Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood 132(21):2249-2259, 2018. e-Pub 2018. PMID: 30254130.
146. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma 59(11):1-6, 2018. e-Pub 2018. PMID: 29465264.
147. Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388-2398, 2018. e-Pub 2018. PMID: 29769624.
148. Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O'Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z. Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia 32(10):2278-2281, 2018. e-Pub 2018. PMID: 29479067.
149. Guha-Thakurta N, Wierda WG. Cerebral edema secondary to chimeric antigen receptor T-cell immunotherapy. Neurology 91(18):843, 2018. e-Pub 2018. PMID: 30373920.
150. Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res 24(18):4371-4379, 2018. e-Pub 2018. PMID: 29895707.
151. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget 9(72):33710-33718, 2018. e-Pub 2018. PMID: 30263097.
152. Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol 182(3):442-444, 2018. e-Pub 2018. PMID: 28616864.
153. Jones J, Mato A, Coutre S, Byrd JC, Furman RR, Hillmen P, Osterborg A, Tam C, Stilgenbauer S, Wierda WG, Heerema NA, Eckert K, Clow F, Zhou C, Chu AD, James DF, O'Brien SM. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. Br J Haematol 182(4):504-512, 2018. e-Pub 2018. PMID: 29873072.
154. Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol 36(19):JCO2017766840, 2018. e-Pub 2018. PMID: 29715056.
155. Naqvi K, Cortes JE, Luthra R, O'Brien S, Wierda W, Borthakur G, Kadia T, Garcia-Manero G, Ravandi F, Rios MB, Dellasala S, Pierce S, Jabbour E, Patel K, Kantarjian H. Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations. Int J Hematol 107(6):689-695, 2018. e-Pub 2018. PMID: 29464484.
156. Vangapandu HV, Chen H, Wierda WG, Keating MJ, Korkut A, Gandhi V. Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma 59(6):1-12, 2018. e-Pub 2018. PMID: 28971726.
157. Vangapandu HV, Alston B, Morse J, Ayres ML, Wierda WG, Keating MJ, Marszalek JR, Gandhi V. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells. Oncotarget 9(38):24980-24991, 2018. e-Pub 2018. PMID: 29861847.
158. O'Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K, Sharman J, Wierda W, Jones J, Zhao W, Heerema NA, Johnson AJ, Luan Y, James DF, Chu AD, Byrd JC. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 131(17):1910-1919, 2018. e-Pub 2018. PMID: 29437592.
159. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget 9(30):21268-21280, 2018. e-Pub 2018. PMID: 29765537.
160. Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia, 2018. e-Pub 2017. PMID: 28972595.
161. Ohanian M, Tari Ashizawa A, Garcia-Manero G, Pemmaraju N, Kadia T, Jabbour E, Ravandi F, Borthakur G, Andreeff M, Konopleva M, Lim M, Pierce S, O'Brien S, Alvarado Y, Verstovsek S, Wierda W, Kantarjian H, Cortes J. Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial. Lancet Haematol 5(4):e136-e146, 2018. e-Pub 2018. PMID: 29550383.
162. Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver N, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15(4):218, 2018. e-Pub 2018. PMID: 29434334.
163. Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A. Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood 131(16):1820-1832, 2018. e-Pub 2018. PMID: 29358183.
164. Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, Chyla B, Zhou L, Agarwal S, Waskiewicz T, Verdugo M, Humerickhouse RA, Potluri J, Wierda WG, Davids MS. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood 131(15):1704-1711, 2018. e-Pub 2018. PMID: 29305552.
165. Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32(4):920-930, 2018. e-Pub 2018. PMID: 29099493.
166. Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2018. PMID: 28718728.
167. Jabbour E, Düll J, Yilmaz M, Khoury JD, Ravandi F, Jain N, Einsele H, Garcia-Manero G, Konopleva M, Short NJ, Thompson PA, Wierda W, Daver N, Cortes J, O'brien S, Kantarjian H, Topp MS. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol 93(3):371-374, 2018. e-Pub 2018. PMID: 29178361.
168. Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124(6):1160-1168, 2018. e-Pub 2018. PMID: 29266206.
169. Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia 32(2):520-531, 2018. e-Pub 2018. PMID: 28725044.
170. Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240-248, 2018. e-Pub 2018. PMID: 29352703.
171. Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O'Brien S, Neuberg D, Kipps T, Burger JA. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol 180(4):597-600, 2018. e-Pub 2018. PMID: 27766619.
172. Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O'Brien S, Keating MJ, Estrov Z. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. Br J Haematol 180(1):33-40, 2018. e-Pub 2018. PMID: 29164608.
173. Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2018. PMID: 29047158.
174. Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, Daver N, Kadia T, Pemmaraju N, Pierce S, Garcia-Manero G, Wierda W, Verstovsek S, Jabbour E, Cortes J. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93(1):84-90, 2018. e-Pub 2018. PMID: 29027261.
175. Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19(1):65-75, 2018. e-Pub 2018. PMID: 29246803.
176. Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M. Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. Oncoimmunology 7(4):e1417720, 2018. e-Pub 2018. PMID: 29632735.
177. Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol 140(1):30-39, 2018. e-Pub 2018. PMID: 30071517.
178. Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M. Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol 8:369, 2018. e-Pub 2018. PMID: 30319961.
179. Strati P, Keating MJ, Burger JA, O'Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A. Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica 102(12):e494-e496, 2017. e-Pub 2017. PMID: 28798068.
180. Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer 123(24):4851-4859, 2017. e-Pub 2017. PMID: 28841236.
181. Jain N, Lu X, Daver N, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica 102(12):e514-e517, 2017. e-Pub 2017. PMID: 28860345.
182. Vangapandu HV, Havranek O, Ayres ML, Kaipparettu BA, Balakrishnan K, Wierda WG, Keating MJ, Davis RE, Stellrecht CM, Gandhi V. B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res 15(12):1692-1703, 2017. e-Pub 2017. PMID: 28835371.
183. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer 141(10):2076-2081, 2017. e-Pub 2017. PMID: 28722170.
184. Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment. Blood 130(19):2084-2091, 2017. e-Pub 2017. PMID: 28835440.
185. Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer 123(22):4430-4439, 2017. e-Pub 2017. PMID: 28708931.
186. Wierda WG, Byrd JC, Abramson JS, Bhat S, Bociek G, Brander D, Brown J, Chanan-Khan A, Coutre SE, Davis RS, Fletcher CD, Hill B, Kahl BS, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Lancet J, Ma S, Malek S, Mosse C, Shadman M, Siddiqi T, Stephens D, Wagner N, Zelenetz AD, Dwyer MA, Sundar H. Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 15(11):1414-1427, 2017. e-Pub 2017. PMID: 29118233.
187. Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer 123(22):4391-4402, 2017. e-Pub 2017. PMID: 28743165.
188. Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian H, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer 123(19):3717-3724, 2017. e-Pub 2017. PMID: 28608976.
189. Vangapandu HV, Ayres ML, Bristow CA, Wierda WG, Keating MJ, Balakrishnan K, Stellrecht CM, Gandhi V. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells. Neoplasia 19(10):762-771, 2017. e-Pub 2017. PMID: 28863345.
190. Stellrecht CM, Chen LS, Ayres ML, Dennison JB, Shentu S, Chen Y, Keating MJ, Wierda WG, Gandhi V. Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy. Br J Haematol 179(2):266-271, 2017. e-Pub 2017. PMID: 28737232.
191. Hacken ET, Gounari M, Back JW, Shimanovskaya E, Scarfò L, Kim E, Burks J, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, Ghia P, Burger JA. Calreticulin as a novel B cell receptor antigen in chronic lymphocytic leukemia. Haematologica 102(10):e394-e396, 2017. e-Pub 2017. PMID: 28751563.
192. Jain P, Kantarjian H, Jain N, Short NJ, Yin CC, Kanagal-Shamanna R, Khoury J, Konopleva M, Sasaki K, Kadia TM, Garris R, Pierce S, Estrov Z, Wierda W, Cortes J, O'Brien S, Ravandi F, Jabbour E. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol 92(10):E595-E597, 2017. e-Pub 2017. PMID: 28646517.
193. Jain P, Kanagal-Shamanna R, Wierda W, Ferrajoli A, Keating M, Jain N. Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab. Hematol Oncol Stem Cell Ther 10(3):151-154, 2017. e-Pub 2017. PMID: 27352257.
194. Patel VM, Balakrishnan K, Douglas M, Tibbitts T, Xu EY, Kutok JL, Ayers M, Sarkar A, Guerrieri R, Wierda WG, O'Brien S, Jain N, Stern HM, Gandhi V. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). Leukemia 31(9):1872-1881, 2017. e-Pub 2017. PMID: 28017967.
195. Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer 123(16):3050-3060, 2017. e-Pub 2017. PMID: 28387922.
196. Jain P, Aoki E, Keating M, Wierda WG, O'Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol 28(7):1554-1559, 2017. e-Pub 2017. PMID: 28379307.
197. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(7):1659, 2017. e-Pub 2017. PMID: 28338082.
198. Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda WG, Gandhi V. Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res 23(14):3734-3743, 2017. e-Pub 2017. PMID: 28034907.
199. Murphy EJ, Neuberg DS, Rassenti LZ, Hayes G, Redd R, Emson C, Li K, Brown JR, Wierda WG, Turner S, Greaves AW, Zent CS, Byrd JC, McConnel C, Barrientos J, Kay N, Hellerstein MK, Chiorazzi N, Kipps TJ, Rai KR. Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. Leukemia 31(6):1348-1354, 2017. e-Pub 2017. PMID: 28115735.
200. Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O'Brien S, Wierda WG. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer 123(12):2268-2273, 2017. e-Pub 2017. PMID: 28171709.
201. Short NJ, Kantarjian HM, Ko H, Khoury JD, Ravandi F, Thomas DA, Garcia-Manero G, Khouri M, Cortes JE, Wierda WG, Verstovsek S, Estrov Z, Ferrajoli A, Thompson PA, Pierce S, O'Brien SM, Jabbour E. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol 92(6):E114-E117, 2017. e-Pub 2017. PMID: 28295472.
202. Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien S, Burger JA. Long term follow up of treatment with ibrutinib and rituximab (IR) in patients with high-risk Chronic Lymphocytic Leukemia (CLL). Clin Cancer Res 23(9):2154-2158, 2017. e-Pub 2017. PMID: 27797975.
203. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol 177(4):567-577, 2017. e-Pub 2017. PMID: 28295181.
204. Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O'Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15(5):610-618, 2017. e-Pub 2017. PMID: 28130399.
205. Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G. Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents. Am J Hematol 92(4):351-358, 2017. e-Pub 2017. PMID: 28076892.
206. Pemmaraju N, Jain P, Medeiros LJ, Jorgenson JL, Jain N, Willis J, Kontoyiannis DP, Estrov Z, Wierda WG. PET-positive lymphadenopathy in CLL - Not always Richter transformation. Am J Hematol 92(4):405-406, 2017. e-Pub 2017. PMID: 27677095.
207. Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, Puvvada S, Kipps TJ, Anderson MA, Salem AH, Dunbar M, Zhu M, Peale F, Ross JA, Gressick L, Desai M, Kim SY, Verdugo M, Humerickhouse RA, Gordon GB, Gerecitano JF. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol 35(8):JCO2016704320, 2017. e-Pub 2017. PMID: 28095146.
208. Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget 8(13):22104-22112, 2017. e-Pub 2017. PMID: 27655665.
209. Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017. J Natl Compr Canc Netw 15(3):293-311, 2017. e-Pub 2017. PMID: 28275031.
210. Coutré SE, Furman RR, Flinn IW, Burger JA, Blum K, Sharman J, Jones J, Wierda W, Zhao W, Heerema NA, Johnson AJ, Tran A, Zhou C, Bilotti E, James DF, Byrd JC, O'Brien S. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clin Cancer Res 23(5):1149-1155, 2017. e-Pub 2017. PMID: 28073846.
211. Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S, Brandt M, McCue D, Luthra R, Patel K, Kornblau S, Kadia T, Daver N, DiNardo C, Jain N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Estrov Z, Foudray M, McCue D, Cortes J, Ravandi F. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood 129(10):1275-1283, 2017. e-Pub 2017. PMID: 28003274.
212. Modi P, Balakrishnan K, Yang Q, Wierda WG, Keating MJ, Gandhi V. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget 8(10):16259-16274, 2017. e-Pub 2017. PMID: 28187444.
213. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K. Chronic lymphocytic leukaemia. Nat Rev Dis Primers 3:17008, 2017. e-Pub 2017. PMID: 28179635.
214. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, Pemmaraju N, Cortes J, Verstovsek S, Kadia T, Daver N, Wierda W, Alvarado Y, Konopleva M, Ravandi F, Estrov Z, Jain N, Alfonso A, Brandt M, Sneed T, Chen HC, Yang H, Bueso-Ramos C, Pierce S, Estey E, Bohannan Z, Kantarjian HM, Garcia-Manero G. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31(2):318-324, 2017. e-Pub 2016. PMID: 27795561.
215. Koller PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, Verstovsek S, Borthakur G, Estrov Z, Wierda WG, Garcia-Manero G, Ferrajoli A, Ravandi F, O'Brien SM, Cortes JE. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer 123(4):609-616, 2017. e-Pub 2017. PMID: 27763690.
216. Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O'Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol 4(2):e67-e74, 2017. e-Pub 2017. PMID: 28089238.
217. Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JA. Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. J Immunol 198(4):1740-1747, 2017. e-Pub 2017. PMID: 28077600.
218. Jewell RC, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Smolej L, Mayer J, Hess G, Hernandez-Ilizaliturri FJ, Padmanabhan-Iyer S, Fang L, Goldstein N, Gorczyca M, Gupta I, Lisby S, Wierda WG, Investigators HS. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leuk Lymphoma 58(2):1-9, 2017. e-Pub 2017. PMID: 27389174.
219. Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, Ferrajoli A, Huang X, Kantarjian H, Wierda WG, O'Brien S, Hellerstein MK, Turner SM, Emson CL, Chen SS, Yan XJ, Wodarz D, Chiorazzi N. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight 2(2):e89904, 2017. e-Pub 2017. PMID: 28138560.
220. Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O'Brien SM, Keating MJ, Kantarjian HM, Chhatwal J. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J Clin Oncol 35(2):166-174, 2017. e-Pub 2017. PMID: 27870563.
221. Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, Garcia-Manero G, Kornblau S, Wierda W, Burger J, DiNardo CD, Andreeff M, Konopleva M, Daver N. Buparlisib, a PI3K Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity in a Phase I Trial of Patients with Advanced Leukemias. Am J Hematol 92(1):7-11, 2017. e-Pub 2017. PMID: 27673440.
222. Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K. The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Front Immunol 8:1773, 2017. e-Pub 2017. PMID: 29379494.
223. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ. High-level ROR1 associates with accelerated disease-progression in chronic lymphocytic leukemia. Blood 128(25):2931-2940, 2016. e-Pub 2016. PMID: 27815263.
224. Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov Z. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol 91(11):E478-E479, 2016. e-Pub 2016. PMID: 27468087.
225. Wierda WG. Minimal Residual Disease Provides Treatment Focus for Next Chronic Lymphocytic Leukemia Advances. J Clin Oncol 34(31):3722-3723, 2016. e-Pub 2016. PMID: 27573662.
226. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. J Natl Compr Canc Netw 14(9):1067-79, 2016. e-Pub 2016. PMID: 27587620.
227. Lamothe B, Wierda WG, Keating MJ, Gandhi V. Carfilzomib triggers cell death in chronic lymphocytic leukemia by inducing proapoptotic and endoplasmic reticulum stress responses. Clin Cancer Res 22(18):4712-26, 2016. e-Pub 2016. PMID: 27026200.
228. Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, Ghia P, Caligaris-Cappio F, Burger JA. Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. J Immunol 197(6):2522-31, 2016. e-Pub 2016. PMID: 27534555.
229. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363-76, 2016. e-Pub 2016. PMID: 27482888.
230. Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - A propensity score analysis. Haematologica 101(8):e324-7, 2016. e-Pub 2016. PMID: 27175025.
231. Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O'Brien SM. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer 122(16):2505-11, 2016. e-Pub 2016. PMID: 27182988.
232. Balakrishnan K, Fu M, Onida F, Wierda WG, Keating MJ, Gandhi V. Reactivation of smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of smac mimetic. Oncotarget 7(26):39458-39472, 2016. e-Pub 2016. PMID: 27223062.
233. Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 17(6):768-78, 2016. e-Pub 2016. PMID: 27178240.
234. Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O'Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JA. Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica 101(6):e254-8, 2016. e-Pub 2016. PMID: 27013651.
235. Falchi L, Vitale C, Keating MJ, Lerner S, Wang X, Elhor Gbito KY, Strom S, Wierda WG, Ferrajoli A. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Ann Oncol 27(6):1100-6, 2016. e-Pub 2016. PMID: 26912560.
236. Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun 7:11589, 2016. e-Pub 2016. PMID: 27199251.
237. Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A. Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation Between Responses and Immune Characteristics. Clin Cancer Res 22(10):2359-67, 2016. e-Pub 2016. PMID: 26733610.
238. Rozovski U, Harris DM, Li P, Liu Z, Wu JY, Grgurevic S, Faderl S, Ferrajoli A, Wierda WG, Martinez M, Verstovsek S, Keating MJ, Estrov Z. At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells. J Immunol 196(10):4400-9, 2016. e-Pub 2016. PMID: 27076684.
239. Jain P, Kantarjian H, Sasaki K, Jabbour E, Dasarathula J, Nogueras Gonzalez G, Verstovsek S, Borthakur G, Wierda W, Kadia T, Dellasala S, Pierce S, Ravandi F, O'Brien S, Cortes J. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol 173(1):114-26, 2016. e-Pub 2016. PMID: 26846160.
240. Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P. A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study. Leukemia 30(4):929-36, 2016. e-Pub 2016. PMID: 26639181.
241. Pemmaraju N, Kantarjian H, Ravandi F, Nogueras-Gonzalez GM, Huang X, O'Brien S, Wierda W, Garcia-Manero G, Thomas D, Pierce S, Verstovsek S, Borthakur G, Cortes J. Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clin Lymphoma Myeloma Leuk 16(4):213-222.e2, 2016. e-Pub 2016. PMID: 26838606.
242. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Diffuse Large B-Cell Lymphoma Version 1.2016. J Natl Compr Canc Netw 14(2):196-231, 2016. e-Pub 2016. PMID: 26850490.
243. Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG. β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer 122(4):565-73, 2016. e-Pub 2016. PMID: 26588193.
244. Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol 172(3):392-400, 2016. e-Pub 2016. PMID: 26492205.
245. Tambaro FP, Garcia-Manero G, O'Brien SM, Faderl SH, Ferrajoli A, Burger JA, Pierce S, Wang X, Do KA, Kantarjian HM, Keating MJ, Wierda WG. Outcomes for patients with Chronic Lymphocytic Leukemia (CLL) and Acute leukemia or myelodysplastic syndrome. Leukemia 30(2):325-30, 2016. e-Pub 2016. PMID: 26290497.
246. Cervantes-Gomez F, Lavergne B, Keating MJ, Wierda WG, Gandhi V. Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells. Leuk Lymphoma 57(2):1-23, 2016. e-Pub 2016. PMID: 26088877.
247. Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ. Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127(3):303-9, 2016. e-Pub 2016. PMID: 26492934.
248. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, Wong S, Dunbar M, Zhu M, Desai MB, Cerri E, Heitner Enschede S, Humerickhouse RA, Wierda WG, Seymour JF. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 374(4):311-22, 2016. e-Pub 2016. PMID: 26639348.
249. Kellner J, Wierda W, Shpall E, Keating M, McNiece I. Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLL. Leuk Res 40:54-9, 2016. e-Pub 2016. PMID: 26601610.
250. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RR. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 374(4):323-32, 2016. e-Pub 2016. PMID: 26641137.
251. Thompson PA, Wierda WG. Eliminating minimal residual disease as a therapeutic endpoint: working toward cure for patients with CLL. Blood 127(3):279-86, 2016. e-Pub 2016. PMID: 26576865.
252. Patel V, Keating MJ, Wierda WG, Gandhi V. Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia. Leuk Lymphoma 57(6):1-4, 2016. e-Pub 2016. PMID: 26440741.
253. Jiang Y, Chen HC, Su X, Thompson PA, Liu X, Do KA, Wierda W, Keating MJ, Plunkett W. ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2). Blood Cancer J 6(9):e465, 2016. e-Pub 2016. PMID: 27588518.
254. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol 171(5):726-35, 2015. e-Pub 2015. PMID: 26358140.
255. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121(23):4158-64, 2015. e-Pub 2015. PMID: 26308885.
256. Badar T, Kantarjian HM, Nogueras-Gonzalez GM, Borthakur G, Garcia Manero G, Andreeff M, Konopleva M, Kadia TM, Daver N, Wierda WG, Luthra R, Patel K, Oran B, Champlin R, Ravandi F, Cortes JE. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol 90(11):1065-70, 2015. e-Pub 2015. PMID: 26299958.
257. Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 16(15):1547-55, 2015. e-Pub 2015. PMID: 26432046.
258. Short NJ, Keating MJ, WG||B W, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O'Brien SM. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer 121(21):3869-76, 2015. e-Pub 2015. PMID: 26218678.
259. Thompson PA, Rozovski U, Keating MJ, Stingo F, Smith SC, Wierda WG, Falchi L, O'Brien SM, Estrov Z, Burger JA, Ferrajoli A. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience. Br J Haematol 171(2):281-284, 2015. e-Pub 2015. PMID: 25824652.
260. Thompson PA, O'Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer 121(20):3612-21, 2015. e-Pub 2015. PMID: 26193999.
261. Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O'Brien S, Kutok JL, Gandhi V. The Phosphoinositide-3-Kinase (PI3K)-Delta and Gamma Inhibitor, IPI-145, Overcomes Signals from the PI3K/AKT/S6 Pathway and Promotes Apoptosis in CLL. Leukemia 29(9):1811-22, 2015. e-Pub 2015. PMID: 25917267.
262. Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, Gandhi V. Pharmacological and protein profiling suggest ABT-199 as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res 21(16):3705-15, 2015. e-Pub 2015. PMID: 25829398.
263. Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmenn P, Trnený M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica 100(8):e311-4, 2015. e-Pub 2015. PMID: 25769539.
264. Strati P, Abruzzo LV, Wierda WG, O'Brien S, Ferrajoli A, Keating MJ. Second Cancers and Richter Transformation Are the Leading Causes of Death in Patients With Trisomy 12 Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk 15(7):420-7, 2015. e-Pub 2015. PMID: 25800543.
265. Österborg A, Wierda WG, Mayer J, Hess G, Hillmen P, Schetelig J, Schuh A, Smolej L, Beck C, Dreyfus B, Hellman A, Kozlowski P, Pfreundschuh M, Rizzi R, Spacek M, Phillips JL, Gupta IV, Williams V, Jewell RC, Nebot N, Lisby S, Dyer MJ. Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. Br J Haematol 170(1):40-9, 2015. e-Pub 2015. PMID: 25825041.
266. Thompson PA, Ferrajoli A, O'Brien S, Wierda WG, Keating MJ, Burger JA. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol 170(1):125-8, 2015. e-Pub 2015. PMID: 25522014.
267. Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O'Brien S. High FISH percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome. Am J Hematol 90(6):471-7, 2015. e-Pub 2015. PMID: 25683856.
268. Strati P, Tong WG, Vitale C, Wierda WG, O'Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. A Phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leuk Lymphoma 56(6):1878-80, 2015. e-Pub 2014. PMID: 25311497.
269. Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S, Wang X, Burger J, Ferrajoli A, Kantarjian H, O'Brien S, Wierda W, Estrov Z, Keating M. Second cancers in patients with Chronic Lymphocytic Leukemia who received frontline FCR therapy - Distribution and clinical outcomes. Leuk Lymphoma:1-28, 2015. e-Pub 2014. PMID: 25308294.
270. Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, D'Abundo L, Qiang J, Lerner S, Nouraee N, Rabe KG, Rassenti LZ, Van Roosbroeck K, Manning JT, Yuan Y, Zhang X, Shanafelt TD, Wierda WG, Sabbioni S, Tarrand JJ, Estrov Z, Radovich M, Liang H, Negrini M, Kipps TJ, Kay NE, Keating M, Calin GA. Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. EBioMedicine 2(6):572-82, 2015. e-Pub 2015. PMID: 26288818.
271. Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O'Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z. Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure. J Clin Oncol 33(14):1557-63, 2015. e-Pub 2015. PMID: 25847930.
272. Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O'Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov Z. Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res 13(5):944-53, 2015. e-Pub 2015. PMID: 25733697.
273. Wierda WG. Updates to the management of chronic lymphocytic leukemia. J Natl Compr Canc Netw 13(5 Suppl):662-5, 2015. e-Pub 2015. PMID: 25995424.
274. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O'Brien S. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 125(16):2497-506, 2015. e-Pub 2015. PMID: 25700432.
275. Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, Dellasala S, Pierce S, Verstovsek S, Wierda W, Borthakur G, Ravandi F, O'Brien S, Cortes J. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol 2(3):e118-28, 2015. e-Pub 2015. PMID: 26687797.
276. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw 13(3):326-62, 2015. e-Pub 2015. PMID: 25736010.
277. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O'Brien S. Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib. Blood 125(13):2062-7, 2015. e-Pub 2015. PMID: 25573991.
278. Patel V, Balakrishnan K, Keating MJ, Wierda WG, Gandhi V. Expression of executioner procaspases and their activation by a procaspase activating compound in chronic lymphocytic leukemia cells. Blood 125(7):1126-36, 2015. e-Pub 2015. PMID: 25538042.
279. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol 2(1):e12-20, 2015. e-Pub 2015. PMID: 26687423.
280. Lamothe B, Cervantes-Gomez F, Sivina M, Wierda WG, Keating MJ, Gandhi V. Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood 125(2):407-10, 2015. e-Pub 2015. PMID: 25573971.
281. Yang H, Maddipoti S, Quesada A, Bohannan Z, Cabrero Calvo M, Colla S, Wei Y, Estecio M, Wierda W, Bueso-Ramos C, Garcia-Manero G. Analysis of Class I and II Histone Deacetylase Gene Expression in Human Leukemia. Leuk Lymphoma 56(12):1-20, 2015. e-Pub 2015. PMID: 25944469.
282. Badar T, Cortes J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Ferrajoli A, Kadia T, Poku R, Kantarjian H, Mattiuzzi G. Phase II, Open Label, Randomized Comparative Trial of Ondansetron Alone versus the Combination of Ondansetron and Aprepitant for the Prevention of Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Regimens Containing High-Dose Cytarabine. Biomed Res Int 2015:497597, 2015. e-Pub 2015. PMID: 25654108.
283. Deniger DC, Yu J, Huls MH, Figliola MJ, Mi T, Maiti SN, Widhopf GF, Hurton LV, Thokala R, Singh H, Olivares S, Champlin RE, Wierda WG, Kipps TJ, Cooper LJ. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations. PLoS One 10(6):e0128151, 2015. e-Pub 2015. PMID: 26030772.
284. Balakrishnan K, Burger JA, Fu M, Doifode T, Wierda WG, Gandhi V. Regulation of mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia 16(12):1036-46, 2014. e-Pub 2014. PMID: 25499217.
285. Badar T, Burger JA, Wierda WG, O'Brien S. Ibrutinib: a paradigm shift in management of CLL. Expert Rev Hematol 7(6):705-17, 2014. e-Pub 2014. PMID: 25387837.
286. Tam CS, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, Do KA, Cortes J, Khouri I, Kantarjian H, Lerner S, Keating MJ. Life After FCR: Outcomes of patients with chronic lymphocytic leukemia who progress after frontline treatment with Fludarabine, Cyclophosphamide and Rituximab. Blood 124(20):3059-64, 2014. e-Pub 2014. PMID: 25281606.
287. Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien S. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer 120(22):3494-501, 2014. e-Pub 2014. PMID: 25043749.
288. Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 14(5):401-10, 2014. e-Pub 2014. PMID: 24875590.
289. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 15(10):1090-9, 2014. e-Pub 2014. PMID: 25150798.
290. Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, Burger J, O'Brien S, Faderl S, Keating M, Estrov Z. STAT3-Activated GM-CSFRalpha Translocates to the Nucleus and Protects CLL Cells from Apoptosis. Mol Cancer Res 12(9):1267-82, 2014. e-Pub 2014. PMID: 24836891.
291. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's Lymphomas, Version 4.2014. J Natl Compr Canc Netw 12(9):1282-303, 2014. e-Pub 2014. PMID: 25190696.
292. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG. Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica 99(8):1350-5, 2014. e-Pub 2014. PMID: 24859876.
293. Claus R, Lucas DM, Ruppert AS, Williams KE, Weng D, Patterson K, Zucknick M, Oakes CC, Rassenti LZ, Greaves AW, Geyer S, Wierda WG, Brown JR, Gribben JG, Barrientos JC, Rai KR, Kay NE, Kipps TJ, Shields P, Zhao W, Grever MR, Plass C, Byrd JC. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood 124(1):42-8, 2014. e-Pub 2014. PMID: 24868078.
294. James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol 32(19):2067-73, 2014. e-Pub 2014. PMID: 24868031.
295. Struemper H, Sale M, Patel BR, Østergaard M, Österborg A, Wierda WG, Hagenbeek A, Coiffier B, Jewell RC. Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. J Clin Pharmacol 54(7):818-27, 2014. e-Pub 2014. PMID: 24443277.
296. El-Mabhouh AA, Ayres ML, Shpall EJ, Baladandayuthapani V, Keating MJ, Wierda WG, Gandhi V. Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. Blood 123(24):3780-9, 2014. e-Pub 2014. PMID: 24747434.
297. Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, Kantarjian H, James D, O'Brien S, Burger JA. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood 123(26):4132-5, 2014. e-Pub 2014. PMID: 24829205.
298. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123(24):3797-802, 2014. e-Pub 2014. PMID: 24778152.
299. Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 123(24):3727-32, 2014. e-Pub 2014. PMID: 24705492.
300. Wierda W. The use of obinutuzumab in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 12(6):395-7, 2014. e-Pub 2014. PMID: 25003571.
301. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Non-Hodgkin's Lymphomas, Version 2.2014. J Natl Compr Canc Netw 12(6):916-46, 2014. e-Pub 2014. PMID: 24925202.
302. O'Reilly M, Federoff HJ, Fong Y, Kohn DB, Patterson AP, Ahmed N, Asokan A, Boye SE, Crystal RG, De Oliveira S, Gargiulo L, Harper SQ, Ikeda Y, Jambou R, Montgomery M, Prograis L, Rosenthal E, Sterman DH, Vandenberghe LH, Zoloth L, Abedi M, Adair J, Adusumilli PS, Goins WF, Gray J, Monahan P, Popplewell L, Sena-Esteves M, Tannous B, Weber T, Wierda W, Gopal-Srivastava R, McDonald CL, Rosenblum D, Corrigan-Curay J. Gene therapy: charting a future course-summary of a national institutes of health workshop, april 12, 2013. Hum Gene Ther 25(6):488-97, 2014. e-Pub 2014. PMID: 24773122.
303. Mehta RS, Di Stasi A, Hosing C, Shah N, Rezvani K, Alousi A, O'Brien S, Wierda W, Keating M, Shpall EJ. Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. Clin Lymphoma Myeloma Leuk 14(3):e105-9, 2014. e-Pub 2014. PMID: 24502832.
304. Foran J, Ravandi F, Wierda W, Garcia-Manero G, Verstovsek S, Kadia T, Burger J, Yule M, Langford G, Lyons J, Ayrton J, Lock V, Borthakur G, Cortes J, Kantarjian H. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk 14(3):223-30, 2014. e-Pub 2014. PMID: 24355079.
305. Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, Trinh L, Wang X, Smith SC, Jain N, Estrov Z, O'Brien S, Wierda WG, Lerner S, Ferrajoli A. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood 123(18):2783-90, 2014. e-Pub 2014. PMID: 24615780.
306. Strati P, Ferrajoli A, Lerner S, O'Brien S, Wierda W, Keating MJ, Faderl S. Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leuk Lymphoma 55(4):828-33, 2014. e-Pub 2013. PMID: 23808813.
307. Patel V, Balakrishnan K, Wierda WG, Gandhi V. Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia. Leuk Lymphoma 55(4):899-910, 2014. e-Pub 2013. PMID: 23837491.
308. Kharfan-Dabaja MA, Wierda WG, Cooper LJ. Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia 28(3):507-17, 2014. e-Pub 2014. PMID: 24157582.
309. Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski A, Burger JA. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood 123(7):1032-9, 2014. e-Pub 2014. PMID: 24277076.
310. Chae YK, Trinh L, Jain P, Wang X, Rozovski U, Wierda WG, Keating MJ, Estrov Z. Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. Blood 123(9):1424-6, 2014. e-Pub 2014. PMID: 24578497.
311. O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 15(1):48-58, 2014. e-Pub 2014. PMID: 24332241.
312. Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien S. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia. Cancer 119(21):3805-11, 2013. e-Pub 2013. PMID: 23943357.
313. Jabbour E, Takahashi K, Wang X, Cornelison AM, Abruzzo L, Kadia T, Borthakur G, Estrov Z, O'Brien S, Mallo M, Wierda W, Pierce S, Wei Y, Sole F, Chen R, Kantarjian H, Garcia-Manero G. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol 88(10):831-7, 2013. e-Pub 2013. PMID: 23760779.
314. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ, Research Consortium CLL. Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome. Clin Lymphoma Myeloma Leuk 13(5):568-74, 2013. e-Pub 2013. PMID: 23810245.
315. Barreda Garcia J, Lei X, Wierda W, Cortes JE, Dickey BF, Evans SE, Ost DE. Pneumonia during Remission Induction Chemotherapy in Patients with Acute Leukemia. Ann Am Thorac Soc 10(5):432-40, 2013. e-Pub 2013. PMID: 23987587.
316. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic leukemia. Blood 122(11):1891-9, 2013. e-Pub 2013. PMID: 23821659.
317. Falchi L, Keating MJ, Wang X, Coombs CC, Lanasa MC, Strom S, Wierda WG, Ferrajoli A. Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: Joint experience of the MD Anderson Cancer Center and Duke University Medical Center. Cancer 119(17):3177-85, 2013. e-Pub 2013. PMID: 24022787.
318. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood 122(5):734-7, 2013. e-Pub 2013. PMID: 23801633.
319. Kontoyiannis DP, Georgiadou SP, Wierda WG, Wright S, Albert ND, Ferrajoli A, Keating M, Lewis RE. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. Leuk Lymphoma 54(8):1730-3, 2013. e-Pub 2013. PMID: 23163595.
320. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369(1):32-42, 2013. e-Pub 2013. PMID: 23782158.
321. Rozovski U, Calin GA, Setoyama T, D'Abundo L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O'Brien S, Wierda WG, Keating MJ, Estrov Z. Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. Mol Cancer 12:50, 2013. e-Pub 2013. PMID: 23725032.
322. Malik A, Shoukier M, Garcia-Manero G, Wierda W, Cortes J, Bickel S, Keating MJ, Estrov Z. Azacitidine in Fludarabine-Refractory Chronic Lymphocytic Leukemia: A Phase II Study. Clin Lymphoma Myeloma Leuk 13(3):292-5, 2013. e-Pub 2013. PMID: 23265768.
323. Balakrishnan K, Aggarwal S, Wierda W, Gandhi V. Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leuk Lymphoma 54(5):1097-100, 2013. e-Pub 2013. PMID: 22866921.
324. Jabbour E, Garcia-Manero G, Ravandi F, Faderl S, O'Brien S, Fullmer A, Cortes JE, Wierda W, Kantarjian H. Prognostic Factors Associated With Disease Progression and Overall Survival in Patients With Myelodysplastic Syndromes Treated With Decitabine. Clin Lymphoma Myeloma Leuk 13(2):131-8, 2013. e-Pub 2013. PMID: 23260600.
325. Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, Lacasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M. Non-Hodgkin's Lymphomas, Version 1.2013. J Natl Compr Canc Netw 11(3):257-273, 2013. e-Pub 2013. PMID: 23486452.
326. Schweighofer CD, Coombes KR, Majewski T, Barron LL, Lerner S, Sargent RL, O'Brien S, Ferrajoli A, Wierda WG, Czerniak BA, Medeiros LJ, Keating MJ, Abruzzo LV. Genomic Variation by Whole-Genome SNP Mapping Arrays Predicts Time-to-Event Outcome in Patients with Chronic Lymphocytic Leukemia: A Comparison of CLL and HapMap Genotypes. J Mol Diagn 15(2):196-209, 2013. e-Pub 2013. PMID: 23273604.
327. Hosing C, Kebriaei P, Wierda W, Jena B, Cooper LJN, Shpall E. CARs in Chronic Lymphocytic Leukemia - Ready to Drive. Curr Hematol Malig Rep 8(1):60-70, 2013. e-Pub 2013. PMID: 23225251.
328. Badoux XC, Keating MJ, Wen S, Wierda WG, O'Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli A. Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 31(5):584-91, 2013. e-Pub 2013. PMID: 23270003.
329. Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA. The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. PLoS One 8(12):e83830, 2013. e-Pub 2013. PMID: 24376763.
330. Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA. Non-Hodgkin's Lymphomas, Version 3.2012. J Natl Compr Canc Netw 10(12):1487-1498, 2012. e-Pub 2012. PMID: 23221787.
331. Tong WG, Quintás-Cardama A, Kadia T, Borthakur G, Jabbour E, Ravandi F, Faderl S, Wierda W, Pierce S, Shan J, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Predicting survival of patients with hypocellular myelodysplastic syndrome: Development of a disease-specific prognostic score system. Cancer 118(18):4462-70, 2012. e-Pub 2012. PMID: 22252728.
332. Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, Wierda WG, Rosenwald A, Herling M, Burger JA. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia 26(8):1812-20, 2012. e-Pub 2012. PMID: 22460735.
333. Garg R, Wierda W, Ferrajoli A, Abruzzo L, Pierce S, Lerner S, Keating M, O'Brien S. The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer 118(14):3531-7, 2012. e-Pub 2012. PMID: 22139735.
334. Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O'Brien S, Keating MJ, Burger JA. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 26(7):1576-83, 2012. e-Pub 2012. PMID: 22362000.
335. Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, Ravandi F, Wierda W, O'Brien S, Cortes J. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica 97(7):1029-35, 2012. e-Pub 2012. PMID: 22271898.
336. Kater AP, Shanafelt T, Fischer K, Wierda W. Highlights of the 6th Young Investigators' Meeting on Chronic Lymphocytic Leukemia. Leuk Lymphoma. e-Pub 2012. PMID: 22646797.
337. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182-9, 2012. e-Pub 2012. PMID: 22180443.
338. Zhou Y, Tang G, Medeiros LJ, McDonnell TJ, Keating MJ, Wierda WG, Wang SA. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol 25(2):237-45, 2012. e-Pub 2012. PMID: 22080061.
339. Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG, Keating MJ. Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia. Blood 119(5):1162-72, 2012. e-Pub 2012. PMID: 22096249.
340. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R. Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. J Clin Oncol 30(5):488-96, 2012. e-Pub 2012. PMID: 22184378.
341. Decker WK, Shah N, Xing D, Lapushin R, Li S, Robinson SN, Yang H, Parmar S, Halpert MM, Keating MJ, Gribben JG, Molldrem JJ, Shpall EJ, Wierda WG. Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC. PLoS One 7(12):e51390, 2012. e-Pub 2012. PMID: 23284688.
342. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia. J Clin Oncol 29(31):4088-95, 2011. e-Pub 2011. PMID: 21969505.
343. Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A, Investigators HS. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study. Blood 118(19):5126-9, 2011. e-Pub 2011. PMID: 21856867.
344. Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 118(13):3489-98, 2011. e-Pub 2011. PMID: 21725050.
345. Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, Faderl SH, Keating MJ, Ferrajoli A, Reuben JM. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 117(17):3999-4008, 2011. e-Pub 2011. PMID: 21858802.
346. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 118(13):3603-12, 2011. e-Pub 2011. PMID: 21803855.
347. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, rituximab and alemtuzumab (CFAR) as salvage therapy for heavily pre-treated patients with chronic lymphocytic leukemia. Blood 118(8):2085-93, 2011. e-Pub 2011. PMID: 21670470.
348. Parikh SA, Keating MJ, O'Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab (CFAR) for high-risk chronic lymphocytic leukemia. Blood 118(8):2062-8, 2011. e-Pub 2011. PMID: 21750315.
349. Dayyani F, Mougalian SS, Naqvi K, Shan J, Ravandi F, Cortes J, Weinberg J, Jabbour E, Faderl S, Wierda W, Thomas D, O'Brien S, Pierce S, Kantarjian H, Garcia-Manero G. Prediction model for mortality after intracranial hemorrhage in patients with leukemia. Am J Hematol 86(7):546-9, 2011. e-Pub 2011. PMID: 21509801.
350. Zecevic A, Sampath D, Ewald B, Chen R, Wierda W, Plunkett W. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease. Clin Cancer Res 17(14):4731-41, 2011. e-Pub 2011. PMID: 21632856.
351. Ma D, Chen Z, Patel KP, Mishra BM, Yao H, Abruzzo LV, Medeiros LJ, Wierda W, Keating M, Sargent R, Luthra R. Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 11 Suppl 1(Suppl 1):S17-24, 2011. e-Pub 2011. PMID: 22035742.
352. Shah N, Decker WK, Lapushin R, Xing D, Robinson SN, Yang H, Parmar S, Tung SS, O'Brien S, Fernandez-Viña M, Shpall EJ, Wierda WG. HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance. Leukemia 25(6):1036-9, 2011. e-Pub 2011. PMID: 21350559.
353. Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Gorczyca M, Chang CN, Chan G, Gupta I, Nielsen TG, Russell CA, Investigators S. Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic leukemia. Blood 117(24):6450-8, 2011. e-Pub 2011. PMID: 21498674.
354. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N. Non-Hodgkin's Lymphomas. J Natl Compr Canc Netw 9(5):484-560, 2011. e-Pub 2011. PMID: 21550968.
355. Duzkale H, Schweighofer CD, Coombes KR, Barron LL, Ferrajoli A, O'Brien S, Wierda WG, Pfeifer J, Majewski T, Czerniak BA, Jorgensen JL, Medeiros LJ, Freireich EJ, Keating MJ, Abruzzo LV. LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. Blood 117(15):4076-84, 2011. e-Pub 2011. PMID: 21310924.
356. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117(11):3016-24, 2011. e-Pub 2011. PMID: 21245487.
357. Badoux XC, Keating MJ, Wierda WG. What is the best frontline therapy for patients with CLL and 17p deletion?. Curr Hematol Malig Rep 6(1):36-46, 2011. e-Pub 2011. PMID: 21153774.
358. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1{alpha}) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 117(5):1662-9, 2011. e-Pub 2011. PMID: 21115978.
359. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB, Cortes J. Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. Blood 117(6):1822-7, 2011. e-Pub 2011. PMID: 21030554.
360. Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 117(1):156-64, 2011. e-Pub 2011. PMID: 20971952.
361. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM, Consortium CLL. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer 117(1):116-24, 2011. e-Pub 2011. PMID: 20806349.
362. Schweighofer CD, Coombes KR, Barron LL, Diao L, Newman RJ, Ferrajoli A, O'Brien S, Wierda WG, Luthra R, Medeiros LJ, Keating MJ, Abruzzo LV. A Two-Gene Signature, SKI and SLAMF1, Predicts Time-to-Treatment in Previously Untreated Patients with Chronic Lymphocytic Leukemia. PLoS One 6(12):e28277, 2011. e-Pub 2011. PMID: 22194822.
363. Parikh SA, Bhusal Y, Faderl SH, Wierda WG, O'Brien S, Kantarjian H, Adachi JA, Burger JA. The Great Imitator: Systemic Nocardiosis Mimicking Richter's Transformation in Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol 28(35):e732-4, 2010. e-Pub 2010. PMID: 20823404.
364. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116(22):4422-9, 2010. e-Pub 2010. PMID: 20668231.
365. Admirand JH, Knoblock RJ, Coombes KR, Tam C, Schlette EJ, Wierda WG, Ferrajoli A, O'Brien S, Keating MJ, Luthra R, Medeiros LJ, Abruzzo LV. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. Mod Pathol 23(11):1518-23, 2010. e-Pub 2010. PMID: 20657554.
366. Wierda WG, Castro JE, Aguillon R, Sampath D, Jalayer A, McMannis J, Prussak CE, Keating M, Kipps TJ. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia 24(11):1893-900, 2010. e-Pub 2010. PMID: 20882050.
367. Konoplev SN, Fritsche HA, O'Brien S, Wierda WG, Keating MJ, Gornet TG, St Romain S, Wang X, Inamdar K, Johnson MR, Medeiros LJ, Bueso-Ramos CE. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. Am J Clin Pathol 134(3):472-7, 2010. e-Pub 2010. PMID: 20716805.
368. Lahoti A, Kantarjian H, Salahudeen AK, Ravandi F, Cortes JE, Faderl S, O'Brien S, Wierda W, Mattiuzzi GN. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer 116(17):4063-8, 2010. e-Pub 2010. PMID: 20564156.
369. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070-7, 2010. e-Pub 2010. PMID: 20466853.
370. Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, Gandhi V. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood 116(7):1083-91, 2010. e-Pub 2010. PMID: 20442367.
371. Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics 5(6):499-508, 2010. e-Pub 2010. PMID: 20484983.
372. Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 28(24):3880-9, 2010. e-Pub 2010. PMID: 20660823.
373. Santos FP, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Ravandi F, Wierda W, Thomas D, Shan J, Cortes J. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol 150(3):303-12, 2010. e-Pub 2010. PMID: 20553275.
374. Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood 116(6):945-52, 2010. e-Pub 2010. PMID: 20393129.
375. Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, Badros AZ, Popplewell L, Coutre S, Fox JA, Mahadocon K, Chen T, Kegley P, Hoch U, Wierda WG. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 28(18):3015-22, 2010. e-Pub 2010. PMID: 20479412.
376. Faderl S, Ferrajoli A, Wierda W, O'Brien S, Lerner S, Keating MJ. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer 116(10):2360-5, 2010. e-Pub 2010. PMID: 20225334.
377. Koehrer S, Keating MJ, Wierda WG. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia 24(5):1096-8, 2010. e-Pub 2010. PMID: 20339441.
378. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A, Investigators HS. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28(10):1749-55, 2010. e-Pub 2010. PMID: 20194866.
379. Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. Leuk Res 34(3):284-8, 2010. e-Pub 2010. PMID: 19646755.
380. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw 8(3):288-334, 2010. e-Pub 2010. PMID: 20202462.
381. Alatrash G, Albitar M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol 148(3):386-93, 2010. e-Pub 2010. PMID: 19895616.
382. Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, Heerema N, Woodworth J, Hughes S, Tangri S, Harris S, Wynne D, Molina A, Leigh B, O'Brien S. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 115(3):489-95, 2010. e-Pub 2010. PMID: 19843887.
383. Al-Kali A, Wierda W, Keating M, O'Brien S. Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). J Blood Med 1:115-22, 2010. e-Pub 2010. PMID: 22282690.
384. Thomas DA, Kantarjian HM, Stock W, Heffner LT, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Pierce S, Lu B, Deitcher SR, O'Brien S. Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer 115(23):5490-8, 2009. e-Pub 2009. PMID: 19708032.
385. Wierda W, Kipps T, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabham S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell C, Osterborg A. Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine-and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab. Clin Lymphoma Myeloma 9(6):E36, 2009. e-Pub 2009. PMID: 19951868.
386. Badoux X, Tam C, Lerner S, Wierda W, Keating MJ. Outcome of First Salvage Therapy in Patients With Chronic Lymphocytic Leukemia Relapsing After First-line Fludarabine, Cyclophosphamide, and Rituximab. Clin Lymphoma Myeloma 9(6):E39-40, 2009. e-Pub 2009. PMID: 19951871.
387. Kurtova AV Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jager U, Gandhi V, Kay NE, Plunkett W, Burger JA. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 114(20):4441-50, 2009. e-Pub 2009. PMID: 19762485.
388. Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 114(19):4150-7, 2009. e-Pub 2009. PMID: 19734450.
389. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II Study of Alemtuzumab in Combination with Pentostatin in Patients with T-Cell Neoplasms. J Clin Oncol 27(32):5425-30, 2009. e-Pub 2009. PMID: 19805674.
390. Jain N, Wierda W, Ferrajoli A, Wong F, Lerner S, Keating M, O'Brien S. A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer 115(19):4533-9, 2009. e-Pub 2009. PMID: 19637351.
391. Schlette EJ, Admirand J, Wierda W, Abruzzo L, Lin KI, O'Brien S, Lerner S, Keating MJ, Tam C. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma 50(10):1597-605, 2009. e-Pub 2009. PMID: 19863337.
392. Jabbour E, Jones D, Kantarjian HM, O'Brien S, Tam C, Koller C, Burger JA, Borthakur G, Wierda WG, Cortes J. Long-term outcome of patients with chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood 114(10):2037-43, 2009. e-Pub 2009. PMID: 19567878.
393. Alvarado Y, Kantarjian H, O'Brien S, Faderl S, Borthakur G Burger J, Wierda W, Garcia-Manero G, Shan J, Cortes J. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115(16):3709-18, 2009. e-Pub 2009. PMID: 19517462.
394. Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O'Brien S, Ferrajoli A, Lerner SA, Lynn A, Kay NE, Keating MJ. De novo deletion 17p13,1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the MD Anderson and Mayo Clinic experience. Blood 114(5):957-64, 2009. e-Pub 2009. PMID: 19414856.
395. Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel Syk inhibitor, R406. Blood 114(5):1029-37, 2009. e-Pub 2009. PMID: 19491390.
396. Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 113(25):6330-37, 2009. e-Pub 2009. PMID: 18703706.
397. Quintas-Cardama A, Kantarjian H Ravnadi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115(11):2482-90, 2009. e-Pub 2009. PMID: 19280591.
398. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. Mechanism of action of SNS-032, a novel cyclin dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113(19):4637-45, 2009. e-Pub 2009. PMID: 19234140.
399. Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 113(22):5549-57, 2009. e-Pub 2009. PMID: 19318683.
400. Miller CP, Rudra S, Keating MJ, Wierda WG, Palladino M, Chandra J. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 113(18):4289-99, 2009. e-Pub 2009. PMID: 19182209.
401. Lin KI, Tam CS, Keating MJ, Wierda WG, O'Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 113(14):3168-71, 2009. e-Pub 2009. PMID: 19050308.
402. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics Associated With Important Clinical End Points in Patients With Chronic Lymphocytic Leukemia at Initial Treatment. J Clin Oncol 27(10):1637-43, 2009. e-Pub 2009. PMID: 19224852.
403. Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ, Rosenwald A. High-level expression of the T cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell co-cultures and after BCR stimulation. Blood 113(13):3050-8, 2009. e-Pub 2009. PMID: 19074730.
404. Jabbour E, Kantarjian HM, Jones D, Shan J, O'Brien S, Reddy N, Wierda WG, Faderl S, Garcia-Manero G, Verstovsek S, Rios MB, Cortes J. Imatinib mesylate dose escalation is associated with durable resonses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy. Blood 113(10):2154-60, 2009. e-Pub 2009. PMID: 19060245.
405. Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ. Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. J Clin Oncol 27(6):904-10, 2009. e-Pub 2009. PMID: 19114699.
406. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W, Ferrajoli A, Verstovsek S, Garcia-Manero G, Cortes J, Kantarjian H. Effective Treatment of Acute Promyelocytic Leukemia with ALL-Trans Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin. J Clin Oncol 27(4):504-10, 2009. e-Pub 2009. PMID: 19075265.
407. Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M. Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol 31(1):97-105, 2009. e-Pub 2009. PMID: 18190591.
408. Tsimberidou AM, Tam C, Abruzzo LV, O'Brien S, Wierda WG, Lerner S, Kantarjian HM, Keating MJ. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 115(2):373-80, 2009. e-Pub 2009. PMID: 19117034.
409. Balakrishnan K, Burger JA, Wierda WG, Gandhi V. AT-101 induces apoptosis in CLL B-cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 113(1):149-53, 2009. e-Pub 2009. PMID: 18836097.
410. Sargent R, Jones D, Abruzzo LV, Yao H, Bonderover J, Cisneros M, Wierda WG, Keating MJ, Luthra R. Customized Oligonucleotide Array-based Comparative Genomic Hybridization as a Clinical Assay for Genomic Profiling of Chronic Lymphocytic Leukemia. J Mol Diagn 11(1):25-34, 2009. e-Pub 2009. PMID: 19074592.
411. Wierda W. New prognostic factors in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 7(1):32-42, 2009. e-Pub 2009. PMID: 19274038.
412. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113(8):2090-6, 2008. e-Pub 2008. PMID: 18756533.
413. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 112(5):1971-80, 2008. e-Pub 2008. PMID: 18566329.
414. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, Keating MJ, Huang P. Effective Elimination of Fludarabine-Resistant CLL Cells by PEITC through a Redox-Mediated Mechanism. Blood 112(5):1912-22, 2008. e-Pub 2008. PMID: 18574029.
415. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112(5):1923-30, 2008. e-Pub 2008. PMID: 18577710.
416. Stock W, Undevia SD, Bivins C, Ravandi F, Odenike O, Faderl S, Rich E, Borthakur G, Godley L, Verstovsek S, Artz A, Wierda W, Larson RA, Zhang Y, Cortes J, Ratain MJ, Giles FJ. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs 26(4):331-8, 2008. e-Pub 2008. PMID: 18425419.
417. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Long term results of the fludarabine, cyclophosphamide & rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112(4):975-80, 2008. e-Pub 2008. PMID: 18411418.
418. Safdar A, Rodriguez GH, Rueda AM, Wierda WG, Ferrajoli A, Musher DM, O'Brien S, Koller CA, Bodey GP, Keating MJ. Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity. Cancer 113(2):383-7, 2008. e-Pub 2008. PMID: 18470901.
419. Ferrajoli A, Lee BN, Schlette EJ, O'Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111(11):5291-7, 2008. e-Pub 2008. PMID: 18334676.
420. Ghia EM, Jain S, Widhopf GF, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood 111(10):5101-8, 2008. e-Pub 2008. PMID: 18326815.
421. Ferrajoli A, Wierda WG, LaPushin R, O'Brien SM, Faderl S, Browning ML, Keating MJ. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Eur J Haematol 80(4):296-8, 2008. e-Pub 2008. PMID: 18182081.
422. Tam CS, Otero-Palacios J, Abruzzo LV, Jorgensen JL, Ferrajoli A, Wierda WG, Lerner S, O'Brien S, Keating MJ. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol 141(1):36-40, 2008. e-Pub 2008. PMID: 18324964.
423. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22(3):538-43, 2008. e-Pub 2008. PMID: 18079733.
424. Widhopf GF, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, Keating MJ, Gribben JG, Rai KR, Kipps TJ. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood 111(6):3137-44, 2008. e-Pub 2008. PMID: 17675554.
425. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating M. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111(4):1816-9, 2008. e-Pub 2008. PMID: 18039954.
426. Tsimberidou AM, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey EH. The Prognostic Significance of Serum {beta}2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 Patients. Clin Cancer Res 14(3):721-30, 2008. e-Pub 2008. PMID: 18245532.
427. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid (SAHA) in patients with advanced leukemias and myelodysoplastic syndromes. Blood 111(3):1060-6, 2008. e-Pub 2008. PMID: 17962510.
428. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 26(2):196-203, 2008. e-Pub 2008. PMID: 18182662.
429. Luqman M, Klabunde S, Lin K, Georgakis GV, Cherukuri A, Holash J, Goldbeck C, Xu X, Kadel EE, Lee SH, Aukerman SL, Jallal B, Aziz N, Weng WK, Wierda W, O'Brien S, Younes A. The anti-leukemia activity of a human anti-CD40 antagonist antibody, HCD122, a human chronic lymphocytic leukemia cells. Blood 112(3):711-20, 2008. e-Pub 2008. PMID: 18497318.
430. Borthakur G, Lin E, Faderl S, Ferrajoli A, Wierda W, Giles F, Browning ML, Kantarjian H, Keating M, O'Brien S. Low serum albumi level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies. Cancer 110(11):2478-83, 2007. e-Pub 2007. PMID: 17960607.
431. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S, Garcia-Manero G, Giles F, Breeden M, Reeves N, Wierda WG, Jones D. Dynamics of BCR-ABL kinase domain mutations in chronic lyeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110(12):4005-11, 2007. e-Pub 2007. PMID: 17785585.
432. Tsimberidou AM, Wen S, O'Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai CV, Rodriguez AM, Hess M, Do KA, Freireich EJ, Kantarjian HM, Medeiros LJ, Keating MJ. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol 25(29):4648-4656, 2007. e-Pub 2007. PMID: 17925562.
433. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, Cortes J, Wierda WG, Ouzounian S, Quezada A, Pierce S, Estey EH, Issa JP, Kantarjian HM, Garcia-Manero G. Safety and clinical activity of the combination of 5-azacytidine, valproic acid and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110(7):2302-2308, 2007. e-Pub 2007. PMID: 17596541.
434. Tam CS, O'Brien S, Lerner S, Khouri I, Ferrajoli A, Faderl S, Browning M, Tsimberidou AM, Kantarjian H, Wierda WG. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. Leuk Lymphoma 48(10):1931-1939, 2007. e-Pub 2007. PMID: 17917961.
435. Abruzzo LV, Barron LL, Anderson K, Newman RJ, Wierda WG, O'Brien S, Ferrajoli A, Luthra M, Talwalkar S, Luthra R, Jones D, Keating MJ, Coombes KR. Identification and validation of biomarkers of IgVH mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology. J Mol Diagn 9(4):546-55, 2007. e-Pub 2007. PMID: 17690214.
436. Wierda W, O'Brien S, Wang X, Faderl S, Ferrajoli A, K-A D, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109(11):4679-4685, 2007. e-Pub 2007. PMID: 17299097.
437. Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol 136(6):800-5, 2007. e-Pub 2007. PMID: 17341265.
438. Tam C, Wierda W, Lerner S, Keating M. Chronic lymphocytic leukemia: How do you assess prognosis in 2007?. Clinical Leukemia 1(3):162-167, 2007. e-Pub 2007.
439. Giles FJ, Borthakur G, Ravandi F, Faderl S, Verstovsek S, Thomas D, Wierda W, Ferrajoli A, Kornblau S, Pierce S, Albitar M, Cortes J, Kantarjian H. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136(4):624-7, 2007. e-Pub 2007. PMID: 17223919.
440. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Giles F, Thomas D, Wierda W, Cortes J. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 48(2):283-289, 2007. e-Pub 2007. PMID: 17325887.
441. Spoo AC, Lübbert M, Wierda WG, Burger JA. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 109(2):786-791, 2007. e-Pub 2007. PMID: 16888090.
442. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1):52-7, 2007. e-Pub 2007. PMID: 16882708.
443. Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL1 in B cell chronic lymphocytic leukemia. Blood 110(9):3316-25, 2007. e-Pub 2007. PMID: 17652619.
444. Wierda WG, Kipps J. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol 20(3):557-68, 2007. e-Pub 2007.
445. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 108(10):3271-9, 2006. e-Pub 2006. PMID: 16882711.
446. Yee K, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles F. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12(17):5163-5173, 2006. e-Pub 2006. PMID: 16951235.
447. Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O'Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 108(1):45-51, 2006. e-Pub 2006. PMID: 16403905.
448. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 107(1):125-35, 2006. e-Pub 2006. PMID: 16700034.
449. Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'Brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res 30(7):813-22, 2006. e-Pub 2006. PMID: 16478631.
450. Giles F, Verstovsek S, Garcia-Manero G, Thomas D, Ravandi F, Wierda W, Ferrajoli A, Kornblau S, Jabbour E, Shan J, O'brien S, Albitar M, Kantarjian H. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol 134(1):58-60, 2006. e-Pub 2006. PMID: 16803568.
451. Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O'Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer 106(12):2645-2651, 2006. e-Pub 2006. PMID: 16688777.
452. Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. Eradication of minimal residual disease in hairy cell leukemia. Blood 107(12):4658-62, 2006. e-Pub 2006. PMID: 16497968.
453. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7):1569-1580, 2006. e-Pub 2006. PMID: 16502413.
454. Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106(5):1090-8, 2006. e-Pub 2006. PMID: 16435386.
455. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 107(3):880-4, 2006. e-Pub 2006. PMID: 16123215.
456. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106(2):337-45, 2006. e-Pub 2006. PMID: 16353201.
457. Aribi A, Huh Y, Keating M, O'Brien S, Ferrajoli A, Faderl S, Wierda W, Kantarjian H Ravandi F. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. Leuk Res 31(7):939-45, 2006. e-Pub 2006.
458. Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, Thomas D, Faderl S, King I, O'Brien SM, Jeha S, Andreeff M, Cahill A, Sznol M, Giles FJ. Triapine and cytrarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res 30(7):813-22, 2006. e-Pub 2006.
459. Belov L, Mulligan S, Barber N, Woolfson A, Scott M, Stone K, Chrisp J, Sewell W, Bradstock K, Bendall L, Pascovici D, Thomas M, Erber W, Huang P, Sartor M, Young G, Wiley J, Juneja S, Wierda W, Green A, Keating M, Christopherson R. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br J Haematol 135(2):184-197, 2006. e-Pub 2006.
460. Wierda W, OBrien S, Faderl S, Ferrajoli A, Wang X, Do K, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of relapsed/refractory patients with chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106(2):337-345, 2006. e-Pub 2006.
461. Gandhi V, Kilpatrick JM, Plunkett W, Ayres M, Harman L, Du M, Bantia S, Davisson J, Wierda WG, Faderl S, Kantarjian H, Thomas D. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 106(13):4253-60, 2005. e-Pub 2005. PMID: 16131572.
462. Ravandi F, O'Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma 6(3):234-239, 2005. e-Pub 2005. PMID: 16354329.
463. Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ, Wierda WG. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 19(10):1788-93, 2005. e-Pub 2005. PMID: 16094420.
464. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 11(18):6615-24, 2005. e-Pub 2005. PMID: 16166440.
465. Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res 11(18):6745-6752, 2005. e-Pub 2005. PMID: 16166456.
466. Kantarjian HM, Bueso-Ramos CE, Talpaz M, O'Brien S, Giles F, Faderl S, Wierda W, Rios MB, Shan J, Cortes J. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer 104(4):777-780, 2005. e-Pub 2005. PMID: 15971197.
467. Keating MJ, Rai KR, Wierda WG. Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignancies. Clin Adv Hematol Oncol 3(8):1-10; quiz 11-2, 2005. e-Pub 2005. PMID: 16201050.
468. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23(18):4079-4088, 2005. e-Pub 2005. PMID: 15767648.
469. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23(18):4070-4078, 2005. e-Pub 2005. PMID: 15767647.
470. Giles FJ, Kantarjian HM, Cortes JE, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Mattiuzzi GN, Tsimberidou AM, Albitar M, O'Brien SM, Estey E. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes. Leuk Res 29(6):649-652, 2005. e-Pub 2005. PMID: 15863204.
471. Balakrishnan K, Stellrecht CM, Genini D, Ayres M, Wierda WG, Keating MJ, Leoni LM, Gandhi V. Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood 105(11):4455-4462, 2005. e-Pub 2005. PMID: 15718423.
472. Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105(3):940-7, 2005. e-Pub 2005. PMID: 15486072.
473. Carew JS, Nawrocki ST, Xu RH, Dunner K, McConkey DJ, Wierda WG, Keating MJ, Huang P. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia 18(12):1934-1940, 2004. e-Pub 2004. PMID: 15483672.
474. Widhopf G II, Rassenti L, Toy T, Gribben J, Wierda W, Kipps T. Chronic lymphocytic leukemia B cells of over one percent of patients express virtually identical immunoglobulins. Blood 104(8):2499-2504, 2004. e-Pub 2004. PMID: 15217828.
475. Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer 100(12):2583-2591, 2004. e-Pub 2004. PMID: 15197800.
476. Tsimberidou AM, Murray JL, O'Brien S, Wierda WG, Keating MJ. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer 100(10):2195-2200, 2004. e-Pub 2004. PMID: 15139064.
477. Giles FJ, Tallman MS, Garcia-Manero G, Cortes JE, Thomas DA, Wierda WG, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian HM. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer 100(7):1449-1458, 2004. e-Pub 2004. PMID: 15042679.
478. Mattiuzzi GN, Kantarjian H, Faderl S, Lim J, Kontoyiannis D, Thomas D, Wierda W, Raad I, Garcia-Manero G, Zhou X, Ferrajoli A, Bekele N, Estey E. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 100(3):581-589, 2004. e-Pub 2004. PMID: 14745876.
479. Kantarjian H, O'Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res 10(1 Pt 1):68-75, 2004. e-Pub 2004. PMID: 14734453.
480. Sneed TB, Kantarjian HM, Talpaz M, O'Brien S, Rios MB, Bekele BN, Zhou X, Resta D, Wierda W, Faderl S, Giles F, Cortes JE. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 100(1):116-121, 2004. e-Pub 2004. PMID: 14692031.
481. Wierda WG, Keating MJ, O’Brien S. Refractory chronic lymphocytic leukemia – prognosis and treatment options. Am J Cancer 3(3):163-178, 2004. e-Pub 2004.
482. Scappini B, Gatto S, Onida F, Ricci C, Divoky V, Wierda WG, Andreeff M, Dong L, Hayes K, Verstovsek S, Kantarjian HM, Beran M. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein. Cancer 100(7):1459-1471, 2004. e-Pub 2004. PMID: 15042680.
483. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Rios MB, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Keating M, Talpaz M. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 98(12):2636-2642, 2003. e-Pub 2003. PMID: 14669283.
484. O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98(12):2657-2663, 2003. e-Pub 2003. PMID: 14669286.
485. Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98(6):1105-1113, 2003. e-Pub 2003. PMID: 12973833.
486. McCarthy H, Wierda WG, Barron LL, Cromwell CC, Wang J, Coombes KR, Rangel R, Elenitoba-Johnson KS, Keating MJ, Abruzzo LV. High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor prognosis chronic lymphocytic leukemia. Blood 101(12):4903-4908, 2003. e-Pub 2003. PMID: 12586616.
487. Cortes J, Ault P, Koller C, Thomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L, Kaled ES, Kantarjian H. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood 101(12):4714-4716, 2003. e-Pub 2003. PMID: 12595304.
488. Garcia-Manero G, Talpaz M, Giles FJ, Cortes J, Faderl S, O'Brien S, Thomas D, Verstovsek S, Beth Rios M, Shan J, Ferrajoli A, Wierda W, Kantarjian HM. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside. Cancer 97(12):3010-3016, 2003. e-Pub 2003. PMID: 12784336.
489. Duzkale H, Pagliaro LC, Rosenblum MG, Varan A, Liu B, Reuben J, Wierda WG, Korbling M, McMannis JD, Glassman AB, Scheinberg DA, Freireich EJ. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biol Blood Marrow Transplant 9(6):364-372, 2003. e-Pub 2003. PMID: 12813444.
490. Battle TE, Wierda WG, Rassenti LZ, Zahrieh D, Neuberg D, Kipps TJ, Frank DA. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. Clin Cancer Res 9(6):2166-2172, 2003. e-Pub 2003. PMID: 12796382.
491. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 101(10):3794-3800, 2003. e-Pub 2003. PMID: 12560227.
492. Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101(9):3413-3415, 2003. e-Pub 2003. PMID: 12522009.
493. Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 97(9):2225-2228, 2003. e-Pub 2003. PMID: 12712475.
494. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O'Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 97(7):1711-20, 2003. e-Pub 2003. PMID: 12655528.
495. Kantarjian HM, O'Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 97(4):1033-1041, 2003. e-Pub 2003. PMID: 12569603.
496. Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O'Brien S, Giles FJ, Kantarjian H, Thomas D, Faderl S, Lerner S, Keating M, Albitar M. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol 120(3):452-6, 2003. e-Pub 2003. PMID: 12580959.
497. Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 8(7):2167-2176, 2002. e-Pub 2002. PMID: 12114417.
498. Cantwell MJ, Wierda WG, Lossos IS, Levy R, Kipps TJ. T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154. Leukemia 15(9):1451-1457, 2001. e-Pub 2001. PMID: 11516107.
499. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96(9):2917-2924, 2000. e-Pub 2000. PMID: 11049967.
500. Chu P, Wierda WG, Kipps TJ. CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes. Blood 95(12):3853-3858, 2000. e-Pub 2000. PMID: 10845920.
501. Wierda WG, Johnson BD, Dato ME, Kim YB. Induction of porcine granulocyte-mediated tumor cytotoxicity by two distinct monoclonal antibodies against lytic trigger molecules (PNK-E/G7). J Immunol 151(12):7117-7127, 1993. e-Pub 1993. PMID: 8258715.
502. Wierda WG, Johnson BD, Dato ME, Kim YB. Two distinct porcine natural killer lytic trigger molecules as PNK-E/G7 molecular complex. Cell Immunol 146(2):270-283, 1993. e-Pub 1993. PMID: 8174170.
503. Wierda WG, Kim YB, Halloran PJ. Enhancement of Natural-Killer-Cell Tumoricidal Activity by Monoclonal-Antibodies Against Unique Cytolytic Trigger Molecules. J Leukocyte Biology S:39, 1993. e-Pub 1993.
504. Dato ME, Wierda WG, Kim YB. A triggering structure recognized by G7 monoclonal antibody on porcine lymphocytes and granulocytes. Cell Immunol 140(2):468-477, 1992. e-Pub 1992. PMID: 1544170.
505. Kim JW, Wierda WG, Kim YB. Immobilized IgG immune complex induces secretion of tumor-necrosis-factor-alpha by porcine alveolar macrophages. Am J Respir Cell Mol Biol 5(3):249-255, 1991. e-Pub 1991. PMID: 1832880.
506. Johnson BD, Wierda WG, Kim YB. Further characterization of PNK-E: a monoclonal antibody enhancing porcine natural killer cell activity. Cell Immunol 134(2):378-389, 1991. e-Pub 1991. PMID: 2021974.
507. Wierda WG, Mehr DS, Kim YB. Comparison of fluorochrome-labeled and 51Cr-labeled targets for natural killer cytotoxicity assay. J Immunol Methods 122(1):15-24, 1989. e-Pub 1989. PMID: 2760476.

Invited Articles

1. Wierda WG. ASCO 2008 Editorial Season Review. e-Pub 2008.
2. Wierda WG. Treatments for Patients with Chronic Lymphocytic Leukemia. J Clin Oncology 2008 Educational Book 1(1):297-305, 2008. e-Pub 2008.
3. Wierda WG, Kipps TJ. Gene Therapy and Active Immune Therapy of Hematologic Malignancies. Best Pract Res Clin Haematol 20(3):557-568, 2007. e-Pub 2007. PMID: 17707840.
4. Aribi A, Huh Y, Keating M, O'Brien S, Ferrajoli A, Faderl S, Wierda W, Kantarjian H, Ravandi F. T-cell large granular lymphocytic (T-LGL) Leukemia: Experience in a single institution over 8 years. Leuk Res 31(7):939-945, 2007. e-Pub 2007. PMID: 17045649.
5. Aribi A, Huh Y, Keating M, O'Brien S, Ferrajoli A, Faderl S, Wierda W, Kantarjian H, Ravandi F. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. Leuk Res 31(7):939-945, 2007. e-Pub 2007.
6. Wierda WG, Kipps TJ. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol 20(3):557-568, 2007. e-Pub 2007.
7. Wierda WG, O'Brien SM. Initial therapy for patients with chronic lymphocytic leukemia. Semin Oncol 33(2):202-209, 2006. e-Pub 2006. PMID: 16616067.
8. Wierda WG. Current and investigational therapies for patients with CLL. Hematology Am Soc Hematol Educ Program:285-294, 2006. e-Pub 2006.
9. Tam C, Wierda W. Combining biologic agents in CLL - rationale and clinical status. Chronic Lymphocytic Leukemia - The Cutting Edge 11(3):7-10, 2006. e-Pub 2006.
10. Tam C, Wierda W. Salvage chemoimmunotherapy for patients with relapsed / refractory chronic lymphocytic leukemia. Am Jour of Onc Rev 5(8):2-5, 2006. e-Pub 2006.
11. Wierda WG. Current and investigational therapies for patients with CLL. Hematology Am Soc Hematol Educ Program:285-294, 2006. e-Pub 2006. PMID: 17124074.
12. Wierda WG, Kipps TJ, Keating MJ. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 23(26):6325-6332, 2005. e-Pub 2005. PMID: 16155015.
13. Carney DA, Wierda WG. Genetics and molecular biology of chronic lymphocytic leukemia. Curr Treat Options Oncol 6(3):215-225, 2005. e-Pub 2005. PMID: 15869733.
14. Keating MJ, Rai KR, Wierda WG. Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-part series: Advances in the treatment of hematologic malignancies. Clin Adv Hematol Oncol 3(8):1-10, 2005. e-Pub 2005.
15. Wierda WG. Novel combinations and schedules of alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: an update from ASH 2004. The Cutting Edge: Chronic Lymphocytic Leukemia 10(1):2-7, 2005. e-Pub 2005.
16. Wierda W, Schlette E, Al-Atrash G. Initial treatment of chronic lymphocytic leukemia: A case report. Biological Therapy of Lymphoma 8(4):6-9, 2005. e-Pub 2005.
17. Wierda WG, Keating MJ, OBrien, S. Refractory chronic lymphocytic leukemia: prognosis and treatment options. Am J Cancer 3(3):163-178, 2004. e-Pub 2004.
18. Wierda, WG, OBrien SM, Keating MJ. Rituximab in the management of patients with untreated or relapsed chronic lymphocytic leukemia. Monographs in Leukemia 5(1):8-14, 2004. e-Pub 2004.
19. Wierda WG. Immunologic monitoring in chronic lymphocytic leukemia. Curr Oncol Rep 5(5):419-425, 2003. e-Pub 2003. PMID: 12895395.
20. Wierda WG, O'Brien S. Immunotherapy of chronic lymphocytic leukemia. Expert Rev Anticancer Ther 1(1):73-83, 2001. e-Pub 2001. PMID: 12113136.
21. Kipps TJ, Chu P, Wierda WG. Immunogenetic therapy of B-cell malignancies. Semin Oncol 27(6 Suppl 12):104-109, 2001. e-Pub 2001.
22. Wierda WG, Kipps TJ. Gene therapy of hematologic malignancies. Semin Oncol 27(5):502-511, 2000. e-Pub 2000. PMID: 11049018.
23. Wierda WG, Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol 6(4):253-261, 1999. e-Pub 1999. PMID: 10400375.
24. Kim YB, Dato ME, Johnson BD, Wierda WG. Development and regulation of porcine natural killer cells. Proceedings of Xth International Symposium on Gnotobiology, 1990. e-Pub 1990.
25. Wierda WG, Kim YB. Cell-mediated cytotoxicity assay for simultaneous and direct measure of two target killing. 1990 Pandex Users Symposium. Pandex Division, Baxter Healthcare Corporation, Mundelein, IL:11-19, 1990. e-Pub 1990.

Other Articles

1. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia. Leukemia 39(2):529, 2025. PMID: 39627506.
2. Jain N, Wierda WG, O'Brien S Chronic lymphocytic leukaemia. Lancet 404(10453):694-706, 2024. PMID: 39068951.
3. Cacace F, Iula R, De Novellis D, Caprioli V, D'Amico MR, De Simone G, Cuccurullo R, Wierda WG, Mahadeo KM, Menna G, Tambaro FP High-Risk Acute Myeloid Leukemia: A Pediatric Prospective. Biomedicines 10(6), 2022. PMID: 35740427.
4. Sharman JP, Biondo JML, Boyer M, Fischer K, Hallek M, Jiang D, Kater AP, Porro Lura M, Wierda WG A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies. EJHaem 3(2):492-506, 2022. PMID: 35846043.
5. Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, Jabbour EJ The cure of leukemia through the optimist's prism. Cancer 128(2):240-259, 2022. PMID: 34614211.
6. De Novellis D, Cacace F, Caprioli V, Wierda WG, Mahadeo KM, Tambaro FP The TKI Era in Chronic Leukemias. Pharmaceutics 13(12), 2021. PMID: 34959482.
7. Wierda WG, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown JR, Egle A, Abello V, Cervera Ceballos E, Herishanu Y, Mulligan SP, Niemann CU, Diong CP, Soysal T, Suzuki R, Tran HTT, Wu SJ, Owen C, Stilgenbauer S, Ghia P, Hillmen P Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia 35(11):3059-3072, 2021. PMID: 34168283.
8. Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Tejada FNH, Martin PL, Auletta J, Choi SW, Bajwa R, Garnes ND, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM Author Correction: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):468, 2021. PMID: 33731864.
9. Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Hernandez Tejada FN, Martin PL, Auletta J, Choi SW, Bajwa R, Dailey Garnes N, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):435-453, 2021. PMID: 33608690.
10. Paul S, Rausch CR, Jain N, Kadia T, Ravandi F, DiNardo CD, Welch MA, Dabaja BS, Daver N, Garcia-Manero G, Wierda W, Pemmaraju N, Montalban Bravo G, Thompson P, Verstovsek S, Konopleva M, Kantarjian H, Jabbour E Treating Leukemia in the Time of COVID-19. Acta Haematol 144(2):132-144, 2021. PMID: 32392559.
11. Tambaro FP, De Novellis D, Wierda WG The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View. J Exp Pharmacol 13:923-935, 2021. PMID: 34744463.
12. Abbas HA, Wierda WG Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies. Front Oncol 11:668162, 2021. PMID: 34055635.
13. Tambaro FP, Khazal S, Nunez C, Ragoonanan D, Tewari P, Petropoulos D, Kebriaei P, Wierda WG, Mahadeo KM Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy. Clin Case Rep 8(9):1678-1681, 2020. PMID: 32983475.
14. Wierda WG, Tambaro FP How I manage CLL with venetoclax-based treatments. Blood 135(17):1421-1427, 2020. PMID: 32076705.
15. Tambaro FP, Wierda WG Tumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations. Lancet Haematol 7(2):e168-e176, 2020. PMID: 32004486.
16. Shah M, Rajha E, DiNardo C, Muckey E, Wierda WG, Yeung SJ Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. Ann Emerg Med 75(2):264-286, 2020. PMID: 31561995.
17. Yalniz FF, Wierda WG Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies. Drugs 79(12):1287-1304, 2019. PMID: 31313099.
18. Neelapu SS, Tummala S, Kebriaei P, Wierda WG, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47-62, 2018. PMID: 28925994.
19. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K Chronic lymphocytic leukaemia. Nat Rev Dis Primers 3:16096, 2017. PMID: 28102226.
20. Sanford DS, Wierda WG, Burger JA, Keating MJ, O'Brien SM Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice. Clin Lymphoma Myeloma Leuk 15(7):385-91, 2015. PMID: 25817936.
21. Shah N, Rezvani K, Hosing C, Kebriaei P, Wierda W, Cooper L, Shpall E Progress in Novel Cellular Therapy Options for Chronic Lymphocytic Leukemia: The MD Anderson Perspective. Clin Lymphoma Myeloma Leuk 14S(Suppl):S18-S22, 2014. PMID: 25486950.
22. Wierda WG, Chiorazzi N, Dearden C, Brown JR, Montserrat E, Shpall E, Stilgenbauer S, Muneer S, Grever M Chronic lymphocytic leukemia: new concepts for future therapy. Clin Lymphoma Myeloma Leuk 10(5):369-78, 2010. PMID: 21030350.
23. Parikh SA, Wierda WG Role of CD20 monoclonal antibodies in previously untreated chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 10 Suppl 1:S27-33, 2010. PMID: 20529805.
24. Burger JA, Velev NS, Jabbour EJ, Wierda WG, Ravandi F, Cortes JE, Kantarjian H, Nieto YL, Shpall EJ, Jorgensen JL Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia 24(3):666-8, 2010. PMID: 20054352.
25. Quintás-Cardama A, Wierda W, O'Brien S Investigational Immunotherapeutics for B-Cell Malignancies. J Clin Oncol 28(5):884-92, 2010. PMID: 20048186.
26. Motta M, Wierda WG, Ferrajoli A Chronic lymphocytic leukemia: treatment options for patients with refractory disease. Cancer 115(17):3830-41, 2009. PMID: 19536902.
27. Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 113(S7):1933-1952, 2008. PMID: 18798533.
28. Gollard R, Wierda W, Trent J Chronic myeloid leukemia and gastrointestinal stromal tumor: simultaneous presentation. J Clin Oncol 25(29):4682-4683, 2007. PMID: 17925564.
29. Wierda W NIH 101: Challenges of research funding. ASH News Daily 3:A-14, 2006.
30. Rytting ME, Wierda WG Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy. Leuk Lymphoma 45(8):1623-1626, 2004. PMID: 15370215.
31. Kipps TJ, Chu P, Wierda WG Immunogenetic therapy for B-cell malignancies. Semin Oncol 27(6 Suppl 12):104-9, 2000. PMID: 11225994.

Editorials

1. Allan JN, Flinn IW, Siddiqi T, Ghia P, Tam CS, Kipps TJ, Barr PM, Elinder Camburn A, Tedeschi A, Badoux XC, Jacobs R, Kuss BJ, Trentin L, Zhou C, Szoke A, Abbazio C, Wierda WG. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia. Clin Cancer Res 29(14):2593-2601, 2023. PMID: 37282671.
2. Wierda WG. Ibrutinib Plus Venetoclax for First-Line Chronic Lymphocytic Leukemia Treatment. NEJM Evid 1(7):EVIDe2200093, 2022. PMID: 38319264.
3. Wierda WG. Making Advances in First-Line Chronic Lymphocytic Leukemia Treatment. J Clin Oncol 30(26):3162-4, 2012. PMID: 22869876.
4. Wierda W, Al-Atrash G. ASH/EHA Policy Forum: Roadmaps? We Need GPS Navigation?. The Hematologist 4(1):2, 2007.

Abstracts

1. Short NJ, Jabbour EJ, Senapati J, Nasr LF, Haddad FG, Li Z, Hsiao Y, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian HM. A Phase 1/2 Study of Mini-Hyper-CVD plus Venetoclax in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood Advances 8(4):909-915, 2024. e-Pub 2024. PMID: 38207208.
2. Thompson PA, Bazinet A, Wierda WG, Tam CS, O’Brien SM, Saha S, Peterson CB, Plunkett W, Keating MJ. Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up. Blood 142(Issue 21):1784-1788, 2023. e-Pub 2023. PMID: 37595283.
3. Haddad F, Jabbour E, Zoghbi M, Short N, Senapati J, Macaron W, Nasnas C, Nasr L, Pemmaraju N, Jain N, Wierda WG, Borthakur G, Montalban-Bravo G, Ravandi F, Garcia-Manero G, Kadia T, Chien K, Thankachan J, Garris R, Kantarjian H. A Phase II Trial of Mini-Hyper-CVD with Venetoclax for Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (All). EHA Library, 2023. e-Pub 2023.
4. Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Wierda WG, Ghia P. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood 139(22):3278-3289, 2022. e-Pub 2022.
5. Siddiqi T, JDi S, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang K, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 139(12):1794-1806, 2022. e-Pub 2022.
6. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, WG <. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 139(12):1794-1806, 2022. e-Pub 2022.
7. Jain N, MD, Keating MJ, MBBS, Thompson PA, MBBS, Burger JA, PhD MD, Ferrajoli A, MD, Estrov ZE, MD, Borthakur GM, MD, Takahashi K, MD, Bose P, MD, Fowler NH, MD, Kadia TM, MD, Daver NG, MD, Konopleva MY, PhD MD, Alvarado Y, MD, Yilmaz M, MD, DiNardo CD, MSc MD, Ohanian M, DO, Pemmaraju N, MD, Jabbour E, MD, Sasaki K, MD, Kanagal-Shamanna R, MD, Patel K, PhD MD, Jorgensen JL, PhD MD, Wang SA, MD, Garg N, MD, Wang X, MS, Sondermann K, BA, Cruz N, RN, Wei C, PhD, Ayala A, RN, Plunkett W, PhD, Kantarjian HM, MD, Gandhi V, PhD, Wierda WG, PhD MD. Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 2019. e-Pub 2019.
8. Parry E, PhD MD, Lemvigh CK, MSc, Anandappa AJ, MD, Li S, PhD, Werner L, MS, Lako A, Purroy N, PhD MD, Gohil SH, PhD, MB, BS, Oliveira G, PhD, Bachireddy P, MD, Huang T, Leshchiner I, PhD, Martinez AZ, Olsen LR, PhD, Livak K, PhD, Getz G, PhD, Neuberg DS, ScD, Rodig SJ, PhD MD, Wierda WG, PhD MD, Kharchenko P, PhD, Jain N, MD, Wu CJ, MD. T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation. Blood, 2019. e-Pub 2019.
9. Sivina M, Duncan G, MSc, Sakamoto T, PhD MD, Kim E, MS, Vaca A, PhD, Hartmann EM, MD, Keating MJ, MBBS, Ferrajoli A, MD, Wierda WG, PhD MD, Mak T, DSc P, Rosenwald A, MD, Burger JA, PhD MD. Ibrutinib Therapy Downregulates Toso, the Fcr for IgM, Expression in CLL Patients. Blood, 2019. e-Pub 2019.
10. Giacopelli B, Zhao Q, Ruppert A, Agyeman A, Weigel C, Wu YZ, Gerber M, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda, WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC. Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood 134(8):688-698, 2019. e-Pub 2019.
11. Wierda W, Byrd J, Chanan-Khan A, Burger J, Cramer P, Tedeschi A, Brown J, Barr P, O'Brien S, Demirkan F, Barrientos J, Fraser G, Robak T, Phelps C, Howes A, Zhou C, Dean J, James D, Hillmen P, Kipps T, Hallek M. Analysis of Sustained Hematologic Improvement with Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. EHA Library:PF352, 2018. e-Pub 2018.
12. Wierda W, Sail K, Potluri J, Noe L, Kamalakar R, Gdovin J, Humerickhouse R, Verdugo M. Impact of Venetoclax on the Quality of Life of CLL Patients Relapsed/Refractory to B-Cell Receptor (BCR) Signaling Pathway Inhibitor Treatment. EHA Library, 2017. e-Pub 2017.
13. Wierda W, Sail K, Noe S, Kamalakar R, Gdovin J, Verdugo M, Kim S, Humerickhouse R, Stilgenbauer S. Impact of Venetoclax on the Quality of Life of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of A Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy. EHA Library, 2017. e-Pub 2017.
14. Wierda W, Jones J, Furman R, Stephens D, Devereux S, Brown J, Hillmen P, Hamdy A, Fardis M, Tawashi M, Wang MH, Patel P, Mittag D, Krantz F, Rothbaum W, Izumi R, O'Brien S, Byrd J. Acalabrutinib, A Second-Generation Bruton Tyrosine Kinase (BTK) Inhibitor, in Previously Untreated Chronic Lymphocytic Leukemia (CLL). EHA Library, 2016. e-Pub 2016.
15. DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Wei Y, Wierda WG, Bueso-Ramos CE, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero G. A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood 124(21), 2014. e-Pub 2014.
16. Jabbour E, Kantarjian HM, Thomas D, Sasaki K, Ravandi F, Cortes JE, Pemmaraju N, Kadia T, Garris R, Garcia-Manero G, Borthakur G, Wierda WG, O’Brien S. Phase II Study of Combination of Hypercvad with Ponatinib in Front Line Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood 124(21), 2014. e-Pub 2014.
17. Takahashi K, Kantarjian HM, Jain P, Jabbour E, Wierda WG, Pemmaraju N, Ferrajoli A, Dellasala SE, Pierce SR, Verstovsek S, Ravandi F, O’Brien S, Cortes JE. Propensity Score Matched Comparison of Dasatinib and Nilotinib As a Frontline Therapy in Newly Diagnosed CML with Chronic Phase. Blood 124(21), 2014. e-Pub 2014.
18. Duque AD, Randhawa J, Kantarjian HM, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Gandhi V, Borthakur G, Cortes JE. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Refractory / Relapsed AML. Blood 124(21), 2014. e-Pub 2014.
19. Jabbour E, Kantarjian HM, Thomas DA, Ravandi F, Cortes JE, Faderl S, Pemmaraju N, Kadia TM, Garris RS, Garcia-Manero G, Borthakur G, Wierda WG, O'Brien SM. Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology 31, 2013. e-Pub 2013.
20. Davids MS, Seymour JF, Gerecilano JF, Kahl BS, Pagel JM, Wierda WG, Anderson MA, Darden DE, Nolan CE, Gressick LA, Yang J, Chyla BJ, Busman TA, Graham AM, Cerri E, Enchede SH, Humerickhouse RA, Roberts AW. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology 31, 2013. e-Pub 2013.
21. Davids MS, Seymour JF, Gerecilano JF, Kahl BS, Pagel JM, Wierda WG, Anderson MA, Darden DE, Nolan CE, Gressick LA, Yang J, Chyla BJ, Busman TA, Graham AM, Cerri E, Enchede SH, Humerickhouse RA, Roberts AW. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology 31, 2013. e-Pub 2013.
22. Falchi L, Keating MJ, Wang X, Schlette EJ, Sargent RL, Marom EM, Truong M, Wierda WG, Ferrajoli A. Predictors of survival in patients with transformed chronic lymphocytic leukemia (TC). Journal of Clinical Oncology 31, 2013. e-Pub 2013.
23. Hoellenriegel J, O'Brien S, Keating MJ, Wierda WG, Buggy JJ, Burger JA. In Vivo Inhibition of BCR Activation in High-Risk CLL Patients On Therapy with Bruton's Tyrosine Kinase Inhibitor Ibrutinib: Correlative Studies from an Ongoing Phase 2 Clinical Trial. Blood 120, 2012. e-Pub 2012.
24. Takahashi K, Kantarjian HM, Abruzzo LV, Borthakur G, Garcia-Manero G, O'Brien S, Faderl S, Luthra R, Wierda WG, Ferrajoli A, Pierce SA, Ravandi F, Cortes JE. Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis. Blood 120, 2012. e-Pub 2012.
25. Trinh LX, Chae YK, Jain P, Benjamini O, Wang X, Lerner S, Wierda WG, Estrov Z, Keating MJ. Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL. Blood 120, 2012. e-Pub 2012.
26. Keating MJ, Tam CS, Wierda WG, O'Brien S, Thomas DA, Cortes JE, Lerner S, Plunkett W. Is Chronic Lymphocytic Leukemia Still Incurable?. Blood 120, 2012. e-Pub 2012.
27. Claus R, Ruppert AS, Lucas DM, Zucknick M, Rassenti LZ, Greaves A, Neubert DS, Wierda WG, Keating MJ, Brown JR, Gribben JG, Rai KR, Grever MR, Kay NE, Kipps TJ, Plass C, Byrd JC. The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. Blood 120, 2012. e-Pub 2012.
28. Ferrajoli A, Falchi L, O'Brien S, Wierda WG, Faderl S, Smith SC, Ayala AB, Kantarjian HM, Keating MJ. Combination of Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial. Blood 120, 2012. e-Pub 2012.
29. Falchi L, Keating MJ, Lerner S, Wang X, Stron SS, Wierda WG, Ferrajoli A. Other Cancers in Patients with Chronic Lymphocytic Leukemia Requiring Therapy: Association with Prognostic Factors and Impact on Survival. Blood 120, 2012. e-Pub 2012.
30. Uri R, Harris D, Li P, Liu Z, Grgurevic S, Lerner S, Martinez M, Wierda WG, Keating M, Estrov Z. Spontaneous Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells Correlates with Disease Burden and Inversely Correlates with Intracellular Levels of Signal Transducer and Activator of Transcription-3 (STAT3). Blood 120, 2012. e-Pub 2012.
31. Tambaro FP, Garcia-Manero G, Qiao W, Pierce SA, Ripaldi M, Faderl S, Kantarjian HM, Wierda WG, Cortes JE. A Prognostic Score System for Survival in Secondary AML: Review of 1073 Patients Observed At MDACC. Blood 120, 2012. e-Pub 2012.
32. Byrd JC, Furman RR, Coutre S, Flinn IW, Burger JA, Blum KA, Sharman J, Grant B, Jones JA, Wierda WG, Zhao W, Heerema NA, Johnson AJ, Tran A, Clow F, Kunkel L, James DF, O'Brien S. The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or SMall Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study. Blood 120, 2012. e-Pub 2012.
33. Burger JA, Keating MJ, Wierda WG, Hoellenriegel J, Ferrajoli A, Faderl S, Lerner S, Zacharian G, Huang X, James DF, Buggy JJ, Kantarjian HM, O'Brien SM. The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients. Blood 120, 2012. e-Pub 2012.
34. Strati P, Abruzzo LV, Wierda W, Lerner S, O'Brien SM, Kantarjian HM, Ferrajoli A, Keating MJ. Biological and Clinical Features of Patients with Chronic Lymphocytic Leukemia Bearing Trisomy 12. Blood 120, 2012. e-Pub 2012.
35. Yi A, CY, Kantarjian HM, Garcia-Manero G, Wierda WG, Borthakur G, Quintas-Cardama A, Konopleva M, Faderl S, Pierce SA, Andreeff M, Ravandi F, Cortes JE. Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies. Blood 120, 2012. e-Pub 2012.
36. Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Konopleva M, Ravandi F, Garcia-Manero G, Kadia TM, Borthakur G, Burger JA, Verstovsek S, Ferrajoli A, Wierda WG, Garris R, Wang SA, Estrov Z, Cortes JE, O'Brien S. Outcomes Continue to Be Favorable for De Novo Philadelphia Chromosome Negative B-Lymphoblastic Leukemia (ALL) After Therapy with Hyper-CVAD (with or without Rituximab) Regimen. Blood 120, 2012. e-Pub 2012.
37. Rozovski U, Calin G, Tetsirp S, D'Abundo L, Harris D, Li P, Liu Z, Grgurevix S, Ferrajoli A, Faderl S, Burger JA, O'Brien SM, Wierda WG, Keating MJ, Estrov Z. Signal Transducer and Activator of Transcription (STAT)-3-Dependent Regulation of Non-Coding RNA Genes in Chronic Lymphocytic Leukemia (CLL). Blood 120, 2012. e-Pub 2012.
38. Kohrer S, Coffey G, Kim E, Rosin NY, Sinha U, Pandey A, Shehata M, Jager U, O'Brien SM, Wierda WG, Estrov Z, Thomas D, Kantarjian HM, Burger JA. Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL). Blood 120, 2012. e-Pub 2012.
39. Rosin NY, Koehrer S, Kim E, O'Brien S, Wierda WG, Thomas DA, Estrov Z, Kantarjian HM, Lannutti BJ, Burger JA. In Vitro Effects of Pi3K/Inhibitor GS 1101 (CAL-101) in Acute Lymphoblastic Leukemia (ALL). Blood 120, 2012. e-Pub 2012.
40. Romo CG, Kantarjian HM, O'Brien S, Quintas-Cardama A, Kornblau SM, Faderl S, Ferrajoli A, Wierda WG, Pierce SA, Jabbour EJ, Cortes JE. Results of Second Generation Tyrosine Kinase Inhibitor Frontline Therapy in Chronic Myeloid Leukemia with Variant Philadelphia Chromosome. Blood 120, 2012. e-Pub 2012.
41. Jain P, Trinh LX, Benjamini O, Lerner S, Wang X, Ferrajoli, Burger JA, Estrov Z, Wierda WG, Kantarjian HM, O'Brien S, Abruzzo LV, Keating MJ. Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation - Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality. Blood 120, 2012. e-Pub 2012.
42. Takahashi K, Jabbour EJ, Wang X, Ghanem H, Pemmaraju N, Ravandi F, Cortes JE, Faderl S, Kadia TM, Borthakur G, Wierda WG, Pierce SA, Estrov Z, Kantarjian HM, Garcia-Manero G. Very High Rate of Leukemic Tranformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis. Blood 120, 2012. e-Pub 2012.
43. Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O'Brien SM, Kornblau SM, Kantarjian HM, Lee BN, Ferrajoli A. Long-Lasting Responses with Lenalidomide As Initial Therapy of Elderly Patients with Chronic Lymphocytic Leukemia (CLL). Blood 120, 2012. e-Pub 2012.
44. Seymour JF, Davids MS, Anderson MA, Kipps TJ, Wierda WG, Pagel JM, Kahl BS, Miller TP, Darden DE, Nolan CE, Gressick LA, Xiong H, Huang DCS, Chyla BJ, Busman TA, Graham AM, Cerri E, Enchede SH, Humerickhouse RA, Roberts AW. The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study. Blood 120, 2012. e-Pub 2012.
45. Falchi L, Keating MJ, Badoux XC, Wierda WG, O'Brien SM, Smith SC, Wen S, Kantarjian H, Ferrajoli A. Phase II trial of the combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). J Clin Oncol 30, 2012. e-Pub 2012.
46. Wierda WG, O'Brien SM, Faderl S, Ferrajoli A, Burger JA, Estrov Z, Tambaro FP, Kadia TM, Lerner S, Kantarjian H, Keating MJ. Pretreatment prognostic factors associated with outcomes for first-line FCR-based treatments in previously untreated CLL. J Clin Oncol 30, 2012. e-Pub 2012.
47. Osterberg A, Dyer MJS, Mayer J, Hess G, Hillmen P, Schetelig, Schuh A, Smolej L, Beck C, Dreyfus B, Hellman A, Koslowski P, Pfreundschuh M, Rizzi R, Spacek M, Chan G, Gupta I, Phillips J, Lisby S, Wierda WG. Ofatumumab retreatment and maintenance in patients with fludarabine-refractory CLL. J Clin Oncol 30, 2012. e-Pub 2012.
48. Tambaro FP, Wierda WG, Garcia-Manero G, Cortes JE, Pierce S, Annunziata M, Ripaldo M, Borthakur G, Jabbour E, Randi F, Faderl S, Kantarjian H. Factors associated with outcome of secondary MDS and AML: Review of 2,182 patients at MDACC. J Clin Oncol 30, 2012. e-Pub 2012.
49. Lee HJ, Wierda WG, Ferrajoli A, Burger JA, Trinh L, Lerner S, Keating MJ, O'Brien SM. Comparison of fludarabine (F), cyclophosphamide (C), and rituximab (R) versus FCR plus bevacizumab (B) in relapse chronic lymphocytic leukemia (CLL). J Clin Oncol 30, 2012. e-Pub 2012.
50. Ravandi F, Kadia TM, Borthakur G, Wierda WG, Goldberg SL, Wetzler M, Venugopal P, Seiter K, Chiao J, Kantarjian HM. Pooled Analysis of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. Blood 120, 2012. e-Pub 2012.
51. Wierda WG, Balakrishnan K, Ferrajoli A, O'Brien S, Burger JA, Kadia TM, Cortes JE, Tambaro FP, Jalayer A, Lerner S, Keating MJ, Gandhi VV. Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy. Blood 120, 2012. e-Pub 2012.
52. Tambaro FP, Wierda WG, Pierce S, Yang H, Wei Y, Fang Z, Kantarjian HM, Garcia-Manero G. ROS Activation Independent From Iron Overload in MDS. Blood 118, 2011. e-Pub 2011.
53. Ravandi F, Faderl S, Cortes JE, Garcia-Manero G, Jabbour E, Boone PA, Kadia TM, Borthakur G, Wierda WG, Chiao JH, Kantarjian H. Phase I/II Study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 29, 2011. e-Pub 2011.
54. Quintas-Cardama A, Kim H, Shan J, Jabbour E, Faderl S, Wierda WG, Ravandi F, Kadia T, Wang SA, Pierce S, Kantarjian HM, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia. Blood 118, 2011. e-Pub 2011.
55. Quintas-Cardama A, Kantarjian H, Luthra R, O'Brien S, Jabbour E, Borthakur G, Ravandi F, Garcia-Manero G, Faderl S, Konopleva M, Wierda WG, Burton E, Cortes JE. Efficacy of Frontline Nilotinib Therapy in Patients (Pts) with Newly Diagnosed Philadephia Chromosome (Ph)-Positive Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP). Blood 118, 2011. e-Pub 2011.
56. Ferrajoli A, O'Brien S, Wierda WG, Faderl S, Badoux X, Estrov Z, Schlette E, Smith SC, Ayala AB, Falchi L, Calin S, Kantarjian H, Keating MJ. Combination Therapy with Ofatumumab and Lenalidomide in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): Results of a Phase II Trial. Blood 118, 2011. e-Pub 2011.
57. Wierda WG, Jewell RC, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Smolej L, Hess G, Hernandez-Illizaliturri FJ, Padmanabhan S, Lei F, Gorczyca MM, Chan GW, Gupta IV, Lisby S. Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy. Blood 118, 2011. e-Pub 2011.
58. Badoux SC, Keating MJ, O'Brien S, Wierda WG, Faderl S, Estrov Z, Pasia M, Lerner S, Sargent RL, Kantarjian HM, Ferrajoli A. Final Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Blood 118, 2011. e-Pub 2011.
59. Thomas DA, Kantarjian HM, Faderl S, Wierda WG, Jabbour E, Garcia-Manero G, Ferrajoli A, Verstovsek S, Burger JA, Fayad L, Romaguera JE, Garris R, Cortes JE, O'Brien S. Hyper-CVAD and Rituximab for De Novo Burkitt Lymphoma/Leukemia. Blood 118, 2011. e-Pub 2011.
60. James DF, Brown JR, Werner L, Wierda WG, Barrientos JC, Castro J, Greaves A, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ. Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium. Blood 118, 2011. e-Pub 2011.
61. Lee HJ, Kantarjian HM, Thomas DA, Faderl S, Koller C, Ferrajoli A, Jabbour E, Garris R, Kebriaei P, Champlin R, Borthakur G, Wierda WG, Burger JA, Cortes JE, O'Brien S, Ravandi F. Long-Term Follow-up of Combined Bypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). Blood 118, 2011. e-Pub 2011.
62. Lee HJ, O'Brien S, Kantarjian HM, Ravandi F, Faderl S, Koller C, Konopleva M, Verstovsek S, Kadia T, Garcia-Manero G, Borthakur G, Wierda WG, Burger JA, Thomas DA, Cortes JE. Outcome of Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Relapse AFter Tyrosine Kinase Inhibitor (TKI) Therapy. Blood 118, 2011. e-Pub 2011.
63. Thomas DA, Kantarjian HM, Jorgensen JL, Faderl S, Jabbour E, Wierda WG, Ravandi F, Verstovsek S, Garcia-Manero G, Koller CA, Burger JA, Ferrajoli A, Konopleva M, Kadia T, Borthakur G, Kornblau SM, Andreeff M, Garris R, Cortes JE, O'Brien S. Outcomes for Adult Lymphoblastic Leukemia (ALL) Are Mainly Influenced by Age and Status of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) After Therapy with the Modified Hyper-CVAD (with or without Rituximab) Regimen. Blood 118, 2011. e-Pub 2011.
64. Kadia T, Delioukina ML, Kantarjian HM, Keating MJ, Wierda WG, Burger JA, Wieland S, Levitt D. A Pilot Phase II Study of the Lyn Kinase Inhibitor Befetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia. Blood 118, 2011. e-Pub 2011.
65. Garcia-Manero G, Estey EH, Jabbour E, Borthakur G, Kadia T, Naqvi K, Levine RL, Estrov Z, Quintas-Cardama A, Konopleva M, Faderl S, Tanaka M, Yang H, Ravandi F, Wierda WG, Cortes JE, Boone PA, Kantarjian HM. Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities. Blood 118, 2011. e-Pub 2011.
66. Alattar ML, Kantarjian HM, Jabbour E, Quintas-Cardama A, Burton EM, Borthakur G, Verstovsek S, Wierda WG, Konopleva M, Burger JA, O'Brien S, Cortes JE. Clinical Significance of Complete Cytogenetic Response (CCyR) and Major Molecular Response (MMR) Achieved with Different Treatment Modalities Used As Frontline Therapy In Chronic Myeloid Leukemia (CML) Chronic Phase (CP). Blood 118, 2011. e-Pub 2011.
67. Ravandi F, Faderl S, Cortes JE, Garcia-Manero G, Jabbour E, Boone PA, Kadia T, Borthakur G, Wierda WG, Wetzler M, Venugopal P, Chiao J, Kantarjian HM. Phase 1/2 Study of Sapacitabine and Decitabine Administered Sequentially in Elderly Patients with Newly Diagnosed AML. Blood 118, 2011. e-Pub 2011.
68. Cortes JE, Garcia-Manero G, Ravandi F, Andreef M, Borthakur G, Jabbour E, Konopleva M, O'Brien S, Quintas-Cardama A, Verstovsek S, Wierda WG, Kantarjian HM. Safety, Pharmacokinetics, and Efficacy of BP-100.1.01 (L-Grb-2 Antisense Oligonucleotide) in Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelegenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and Myelodysplastic Syndrome (MDS). Blood 118, 2011. e-Pub 2011.
69. Ponader S, Balasubramanian S, Pham LV, Chen J, Tamayo AT, Wang M, O'Brien S, Wierda WG, Keating MJ, Ford RJ, Burger JA. Activity of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Mantle Cell Lymphoma (MCL) Identifies Btk As a Novel Therapeutic Target. Blood 118, 2011. e-Pub 2011.
70. Naqvi K, Kantarjian HM, Luthra R, Jabbour E, O'Brien S, Burton EM, Verstovsek S, Ravandi F, Wierda WG, Borthakur G, Quintas-Cardama A, Cortes JE. Kinetics of Molecular Response with Different Tyrosine Kinase Inhibitors (TKI) Used As Frontline Therapy in Chronic Myeloid Leukemia-Chronic Phase (CML CP). Blood 118, 2011. e-Pub 2011.
71. Fiorcari S, Brown WS, McIntyre BW, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Marasca R, Lannutti BJ, Estrov Z, Burger JA. The PI3 Kinase Inhibitor, CAL-101 (GS-1101), Inhibits Chronic Lymphocytic Leukemia (CLL) Cell Survival in Endothelial and Marrow Stromal Cell Co-Cultures. Blood 118, 2011. e-Pub 2011.
72. Tambaro FP, Garcia-Manero G, Faderl S, O'Brien S, Ferrajoli A, Burger JA, Trinh LX, Lerner S, Kantarjian HM, Keating MJ, Wierda WG. Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) at MD Anderson Cancer Center (MDACC). Blood 118, 2011. e-Pub 2011.
73. Garcia-Manero G, Daver NG, Borthakur G, Konopleva M, Ravandi F, Wierda WG, Estrov Z, Faderl S, Kadia T, Rey K, Cheung C, Kantarjian HM. Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). Blood 118, 2011. e-Pub 2011.
74. Hoellenriegel J, Zboralski D, Estrov Z, Wierda WG, Keating M, Kruschinski A, Burger JA. The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration. Blood 118, 2011. e-Pub 2011.
75. Li P, Liu Z, Harris D, Ferrajoli A, Wang Y, Hazan-Helevy I, Grgurevic S, Wierda WG, Burger JA, O'Brien S, Faderl S, Keating MJ, Estrov Z. Signal Transducer and Activator of Transcription (STAT)-3 Induces Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF) Receptor-a Expression in Chronic Lymphocytic Leukemia (CLL) Cells. Blood 118, 2011. e-Pub 2011.
76. Wierda WG, Balakrishnam K, Ferrajoli A, Kadia T, Cortes JE, O'Brien S, Burger JA, Tambaro FP, Jalayer A, Lerner S, Keating MJ, Gandhi V. A Phase I/II Trial of Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy for Previously Treated Patients in CLL. Blood 118, 2011. e-Pub 2011.
77. Wierda WG, O'Brien S, Ferrajoli A, Koller CA, Burger JA, Faderl S, Garcia-Manero G, Kadia T, Lerner S, Keating MJ. Pretreatment Patient Characteristics Associated with Achieving Bone Marrow Minimal Residual Disease-Free Status with Frontline Fludarabine, Cyclosphosphamide, Rituximab (FCR) Chemoimmunotherapy for CLL. Blood 118, 2011. e-Pub 2011.
78. Kipps TJ, Swinnen LJ, Wierda WG, Jones JA, Coutre SE, Smith MR, Yang J, Cui Y, Busman T, Enschede S, Humerickhouse R. Navitoclax (ABT-263) Plus fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase I Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood 118, 2011. e-Pub 2011.
79. Posadzides JV, Keating MJ, Wierda WG, O'Brien S, Burger JA, Jorgensen JL, Calin S, Wang SA, Lerner S, Ferrajoli A. Initial Experience with Lenalidomide As Consolidation Treatment in Patients with Chronic Lymphocytic Leukemia and Residual Disease After Chemotherapy. Blood 118, 2011. e-Pub 2011.
80. Ponader S, Buggy J, O'Brien S, Wierda WG, Keating M, Burger JA. Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo. Blood 116(21):26-27, 2010. e-Pub 2010.
81. Verma D, Balakrishnan K, O'Brien S, Thomas DA, Ferrajoli A, Wierda WG, Verma A, Faderl S, Bickel SM, Bantia S, Kantarjian HM, Keating MJ, Gandhi V, Ravandi F. Phase II, Single Center Study of Oral Forodesine in Patients with Advanced, Fludarabine-Treated Chronic Lymphocytic Leukemia (CLL). Blood 114(22):935, 2009. e-Pub 2009.
82. Thomas DA, Kantarjian HM, Faderl S, Wierda WG, Cortes J, Burger JA, Ferrajoli A, Estrov Z, Koller C, Konopleva M, Borthakur G, Jabbour E, Ravandi F, Kadia T, Garcia-Manero G, Kornblau SM, Andreeff M, Garris R, Keating MJ, O'Brien S. Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 114(22):344, 2009. e-Pub 2009.
83. W-G T, Kadia T, Borthakur G, Jabbour E, Pierce S, Shan J, Cortes-Franco J, Ravandi F, Wierda W, Thomas D, Kantarjian H, Garcia-Manero G. Prognostic Factors and Survival in Patients with Hypocellular Myelodysplastic Syndrome: Development of a Disease Specific Prognostic Score. Blood 114(22):1469, 2009. e-Pub 2009.
84. Kim H, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cortes J, ravandi F, Wierda WG, Estrov Z, Faderl S, Garcia-Manero G. A Prognostic Model of Therapy-Related Myelodysplastic syndrome. Blood 114(22):1460, 2009. e-Pub 2009.
85. Batty N, Badoux XC, Keating M, Lin E, Lerner S, O'Brien S, Ferrajoli A, Kadia T, Burger JA, Faderl S, Wierda WG. Pretreatment Factors Associated with Second Malignancies Occuring After Frontline Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Patients with Chronic Lymphocytic Leukemia (CLL). Blood 114(22):1339, 2009. e-Pub 2009.
86. Tsimberidou AM, Wierda W, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Smith S, Jalayer A, Kantarjian HM, Keating M. Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS). Blood 114(22):1337, 2009. e-Pub 2009.
87. Osterborg A, Biilmann Ronn B, Jewell RC, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillman P, Trneny M, Dyer M JS, Padmanabham S, Piotrowska M, Kozak T, chan G, Arning M, Losic N, Davis R, Wilms J, Russell CA, Wierda WG. Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab. Blood 114(22):1334, 2009. e-Pub 2009.
88. Badoux XC, Keating M, O'Brien S, Kadia T, ferrajoli A, Faderl S, Koller C, Garcia-Manero G, Burger JA, Wierda WG. Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL). Blood 114(22):1332, 2009. e-Pub 2009.
89. Keating MJ, Wierda WG, Tam CS, Kantarjian HM. Long Term Outcome following Treatment Failure of FCR Chemoimmunotherapy as Initial Therapy for Chronic Lymphocytic Leukemia. Blood 114(22):940, 2009. e-Pub 2009.
90. Sivina M, Hartmann E, Keating M, Wierda WG, Rosenwald A, Burger JA. Marrow Stromal Cells Induce TCL1 Expression in Chronic Lymphocytic Leukemia B Cells. Blood 114(22):927, 2009. e-Pub 2009.
91. Khouri IF, Bassett Jr RL, Cano P, O'Brien S, Hsu Y, Bueso-Ramos CE, Harrell R, G-J O, De Padua Silva L, Ferrajoli A, Wierda W, Kantarjian H, Champlin R, McMannis J, Fernandez-Vina M. Human-Leukocyte-Histocompatibility Antigens (HLA-A1+, A2-, B44-) and Serum Immunoglobulin (Ig)G with CD4 Levels Predict Response to Graft-Versus-Leukemia (GVL) and Overall Survival, Respectively, After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL). Blood 114(22):902, 2009. e-Pub 2009.
92. Al-Kali A, Kantarjian H, Shan J, Wierda WG, Borthakur G, Estrov Z, Verstovsek S, O'Brien S, Cortes J. Current Leukemia Free Survival After Tyrosine Kinase Inhibitor (TKI) for Chronic Myeloid Leukemia (CML): A New Method That Accounts for Restoring Response with Sequential TKI. Blood 114(22):864, 2009. e-Pub 2009.
93. Ayoubi M, Kantarjian HM, Wierda W, Ferrajoli A, Hiteshew J, Estrov Z, Cortes-Franco J. A Phase 2 study of the Combination of Omacetaxine and Imatinib in the Treatment of Patients with Chronic Myeloid Leukemia (CML) in Advanced Stages or After Failure to Imatinib. Blood 114(22):862, 2009. e-Pub 2009.
94. Rytting M, Thomas DA, Franklin AR, Jabbour E, Wierda W, Faderl S, Wells R, Kadia T, Ravandi F, Ferrajoli A, Cortes J, O'Brien S, Kantarjian H. Pediatric-Based Therapy for Young Adults with Newly Diagnosed Lymphoblastic Leukemia. Blood 114(22):804, 2009. e-Pub 2009.
95. Badoux XC, Keating M, O'Brien S, Ferrajoli A, Burger JA, Faderl S, Garcia-Manero G, Kadia T, Abruzzo LV, Wierda WG. Patients with Relapsed CLL and 17p Deletion by FISH Have Very Poor Survival Outcomes. Blood 114(22):513, 2009. e-Pub 2009.
96. Ravandi F, Cortes J, Faderl S, O'Brien S, Garcia-Manero G, Verstovsek S, de Lima M, Pierce S, Brandt M, Borthakur G, Ferrajoli A, Wierda WG, Koller CA, Kantarjian HM. Characteristics and Outcomes of Patients with Acute Myeloid Leukemia (AML) Refractory to One Cycle of High Dose Cytarabine-Based Induction Chemotherapy. Blood 114(22):430, 2009. e-Pub 2009.
97. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Carney D, Xiong H, Cui Y, Busman T, Enschede S, Krivoshik A, Humerickhouse R. An Ongoing Phase 1/2a Study of ABT-263; Pharmacokinetics (PK), Safety and Anti-Tumor Activity in Patients (pts) with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Blood 114(22):364, 2009. e-Pub 2009.
98. Ravandi F, Kantarjian HM, Thomas DA, Faderl S, Jones D, Koller CA, Dara S, Garris R, Kebriaei P, Champlin R, Borthakur G, Wierda WG, Burger JA, Cortes J, O'Brien S. Phase II Study of Combination of the Hypercvad Regimen with Dasatinib in the Front Line Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood 114(22):345, 2009. e-Pub 2009.
99. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, borthakur G, Rios MB, Cortes J. Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure. Blood 114(22):210, 2009. e-Pub 2009.
100. Sivina M, Hartmann E, Krupnik D, LaPushin R, Keating M, Kipps TJ, Rosenwald A, Wierda WG, Burger JA. CCL3 and CCL4 Plasma Levels Correlate with Established Prognostic Markers in Chronic Lymphocytic Leukemia: Towards a Simple, ELISA-Based Assay for Risk Assessment. Blood 114(22):151, 2009. e-Pub 2009.
101. Kurtova A, Sivina M, Quiroga MP, Wierda WG, Keating MJ, Burger JA. The Immunophenotype Signature CD49d+CD38+ Identifies Chronic Lymphocytic Leukemia Cases with a Higher Potential for Migration Beneath Marrow Stromal Cells. Blood 114(22):150, 2009. e-Pub 2009.
102. Parikh SA, Keating M, O'Brien S, Ferrajoli A, Faderl S, Koller C, Estrov Z, Lerner S, Wierda WG. Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia. Blood 114(22):91, 2009. e-Pub 2009.
103. Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, Padmanabhan S, Strange M, Nielsen TG, Russell CA. Ofatumumab Combined with Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results From a Randomized, Multicenter, International, Two-Dose, Parallel Group, Phase II Trial. Blood 114(22):90, 2009. e-Pub 2009.
104. Ferrajoli A, Badoux XC, O'Brien S, Wierda WG, Faderl S, Estrov Z, Pasia M, B-N L, Reuben JM, Kantarjian H, Keating M. Combination Therapy with Lenolidamide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia. Blood 114(22):89, 2009. e-Pub 2009.
105. Thomas DA, Rytting M, O'Brien S, Faderl S, Wierda WG, Franklin A, Garris R, Ravandi F, Cortes J, Kantarjian HM. Outcome for Adolescents and Young Adults (AYA) with the Hyper-CVAD (with or without Rituximab) Regimens for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma. Blood 114(22):1199, 2009. e-Pub 2009.
106. Tsimberidou AM, Wierda WG, Plunket WK, O'Brien S, Lerner S, Smith SC, Kantarjian HM, Keating MJ. Phase I/II study of oxaliplatin, fludarabine, cytarabine, and rituximab in patients (OFAR2) with Richter's syndrome (RS), and relapsed or refractory B-cell chronic lymphocytic leukemia (CLL). Jour of Clin Oncol 27(15S):363s, 2009. e-Pub 2009.
107. Wierda WG, Kipps T, Mayer J, Stilgenbauer S, Robak T, Williams CD, Furman R, Chan G, Russell C, Osterborg A. Activity of ofatumumab, a novel CD20 mAb, and prior rituximab exposure in patients with fuldarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL). Journal of Clinical Oncology 27(15S):366s, 2009. e-Pub 2009.
108. Kipps TJ, Osterborg A, Mayer J, Stilgenbauer S, Hellmann A, Williams CD, Furman R, Chan G, Russell C, Wierda WG. Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy. Journal of Clinical Oncology 27(15S):366s, 2009. e-Pub 2009.
109. Ravandi F, Thomas D, Kantarjian H, Faderl S, Koller C, Borthakur G, Wierda W, Burger J, Cortes J, O'Brien S. Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood 112(11):1005, 2008. e-Pub 2008.
110. Tong W, S-Q K, Wierda W, Keating MJ, Garcia-Manero G. Identification of Multiple Promoter Associated CpG Islands Commonly Methylated in both Acute Lymphocytic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL) Using Novel Genome-Wide Microarray Technique: Implications for Common Primordial Molecular Pathways in Lymphoid Leukemias. Blood 112(11):789, 2008. e-Pub 2008.
111. Quintas-Cardama A, Kantarjian HM, O'Brien S, Borthakur G, Verstovsek S, Wierda W, Shan J, Cortes J. Prognostic Impact of Deletions of Derivative Chromosome 9 on Patients (PTS) with Chronic Myelogenous Leukemia (CML) in Chronic Phase Treated with Nilotinib or Dasatinib. Blood 112(11):734, 2008. e-Pub 2008.
112. Quiroga MP, Kurtova A, Wierda W, Keating M, Burger JA. Inhibition of BCR Signaling Using the SYK Inhibitor R406 Antagonizes Migratory and Pro-Survival Responses in CLL Cells. Blood 112(11):719, 2008. e-Pub 2008.
113. Ferrajoli A, O'Brien S, Wierda W, Faderl S, Kornblau S, Yerrow K, Estrov Z, Kantarjian H, Keating M. Lenalidomide as Initial Treatment of Elderly Patients with Chronic Lymphocytic Leukemia (CLL). Blood 112(11):23, 2008. e-Pub 2008.
114. Schlette E, Tam CS, Herling M, Bueso-Ramos C, Wierda W, Ferrajoli A, O'Brien S, Keating M, Jones D. High T-Cell Lymphoma Breakpoint (TCL1) Levels Are Associated with Lack of Response and Inferior Outcome Following Fludarabine, Cyclophosphamide, Rituximab (FCR) Frontline Therapy in Patients with Chronic Lymphocytic Leukemia (CLL). Blood 112(11):726, 2008. e-Pub 2008.
115. Wierda WG, Castro J, Aguillon RA, Sampath D, Jalayer A, Prussak C, Keating MJ, Kipps TJ. Active Immune Gene Therapy Using ISF35: Responses Associated with Priming for Death Receptor-Induced Apoptosis and Sensitivity to Fludarabine in Patients with CLL and Del 17p. Blood 112(11):1210, 2008. e-Pub 2008.
116. Wierda WG, Chen R, Plunkett W, Coutre S, Badros AZ, Popplewell L, Siegel D, Sinha R, Harvey D, Fox J, Mahadocon K, Kegley P, Boldon MG. A Phase I Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor, in Chronic Lymphocytic Leukemia and Multiple Myeloma. Blood 112(11):1090, 2008. e-Pub 2008.
117. Roberts AW, Brown J, Seymour JF, Wierda WG, Kipps TJ, Xiong H, Y-L C, Busman T, Knight RA, Enschede S, Krivoshik A, Humerickhouse R. An Ongoing Phase I Study of ABT-263; Pharmacokinetics, Safety and Anti-Tumor Activity in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). Blood 112(11):1089, 2008. e-Pub 2008.
118. Kurtova A, Quiroga MP, Wierda WG, Keating M, Burger JA. Standardizing Co-Culture Conditions Between Chronic Lymphocytic Leukemia Cells and Marrow Stromal Cells: Towards a Reliable and Reproducible System to assess Cell Adhesion-Mediated Drug Resistance. Blood 112(11):1080, 2008. e-Pub 2008.
119. Brown JR, Rassenti L, Neuberg D, Greaves A, Byrd JC, Grever MR, Gribben JG, Kay NE, Keating M, Rai KR, Wierda WG, Kipps TJ. Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort. Blood 112(11):1071, 2008. e-Pub 2008.
120. Ramsay AG, Xing DX, Decker WK, Burks JK, Wierda WG, Gribben JG, Shpall EJ. Compared to Adult Peripheral Blood T Cells, Cord Blood T Cells Show Enhanced Immunological Recognition of Chronic Lymphocytic Leukemia Tumor Cells. Blood 112(11):813, 2008. e-Pub 2008.
121. Tong W, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Wierda WG, Kornblau S, Borthakur G, Garcia-Manero G, Burton E, Rios MB, Cortes J. Imatinib Frontline Therapy is Safe and Effective in Patients with Chronic Myeloid Leukemia (CML) with Liver and/or Renal Dysfunction. Blood 112(11):741, 2008. e-Pub 2008.
122. Quintas-Cardama A, Kantarjian HM, Borthakur G, Faderl S, Garcia-Manero G, Wierda WG, burton EM, Cortes J. Outcome of Patients with Chronic Myeloid Leukemia (CML) with Multiple ABL1 Kinase Domain Mutations during Tyrosine Kinase Inhibitor Therapy. Blood 112(11):735, 2008. e-Pub 2008.
123. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM. Plasma Alemtuzumab levels at End of Treatment Correlate with Response and Response Duration in Patients with CLL Receiving Treatment for Residual Disease. Blood 112(11):734, 2008. e-Pub 2008.
124. Gao H, Ferrajoli A, Cohen EN, B-N L, Tin S, O'Brien S, Wierda WG, Estrov Z, Faderl S, Keating MJ, Reuben JM. Treatment with Lenalidomide Has a Positive Immunomodulatory Effect in Patients with Chronic Lymphocytic Leukemia. Blood 112(11):733, 2008. e-Pub 2008.
125. Wierda WG, O'Brien SM, Faderl SH, Ferrajoli A, Koller C, Estrov Z, Burger JA, Lerner S, Kantarjian HM, Keating MJ. CFAR, An Active Frontline Regimen for High-Risk Patients with CLL, Including Those with Del 17p. Blood 112(11):729, 2008. e-Pub 2008.
126. Wierda WG, O'Brien SM, Wang X, Faderl SH, Ferrajoli A, Garcia-Manero G, Cortes J, Tam CS, Burger JA, Abruzzo LV, Schlette E, Lerner S, Keating MJ. Integrating Newer with Traditional Prognostic Factors in Evaluating Patients with CLL Receiving Frontline Chemoimmunotherapy. Blood 112(11):729, 2008. e-Pub 2008.
127. Keating MJ, Lerner S, Wang X, Rassenti LZ, O'Brien S, Kipps TJ, Wierda WG. Predicting Time to Initial Treatment in Early Stage CLL - Integration of Classical and Novel Prognostic Factors. Blood 112(11):728, 2008. e-Pub 2008.
128. Tam CS, Wierda WG, O'Brien S, Lerner S, Khouri IF, Kantarjian HM, Keating M. Life after Fludarabine, Cyclophosphamide, & Rituximab (FCR) - the Clinical Outcome of Patients with Chronic Lymphocytic Leukemia Who Receive Salvage Treatment after Frontline FCR. Blood 112(11):727, 2008. e-Pub 2008.
129. Henderson JD, O'Brien SM, Wang X, Faderl SH, Ferrajoli A, Garcia-Manero G, Tam CS, Burger JA, Abruzzo LV, Schlette E, Lerner S, Keating MJ, Wierda WG. Integrating Newer Prognostic Factors in Evaluation of Previously Treated Patients with CLL Receiving Salvage Treatment. Blood 112(11):723, 2008. e-Pub 2008.
130. Thomas DA, Kantarjian H, Faderl S, Wierda WG, Ferrajoli A, Burger JA, Cortes J, Koller CA, Borthakur G, Estrov Z, Konopleva M, Ravandi F, Garcia-Manero G, O'Brien S. Outcomes after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL). Blood 112(11):674, 2008. e-Pub 2008.
131. Thomas DA, O'Brien S, Rytting M, Faderl S, Cortes J, Wierda WG, Ravandi F, Kantarjian HM. Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) after Frontline Therapy with Hyper-CVAD Regimens. Blood 112(11):674, 2008. e-Pub 2008.
132. Thomas DA, Kantarjian HM, Cortes J, Faderl S, Wierda WG, Ravandi F, Rodriguez MA, Fayad L, O'Brien S. Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkett (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukemia. Blood 112(11):673, 2008. e-Pub 2008.
133. Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, Lerner S, Lynn A, Kay NE, Keating MJ. De Novo Deletion 17p13.1 Chronic Lymphocytic Leukemia Shows Significant Clinical Heterogeneity: The MD Anderson / Mayo Clinic Experience. Blood 112(11):387, 2008. e-Pub 2008.
134. Osterborg A, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmen A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJS, Padmanabham S, Kozak T, Chan G, Davis RL, Losic N, Russell CA, Piotrowska M, Wilms J, Wierda WG. Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim analysis of An International Pivotal Study. Blood 112(11):126, 2008. e-Pub 2008.
135. Santos FPS, Kantarjian H, Fava C, O'Brien S, Garcia-Manero G, Kornblau S, Ravandi F, Wierda W, Cortes J. Clinical Significance of Dose Reductions of Second-Generation Tyrosiine Kinase Inhibitors (TKI) in Patients (Pts) with Chronic Myeloid Leukemia (CML). Blood 112(11):1104, 2008. e-Pub 2008.
136. Ferrajoli A, Faderl S, O'Brien S, Wierda W, Ayala A, Smith S, Brown TC, Kantarjian H, Keating M. Experience with Fludarabine, Cyclophosphamide, Rituximab (FCR) Plus GM-CSF in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL). Blood 112(11):1088, 2008. e-Pub 2008.
137. Tam CS, Wierda W, O'Brien SM, Lerner S, Abruzzo LV, Ferrajoli A, Kantarjian HM, Keating MJ. The clinical significance of chromosome 17p deletion in chronic lymphocytic leukemia: A study of 180 consecutive patients. Supplement to Journal of Clinical Oncology 2008 ASCO Annual Meeting 26(15S/Part I of II):380s, 2008. e-Pub 2008.
138. Wierda W, O'Brien S, Ferrajoli A, Faderl S, Koller C, Estrov Z, Garcia-Manero G, Verstovsek S, Browning M, Lerner S, Keating M. Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL. Blood 110(11):194a, 2007. e-Pub 2007.
139. Tong W, Wierda W, Bekele N, Kuang S, Keating M, Garcia-Manero G. Genome-Wide DNA Methylation Profile of CLL with 17p del Allowed Identification of Multiple Epigenetically Inactivated Molecular Pathways with Prognostic Value in Human Leukemia. Blood 110(11):152a, 2007. e-Pub 2007.
140. Burger J, Niedermeier M, Burkle A, Hartmann E, Wierda W, Keating M, Rosenwald A. High-Level Expression of the T Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Co-Cultures and in Response to BCR Stimulation. Blood 110(11):107a, 2007. e-Pub 2007.
141. Rytting M, Thomas D, Kantarjian H, Cortes J, Borthakur G, Wierda W, Nunez C, Kornblau S, Ravandi F, Wells R, Muriera B, Franklin A, O'Brien S. Adaptation of Augmented Berlin-Frankfurt-Munster (ABFM) Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL). Blood 110(11):153B, 2007. e-Pub 2007.
142. Schlette E, Tam C, Admirand J, Wierda W, O'Brien S, Lerner S, Keating M. ZAP70 Expression by Immunohistochemistry Correlates with IgVH Mutation Status in Chronic Lymphocytic Leukemia and Predicts Time to Progression, but Survival Is Decreased in p53-Positive CLL, Regardless of ZAP70 Expression. Blood 110(11):907a, 2007. e-Pub 2007.
143. Tam C, Keating M, Tsimberidou A, O'Brien S, Ferrajoli A, Lerner S, Abruzzo L, Schlette E, Kantarjian H, Wierda W. The Clinical Usefulness of Novel Prognostic Factors in CLL: A study of 477 Patients with Low-Risk (Non-11q, Non-17p) FISH and Known IGVH Mutation Status. Blood 110(11):905a, 2007. e-Pub 2007.
144. Thomas D, Kantarjian H, Cortes J, Faderl S, Ravandi-Kashani F, Wierda W, Rodriguez A, Fayad L, O'Brien S. Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukemia (B-ALL). Blood 110(11):831a, 2007. e-Pub 2007.
145. Tam C, Keating M, O'Brien S, Ferrajoli A, Abruzzo L, Lerner S, Faderl S, Kantarjian H, Wierda W. The Natural History and Treatment Outcomes of De-Novo Chromosome 17p Deletion CLL: A Single Institution Experience with 48 Patients. Blood 110(11):608a, 2007. e-Pub 2007.
146. Jabbour E, Kantarjian H, Shan J, O'Brien S, Wierda W, Ravandi F, Borthakur G, Kornblau S, Walker B, Rios M, Cortes J. Prognostic significance of Prior Best Response to Imatinib in Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs). Blood 110(11):577a, 2007. e-Pub 2007.
147. Jabbour E, Kantarjian H, Jones D, Tam C, Koller C, Borthakur G, Wierda W, Cortes J. Event-Free Survival in Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with 2nd Generation Tyrosine Kinase Inhibitors (TKI) after Imatinib Failure Is Dependent on the In Vitro Sensitivity of BCR-ABL Kinase Domain (KD) Mutations. Blood 110(11):577a, 2007. e-Pub 2007.
148. Vega-Ruiz A, Kantarjian H, Shan J, Wierda W, Burger J, Verstovsek S, Garcia-Manero G, Cortes J. Better Molecular Response to Imatinib for Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Carrying the b3a2 Transcript Compared to b2a2. Blood 110(11):576a, 2007. e-Pub 2007.
149. Alvarado Y, Kantarjian H, Faderl S, Burger J, Borthakur G, O'Brien S, Wierda W, Garcia-Manero G, Cortes J. Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in Long-Term Outcome for Patients (Pts) with Chronic Phase (CP) Chronic Myeloid Leukemia (CML). Blood 110(11):573a, 2007. e-Pub 2007.
150. Tam C, Kantarjian H, Borthakur G, Wierda W, Ravandi F, O'Brien S, Shan J, Cortes J. The Time to Cytogenetic Response Determines Survival in CML Patients (Pts) Receiving Second-Line Tyrosine Kinase Inhibitors, and Allows Early Identification of Pts Destined to Fail Therapy. Blood 110(11):573a, 2007. e-Pub 2007.
151. Kadia T, Ferrajoli A, Ravandi F, Cortes J, Thomas D, Wierda W, Verstovsek S, Newsome W, Zwiebel J, Egorin M, Kantarjian H, Garcia-Manero G. A Phase I Study of the Combination of the Histone Deacetylase Inhibitor Vorinostat with Idarubicin in Advanced Acute Leukemia. Blood 110(11):545a, 2007. e-Pub 2007.
152. Jabbour E, Kantarjian H, Atallah E, Borthakur G, Wierda W, Faderl S, Kornblau S, Cortes J. Impact of Imatinib Mesylate dose Escalation on Resistance and Sub-Optimal Responses to Standard-Dose Therapy in Patients (pts) with Chronic Myeloid Leukemia. Blood 110(11):313a, 2007. e-Pub 2007.
153. Ravandi F, Foran J, Verstovsek S, Cortes J, Wierda W, Boone P, Borthakur G, Sweeney T, Kantarjian H. A Phase I Trial of AT9283, a Multitargeted Kinase Inhibitor, in Patients with Refractory Hematological Malignancies. Blood 110(11):275a, 2007. e-Pub 2007.
154. Lin K, Tam C, Abruzzo L, Wierda W, Barron L, O'Brien S, Kipps T, Rassenti L, Lerner S, Kantarjian H, Keating M. IgVH Mutational Status Does Not Affect Complete Remission Rate but Is Associated with Reduced Remission Duration in CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR)-Based Therapy. Blood 110(11):232a, 2007. e-Pub 2007.
155. Faderl S, Wierda W, Ferrajoli A, O'Brien S, Ravandi F, Kantarjian H, Showalter B, Lerner S, Keating M. Update of Experience with Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL). Blood 110(11):193a, 2007. e-Pub 2007.
156. Cortes J, O'Brien S, Jabbour E, Ferrajoli A, Borthakur G, Burger J, Wierda W, Garcia-Manero G, Thomas M, Letvak L, Kantarjian H. Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP). Blood 110(11):17a, 2007. e-Pub 2007.
157. Thomas D, Kantarjian H, Ravandi F, Faderl S, Garcia-Manero G, Wierda W, Ferrajoli A, Verstovsek S, Jones D, Letvak L, Champlin R, Cortes J, O'Brien S. Long-Term Follow-Up after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen in Adults with Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). Blood 110(11):10a, 2007. e-Pub 2007.
158. Safdar A, Rodriguez G, Wierda W, Musher D, Rueda A, O'Brien S, Koller C, Bodey G, Keating M. Immunogenicity and safety of multi-dose granulocyte macrophage-colony stimulating factor (GM-CSF) immune enhancement in patients with chronic lymphocytic leukemia (CLL) receiving 23-valent polysaccharide pneumococcal vaccine (PPV23): A prospective, randomized, controlled trial. 10th Annual Conference on Vaccine Research Sponsored by National Foundation for Infectious Diseases. Bethesda, Maryland, Baltimore, Maryland Oral Presentation:(#183), 2007. e-Pub 2007.
159. Rassenti L, Huynh L, Basak G, Ghia E, Van Dyke D, Heerema N, Zahrieh D, DalCin P, Dell'Aquila M, Koduru P, Byrd J, Kay N, Rai K, Brown J, Wierda W, Greaves A, Kipps T. TCL1 Expression in Chronic Lymphocytic Leukemia Correlates with the Intensity of 11q Deletions and ZAP-70. Blood 110(11):616a, 2007. e-Pub 2007.
160. Chen R, Wierda W, Benaissa S, Hoch U, Hawtin R, Fox J, Keating M, Gandhi V, Plunkett W. Mechanism of Action of SNS-032, A Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol. Blood 110(11):915a, 2007. e-Pub 2007.
161. Chanan-Khan A, Czuczman M, Padmanabhan S, Keating M, O'Brien S, Wierda W, Ferrajoli A. Clinical Efficacy of Lenalidomide in Fludarabine-Refractory Chronic Lymphocytic Leukemia Patients. Blood 110(11):914a, 2007. e-Pub 2007.
162. Garcia-Manero G, Quesada A, Maddipoti S, Kuang S, Tong W, Wierda W, Bueso-Ramos C, Yang H. Analysis of Class I and II Histone Deacetylase Fails to Identify a Human Leukemia Specific Expression Profile. Blood 110(11):634a, 2007. e-Pub 2007.
163. Tsimberidou A, Tam C, Wierda W, O'Brien S, Lerner S, Kantarjian H, Keating M. The Prognostic Significance of 11q Deletion Detected by Fluorescence In Situ Hybridization (FISH) in Untreated Chronic Lymphocytic Leukemia (CLL): The MDACC Experience. Blood 110(11):619a, 2007. e-Pub 2007.
164. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Garcia-Manero G, Burger J, Schlette E, Abruzzo L Lerner S, Keating M. Complex Karyotypic Abnormalities Detected by Conventional Cytogenetic Analysis More Strongly Predict Survival Than FISH, ZAP70, or IgVH Mutation Status for Previously Treated Patients with CLL. Blood 110(11):615a, 2007. e-Pub 2007.
165. Wierda W, Castro J, Aguillon R, Jalayer A, McMannis J, Prussak C, Keating M, Kipps T. A Phase I Study of Immune Gene Therapy for Patients with CLL Using a Membrane-Stable, Humanized CD154. Blood 110(11):607a, 2007. e-Pub 2007.
166. Niedermeier M, Rawluk J, Knight Z, Shokat K Wierda W, Keating M, Burger J. Importance of P13 Kinase Family for Crosstalk between Chronic Lymphocytic Leukemia B ells and the Stromal Microenvironment: Therapeutic Implications. Blood 110(11):341a, 2007. e-Pub 2007.
167. Ferrajoli A, Keating M, Wierda W, O'Brien S, Padmanabhan S, Czuczman M, Chanan-Khan A. Lenalidomide Is Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Carrying Unfavorable Chromosomal Abnormalities. Blood 110(11):232a, 2007. e-Pub 2007.
168. Ghia E, Rassenti L, Widhopf G, Silverman G, Neuberg D, Keating M, Wierda W, Gribben J, Brown J, Rai K, Byrd J, Kay N, Greaves A, Kipps T. Stereotypic IGHV3-21/IGLV3-21 Antibodies Expressed in High-Risk Chronic Lymphocytic Leukemia Bind Peptostreptococcus Magnus Protein L. Blood 110(11):227a, 2007. e-Pub 2007.
169. Soriano AO, Yang H, Tong W, Faderl S, Wierda W, Andreeff M, Estrov Z, Ouzounian S, Clavell J, Kantarjian H, J-P I, Garcia-Manero G. Significant clinical activity of the combination of 5-azacitidine, valproic acid and all-trans retinoic acid (ATRA) in leukemia: results of a Phase I/II study. Blood 108(11):51a, 2006. e-Pub 2006.
170. Thomas DA, Kantarjian HM, Cortes J, Faderl S, Giles F, Garcia-Manero G, Wierda W, Ferrajoli A, Ravandi-Kashani F, Verstovsek S, Andreeff M, Letvak LA, Jones D, Champlin R, O'Brien S. Outcome with the Hyper-CVAD and imatinib mesylate regimen as frontline therapy for adult Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Blood 108(11):87A, 2006. e-Pub 2006.
171. Tam C, Wen S, K-A D, Lerner S, Wierda W, O'Brien S, Keating M. The effect of initial therapy choice in determining long term survival in patients with chronic lymphocytic leukemia (CLL). Blood 108(11):332b, 2006. e-Pub 2006.
172. Tsimberidou A, McLaughlin P, O'Brien S, Wen S, Wierda W, Manning J, Abruzzo L, Lerner S, Hess M, Kantarjian H, Freireich E, Keaitng M. Genomic aberrations in chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte count: analysis of 1694 patients. Blood 108(11):332b, 2006. e-Pub 2006.
173. Tam C, Otero-Palacios J, Lerner S, Abruzzo L, Jorgensen J, Ferrajoli A, Wierda W, O'Brien S, Keating M. CD20 expression is increased in trisomy 12 CLL as compared to other cytogenetic subtypes. Blood 108(11):332b, 2006. e-Pub 2006.
174. Tam C, Kantarjian H, Verstovsek S, Wierda W, Shan J, Otero-Palacios J, Awais A, Ravandi-Kashani F, Cortes J. The clinical significance of biphenotypia in blastic phase CML. Blood 108(11):322b, 2006. e-Pub 2006.
175. Wierda W, Kipps T, Keating M, Brown J, Gribben J, Browning M, Rassenti L, Greaves A, Neuberg D, O'Brien S. Self-administered, subcutaneous (SQ) alemtuzumab to eliminate residual disease in patients (pts) with CLL. Blood 108(11):804a, 2006. e-Pub 2006.
176. Faderl S, Wierda W, O'Brien S, Ferrajoli A, Ravandi-Kashani F, Detry M, Kantarjian H, O'Neal B, Keating M. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) as frontline therapy for CLL: results of a Phase II study. Blood 108(11):803a, 2006. e-Pub 2006.
177. Faderl S, Ferrajoli A, Wierda W, O'Brien S, Ravandi-Kashani F, Fayad L, Thomas D, Kantarjian H, Browning M, Keating M. The combination of alemtuzumab [continuous intravenous infusion (civ)] followed by subcutaneous injection (sci)] plus rituximab as activity in patients (pts) with relapsed chronic lymphocytic leukemia (CLL). Blood 108(11):800a, 2006. e-Pub 2006.
178. Tsimberidou A, Wierda W, O'Brien S, Plunkett W, Kipps T, Brown J, Lerner S, Kantarjian H, Keating M. Combination of oxaliplatin, fludarabine, cytarabine, and rituximab in Richter's syndrome and fludarabine-refractory chronic lymphocytic leukemia. Blood 108(11):799a, 2006. e-Pub 2006.
179. Tsimberidou A, McLaughlin P, O'Brien S, Wen S, Wierda W, Manning J, Lerner S, Hess M, Kantarjian H, Freireich E, Keating M. A prognostic score for chronic lymphocytic leukemia and small lymphocytic lymphoma: analysis of 2189 patients. Blood 108(11):788a, 2006. e-Pub 2006.
180. Rassenti L, Neuberg D, Huynh L, Wierda W, Gribben J, Brown J, Flinn I, Rai K, Byrd J, Kay N. Relative value of CD38 and ZAP-70 versus immunoglobulin mutation status in predicting early disease progression in chronic lymphocytic leukemia. Blood 108(11):786a, 2006. e-Pub 2006.
181. Ghia E, Rassenti L, Widhopf G, Neuberg D, Keating M, Wierda W, Gribben J, Brown J, Flinn I, Rai K, Byrd J, Kay N, Greaves AW, Kipps TJ. Study of VH3-21 in a large cohort of chronic lymphocytic leukemia patients reveals evidence for antigen selection and confirms its predictive value for early disease progression. Blood 108(11):785a, 2006. e-Pub 2006.
182. Jabbour E, Kantarjian H, Cortes J, Wierda W, Ferrajoli A, Faderl S, O'Brien S, Ravandi-Kashani F, Verstovsek S, Garcia-Manero G, Davisson J, Giles F, Shan J, J-P I. Survival benefit with decitabine compared to historical experience with intensive chemotherapy in patients with higher risk myelodysplastic syndrome (MDS). Blood 108(11):749a, 2006. e-Pub 2006.
183. Alatrash G, Keating M, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Kantarjian H, Lerner S, Wierda W. Circulating CD52 and CD20 levels predict for progression and survival in patients with CLL treated with fludarabine (F), cyclophosphamide (C), and rituximab (FCR). Blood 108(11):660a, 2006. e-Pub 2006.
184. Tam C, Kantarjian H, Shan J, Wierda W, Ferrajoli A, Koller C, Cortes J. Sokal and Hasford scores are able to predict cytogenetic response and survival in CML patients who failed prior therapy and are receiving salvage therapy with imatinib or other tyrosine kinase inhibitors. Blood 108(11):612a, 2006. e-Pub 2006.
185. Wierda W, O'Brien S, Aguillon R, Castro J, McMannis J, Prussak C, Kipps T, Keating M. Membrane-stable, humanized CD154 gene therapy for patients with CLL. Blood 108(11):596a, 2006. e-Pub 2006.
186. Quintas-Cardama A, Kantarjian H, Jones D, Garcia-Manero G, O'Brien S, Shan J, Ravandi F, Wierda W, Cortes J. Delayed achievement of molecular responses is associated with increased risk of progression among patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) treated with imatinib (IM). Blood 108(11):132a, 2006. e-Pub 2006.
187. Ferrajoli A, O'Brien S, Faderl S, Wierda W, David D, Bang-Ning L, Reuben J, Schlette E, Kantarjian H, Keating M. Lenalidomide induces complete and partial responses in patients with relapsed and treatment-refractory chronic lymphocytic leukemia (CLL). Blood 108(11):94a, 2006. e-Pub 2006.
188. Faderl S, Ferrajoli A, Ravandi-Kashani F, Verstovsek S, Wierda W, Borthakur G, Thomas D, Cortes J, Kornblau S, Estrov Z, Andreeff M, Beran M, Giles F, Huang X, Kwari M, Kantarjian H. Clofarabine plus anthracycline combination in acute myeloid leukemia (AML) salvage. Blood 108(11):51a, 2006. e-Pub 2006.
189. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Ravandi-Kashani F, Cortes J, Giles F, Andreeff M, Koller C, Lerner S, Kantarjian H, Keating M. Combined cyclophosphamide, fludarabine, elemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood 108(11):14a, 2006. e-Pub 2006.
190. Ravandi-Kashani F, Kantarjian H, Faderl S, Verstovsek S, Koller C, Odinga S, Wierda W, Borthakur G, Jones D, Giles F, O'Brien S, Keating M. Combination therapy with alemtuzumab and pentostatin is effective and has acceptable toxicity in patients with T-lymphoid neoplasms. Blood 108(11):330b, 2006. e-Pub 2006.
191. Thomas D, Kantarjian H, Heffner L, Stock W, Garcia-Manero G, Faderl S, Ferrajoli A, Giles F, Wierda W, Ravandi-Kashani F, Choy G, Berk G, O'Brien S. Phase I trial of sphingosomal vincristine (SV, Marquibo®) and dexamethasone in relapsed or refractory acute lymphocytic leukemia (ALL). Blood 108(11):214b, 2006. e-Pub 2006.
192. Atallah E, Kantarjian H, DeLima M, Borthakur G, Wierda W, Champlin R, Cortes J. The role of dasatinib in patients with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) relapsing after stem cell transplantation (SCT). Blood 108(11):209b, 2006. e-Pub 2006.
193. Tsimberidou A, O'Brien S, McLaughlin P, Wen S, Wierda W, Kantarjian H, Manning H, Lerner S, Hess M, Freireich E, Keating M. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): analysis of 2083 patients. Blood 108(11):790a, 2006. e-Pub 2006.
194. Quintas-Cardama A, Kantarjian H, Wierda W, Ferrajoli A, Chen R, Ravandi F, Plunkett W, Cortes J. A Phase II study of intravenous (IV) homoharringtonine (HHT) and imatinib (IM) in patients (pts) with chronic lyeloid leukemia (CML). Blood 108(11):616a, 2006. e-Pub 2006.
195. Aoki E, Kantarjian H, O'Brien S, Talpaz M, Giles F, Verstovsek S, Wierda W, Salavado A, Letvak L, Garcia-Manero G, Jones D, Luthra R, Shan J, Cortes J. High-dose (HD) imatinib provides better responses in patients with untreated early chronic phase (CP) CML. Blood 108(11):608a, 2006. e-Pub 2006.
196. Giles F, Ravandi F, Cortes J Estrov Z, Faderl S, Ferrajoli A, Garcia-Manero G, Thomas D, Wierda W, Verstovsek S. Phase I study of XL-119, a rebeccamycin analog, in patients with refractory hematological malignancies. Blood 108(11):557A, 2006. e-Pub 2006.
197. Giles F, Freedman S, Xiao A, Borthakur G, Garcia-Manero G, Wierda W, Kornblau S, O'Brien S, Bergstrom D, Rizzieri D. MK-0457, a novel multikinase inhibitor, has activity in refractory AML, and in Philadelphia-positive ALL. Blood 108(11):556a, 2006. e-Pub 2006.
198. Stock W, Undevia S, Faderl S, Odenike O, Ravandi F, Verstovsek S, Rich E, Godley L Borthakur G, Wierda W, Artz A, Bennett D, Ramirez J, Larson R, Ratain M, Giles F. Phase I study of XK469R (NSC 698215), a quinoxaline phemoxypropionic acid derivative, in patients with refractory hematological malignancies. Blood 108(11):552a, 2006. e-Pub 2006.
199. Thomas D, Kantarjian H, Jorgensen J, Faderl S, Cortes J, Giles F, Garcia-Manero G, Wierda W, Ferrajoli A, Ravandi-Kashani F, Koller C, Beran M, Kornblau S, Andreeff M, Jones D, O'Brien S. Outcome after detection of minimal residual disease during treatment with the modified Hyper-CVAD regimen with or without rituximab in newly diagnosed adult acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL). Blood 108(11):527a, 2006. e-Pub 2006.
200. Jabbour E, Jones D, Kantarjian H, O'Brien S, Garcia-Manero G, Giles F, Wierda W, Cortes J. Dynamics of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia (CML) after treatment with one, two or three tyrosine kinase inhibitors (TKI). Blood 108(11):225a, 2006. e-Pub 2006.
201. Faderl S, Ferrajoli A, Wierda W, Ravandi F, Estrov Z, Verstovsek S, Thomas D, Garcia-Manero G, Kwari M, Kantarjian H. Clofarabine combinations in acute myeloid leukemia (AML) salvage: A dose-finding Phase I study of clofarabine plus idarubicin and clofarabine/idarubicin plus cytarabine (ara-C). Blood 106(11):786a, 2006. e-Pub 2006.
202. Mulligan SP, Lerner S, Abruzzo LV, Hayes KJ, Wierda WG, O’Brien S, Keating MJ. Cytogenetics and FISH Analysis in 413 patients with B-cell Chronic Lymphocytic Leukemia. 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2005. e-Pub 2005.
203. Faderl S, Wierda W, Ferrajoli A, O’Brien S, Garcia-Manero G, Thomas D, Kantarjian H, Browning M, Lerner S, Keating M, et al. Alemtuzumab (continuous infusion followed by subcutaneous injection) plus rituximab is active in patients (pts) with relapsed/refractory chronic lymphocytic leukemia (CLL) – an update of the MDACC experience. 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2005. e-Pub 2005.
204. Tsimberidou AM, O’Brien S, Wierda WG, Garcia-Manero G, Lerner S, Keating MJ. A Comparison of outcomes in patients with splenic marginal zone lymphoma or marginal zone leukemia/lymphoma treated with immunotherapy, chemoimmunotherapy, or chemotherapy. 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2005. e-Pub 2005.
205. Ferrajoli A, OBrien S, Faderl S, Wierda W, Ravandi-Kashani F, ONeal B, Schlette E, Keating M. Rituximab in combination with sargramostin (GM-CSF) in patients with chronic lymphocytic leukemia. 9th International Congress on Malignant Lymphoma, Lugano, Switzerland, 2005. e-Pub 2005.
206. Wierda W, Wang X, O'Brien S, Faderl S, Ferrajoli A, Thomas D, Ravandi F, Gortes J, Giles F, Koller C, Kantarjian H, Lerner S, Keating M. Serum beta-2 microglobulin: the universal independent prognostic factor for patients with CLL. Blood 106(11):336b, 2005. e-Pub 2005.
207. Ravandi-Kashani F, O'Brien S, Keating M, Jones D, Faderl S, Ferrajoli A, Wierda W, Odinga S, Pierce S, Koller C, Verstovsek S, Jorgensen J, Kantarjian H. Complete eradication of minimal residual disease (MRD) in patients with hairy cell leukemia (HCL) after cladribine (2CDA) followed by an extended course of rituximab. Blood 106(11):911a, 2005. e-Pub 2005.
208. Tong X, Aukerman S, Kin K, Aziz N, Goldbeck C, Georgiakis G, Younes A, Weng W, O'Brien S, Wierda W, Jallal B, Luqman M. A non-internalizing anti-CD40 antibody, CHIR-12.12, blocks CD40L-induced cytokine production and mediates greater ADCC than rituximab in primary CLL cells. Blood 106(11):831a, 2005. e-Pub 2005.
209. Faderl S, Ferrajoli A, Wierda W Ravandi F, Estrov Z, Verstovsek S, Thomas DA, Garcia-Manero G, Kwari M, Kantarjian H. Clofarabine combinations in acute myeloid leukemia (AML) salvage: A dose-finding Phase I study of clofarabine plus idarubicin and clofarabine/idearubicin plus cytarabine (ara-C). Blood 106(11):786a, 2005. e-Pub 2005.
210. Keating MJ, O'Brien S, Albitar M, Lerner S, Wierda W, Kantarjian H. Extended follow-up of a chemo-immunotherapy regimen FCR (fludarabine, F; cyclophosphamide, C; and Rituximab, R) as initial therapy for chronic lymphocytic leukemia (CLL). Blood 106(11):599a, 2005. e-Pub 2005.
211. Jabbour E, Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E. Results of intensive chemotherapy in 998 patients aged 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - predictive prognostic models for outcome. Blood 106(11):525a, 2005. e-Pub 2005.
212. Faderl S, Ferrajoli A, Wierda W, Ravandi F, O'Brien S, Garcia-Manero G, Thomas D, Browning M, Keating M. Continuous infusion/subcutaneous alemtuzumab (Campath-1H) plus rituximab is active for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Blood 106(11):831a, 2005. e-Pub 2005.
213. Faderl S, Ravandi F, Ferrajoli A, Garcia-Manero G, Estrov Z, Thomas D, O'Brien S, Verstovsek S, Wierda W, Cortes J, Giles F, Kwari M, Jarmon R, Kantarjian H. Clofarabine and clofarabine plus low-dose cytarbine (ara-C) as induction therapy for patients (pts) > 60 years with newly diagnosed acute myeloid leukemia (AML). Blood 106(11):786a, 2005. e-Pub 2005.
214. Tsimberidou A, O'Brien S, Wierda W, Garcia-Manero G, Lerner S, Keating M. A comparison of outcomes in patients with splenic marginal zone lymphoma or marginal zone leukemia/lymphoma treated with immunotherapy, chemoimmunotherapy, or chemotherapy. 9th International Conference on Malignant Lymphoma, Lugano, Switzerland, 2005. e-Pub 2005.
215. Garcia-Manero G, Yang H, Sanchez-Gonzalez B, Verstovsek S, Ferrajoli A, Keating M, Andreeff M, O'Brien S, Cortes J, Wierda W, Faderl S, Koller C, Davis J, Morris G, Issa JP, Frankel S, Richon V, Fine B, Kantarjian H. Final results of a Phase I study of the histone deacetylase inhibitor vorinostat (suberoyanilide lydroxamic acid, SAHA), in patients with leukemia and myelodysplastic syndrome. Blood 106(11):785a, 2005. e-Pub 2005.
216. Thomas D, Cortes J, O'Brien S, Faderl S, Ravandi F, Garcia-Manero G, Giles F, Beran M, Koller C, Wierda W, Verstovsek S, Ferrajoli A, Kornblau S, Keating M, Andreeff M, Kantarjian H. Update of the modified Hyper-CVAD regimen with or without rituximab in newly diagnosed adult acute lymphocytic leukemia (ALL). Blood 106(11):520a, 2005. e-Pub 2005.
217. Tsimberidou A, Keating M, McLaughlin P, O'Brien S, Wierda W, Ferrajoli A, Manning J, Kantarjian H. Comparison of small lymphocytic lymphoma with chronic lymphocytic leukemia. The M. D. Anderson Cancer Center experience. Blood 106(11):270a, 2005. e-Pub 2005.
218. Motta M, Wierda W, O'Brien S, Faderl S, Ferrajoli A, Detry M, Lerner S, Kantarjian H, Keating M. Infections in patients with chronic lymphocytic leukemia treated with chemoimmunotherapy. Blood 106(11):213a, 2005. e-Pub 2005.
219. Thomas D, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles F, Verstovsek S, Wierda W, Pierce S, Brandt M, Hagemeister F, Cabanillas F, Keating MJ, Kantarjian H. Chemo-immunotherapy with hyper-CVAD plus rituximab for adult Birkitt's and Burkitt's type lymphoma (BL) or acute lymphoblastic leukemia (B-ALL). Blood 106(11):47a, 2005. e-Pub 2005.
220. Yee K, Cortes J, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Thomas D, Faderl S, King I, O'Brien S, Sznol M, Giles F. Phase I study of Triapine® and cytarabine (ara-C) in patients with relapsed or refractory acute leukemias and high-risk myelodysplastic syndrome (MDS). Blood 106(11):311b, 2005. e-Pub 2005.
221. Wierda W, Mulligan S, Shelvin B, Belov L, Rassenti L, Kipps T, Lerner S, Thomas M, Kantarjian H, Keating M. Surface antigens identified by antibody microarray that correlate with IgVH mutational status and ZAP70 expression in CLL. Blood 106(11):826a, 2005. e-Pub 2005.
222. O'Brien S, Wierda W, Faderl S, Ferrajoli A, Bueso-Ramos C, Brown M, Kantarjian H, Keating M. FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia (CLL). Blood 106(11):599a, 2005. e-Pub 2005.
223. Tsimberidou A, Catovsky D, Schlette E, O'Brien S, Kantarjian H, Wierda W, Wen S, Lerner S, Keating M. Outcomes in patients with splenic marginal zone lymphoma or marginal zone leukemia/lymphoma treated with immunotherapy, chemoimmunotherapy, or chemotherapy. Blood 106(11):270a, 2005. e-Pub 2005.
224. Ferrajoli A, O'Brien S, Faderl S, Wierda W, Ravandi-Kashani F, O'Neal B, Schlette E, Albitar M, Kantarjian H, Keating M. Rituximab plus GM-CSF for patients with chronic lymphocytic leukemia. Blood 106(11):214a, 2005. e-Pub 2005.
225. Wierda W, O'Brien S, Ferrajoli A, Faderl S, Koller C, Giles F, Cortes J, Thomas D, Ravandi F, Garcia-Manero G, Andreeff M, Lerner S, Kantarjian H, Keating M. Salvage therapy with combined cyclophosphamide (C), fludarabine (F), alemtuzumab (A), and rituximab (R) (CFAR) for heavily pre-treated patients with CLL. Blood 106(11):213a, 2005. e-Pub 2005.
226. Wierda W, O'Brien S, Wang X, Ferrajoli A, Faderl S, Thomas D, Ravandi F, Do K, Kantarjian H, Lerner S, Keating M. Weighted prognostic models for survival in untreated and previously treated patients with CLL. Blood 106(11):334b, 2005. e-Pub 2005.
227. Aribi A, Keating M, O'Brien S, Ferrajoli A, Faderl S, Lerner S, Koller C, Wierda W, Cortes J, Kantarjian H, Ravandi-Kashani F. Long-term follow-up of patients with T-large granular lymphocyte leukemia (T-LGL): experience in a single institution. Blood 106(11):338b, 2005. e-Pub 2005.
228. Ravandi-Kashani F, Kantarjian H, Verstovsek S, Ferrajoli A, Wierda W, Odinga S, Huang X, Pierce S, Faderl S, Giles F, O'Brien S, Keating M. Combined therapy with alemtuzumab and pentostatin is feasible and effective in T-lymphoproliferative disorders. Blood 106(11):338b, 2005. e-Pub 2005.
229. Quintas-Cardama A, Kantarjian H, Ravandi F, Garcia-Manero G, O'Brien S, Wierda W, Faderl S, Cortes J. A pilot trial of imatinib, low-dose cytarabine (ara-C) and idarubicin (Ida) in patients (pts) with chronic myeloid leukemia (CML) in myeloid blastic phase (BP). Blood 106(11):290b, 2005. e-Pub 2005.
230. Cherukuri A, Kadel E, Lee S, Goldbeck C, Heise C, Luqman M, Aukerman S, Aziz N, O'Brien S, Wierda W, Jallal B. Human Antagonistic anti-CD40 antibody, CHIR-12.12, inhibits CD40-mediated survival of chronic lymphocytic leukemia B cells leading to cellular apoptosis. Blood 106(11):832a, 2005. e-Pub 2005.
231. O'Brien S, Ravandi-Kashani F, Wierda W, Giles F, Thomas D, Huang X, Riehl D, Tarrand J, O'Neal B, Kantarjian H, Keating M. A randomized trial of valacyclovir versus valganciclovir to prevent CMV reactivation in patients with CLL receiving alemtuzumab. Blood 106(11):830a, 2005. e-Pub 2005.
232. Spoo A, Wierda W, Burger J. The CXCR4 Score: A new prognostic marker in acute myelogenous leukemia. Blood 104(11):304a, 2004. e-Pub 2004.
233. Jabbour E, Kantarjian H, Verstovsek S, Jones D, O’Brien S, Luthra R, Ravandi-Kashani F, Wierda W, Giles F, Rios MB, Cortes J. Imatinib mesylate for patients (pts) with hypereosinophilic syndrome (HES) and systemic mastocytosis (SM): A Phase II trial. Blood 104(11):2716, 2004. e-Pub 2004.
234. Yee KWL, Wierda W, OBrien S, Thomas D, Kurzrock R, Fayad LE, Hagemeister FB, Cortes J, Prestifilippo J, Szatrowski TP, Kantarjian HM, Giles FJ. A Phase 1/11 study of the oral mTOR inhibitor RAD001 in patients with advanced hematologic malignancies. Blood 104(11):2876, 2004. e-Pub 2004.
235. Garcia-Manero G, Kantarjian H, Sanchez-Gonzalez B, Faderl S, Verstovsek S, Ravandi F, Ryttling M, Cortes J, Wierda W, Hoshino K, Yang H, Santos-Malave C, Fiorentino J, Jabbour E, Rosner G, Issa JP. Results of a Phase I/II study of the combination of 5-aza-2’-deoxycytidine (DAC) and valproic acid (VPA) in patients (pts) with leukemia. Blood 104(11):789, 2004. e-Pub 2004.
236. Thomas DA, Cortes J, Faderl S, O’Brien S, Beran M, Koller C, Garcia-Manero G, Younes A, Fayad L, Wierda W, Pierce S, Giles FJ, Kantarjian H. Outcome with the Hyper-CVAD and rituximab regimen in Burkitt (BL) and Burkitt-like (BLL) leukemia/lymphoma. Blood 104(11):901a, 2004. e-Pub 2004.
237. Cortes J, Talpaz M, O’Brien S, Garcia-Manero G, Ravandi-Kashani F, Giles F, Faderl S, Wierda W, Shan J, Rios MB, Kantarjian H. Survival advantage for patients (pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) treated with imatinib. Blood 104(11):287a, 2004. e-Pub 2004.
238. Thomas D, Garcia-Manero G, Faderl S, O’Brien S, Giles F, Ferrajoli A, Wierda W, Verstovsek S, Cortes J, Kantarjian H. Preliminary results of Phase I trial of sphingosomal vincristine (SV) and dexamethoasone in relapsed or refractory acute lymphocytic leukemia (ALL). Blood 104(11):748a, 2004. e-Pub 2004.
239. Faderl S, Ferrajoli A, Wierda W, Verstovsek S, Ravandi-Kashani F, Garcia-Manero G, Estey E, Thomas DA, Kornblau S, Kwari M, Gandhi V, Kantarjian HM. Phase 1 study of clofarabine plus idarubicin and clofarabine plus idarubicin plus cytarabine (ARA-C) in patients (PTS) with relapsed and refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloid blast phase of chronic myeloid leukemia (CML). Blood 104(11):501a, 2004. e-Pub 2004.
240. Castro J, Wierda W, Kipps T, Keating M, Bole J, Anderson B, Meyer J, Bonyhadi M, Berenson R, Frohlich M. A Phase 1/11 trial of Xcellerated T Cells™ in patients with chronic lymphocytic leukemia. Blood 104(11):687a, 2004. e-Pub 2004.
241. Motta M, Shelvin B, Lerner S, Keating M, Wierda WG. Increased expression of CD152 by normal T lymphocytes in untreated patients with B cell chronic lymphocytic leukemia. Blood 104(11):276a, 2004. e-Pub 2004.
242. Wierda W, Faderl S, O’Brien S, Cortes J, Ferrajoli A, Giles F, Andreeff M, Koller C, Kantarjian H, Keating M. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients with CLL. Blood 104(11):10a, 2004. e-Pub 2004.
243. Faderl S, Ganghi V, Giles F, Estey E, Garcia-Manero G, OBrien S, Wierda W, Kwari M, Craig A, Kantarjian HM. Clofarabine plus cytarabine (ARA-C) is an active induction regimen for newly diagnosed patients (pts) > age 50 with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). JCO 23:582, 2004. e-Pub 2004.
244. Ravandi-Kashani F, O’Brien S, Lerner S, Ferrajoli A, Wierda W, Giles F, Herling M, Jones D, Kantarjian H, Keating M. T-cell prolymphocytic leukemia: 17-year experience at a single institution. JCO 23:573, 2004. e-Pub 2004.
245. Keating MJ, OBrien S, Lerner S, Wierda W, Kantarjian H. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) improves complete response (CR), remission duration and survival as initial therapy of chronic lymphocytic leukemia (CLL). JCO 23:571, 2004. e-Pub 2004.
246. Bonyhadi M, Leis JF, Rasmussen A, Ginardi R, Roehrs H, Ferrand C, Markham E, Leshinsky N, Lindgren R, Grosmaire L, Wierda W, Kipps TJ, Frohlich M. Restoration of T cell function for the immunotherapeutic treatment of CLL. Keystone Symposium, 2003. e-Pub 2003.
247. Garcia-Manero G, Canalli A, Wierda W, Cortes J, OBrien S, Cupo A, Secrist P, Davis J, Faderl S, Giles F, Chiao J, Richon V, Issa J, Kantarjian H. Phase I study of oral suberoylanilide hydroxamic acid (SAHA) in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS). Blood 102(11):254b, 2003. e-Pub 2003.
248. Estey E, Giles F, Cortes J, Garcia-Manero G, Faderl S, Verstovsek S, Wierda W, Thomas D, Ryttig M, Kantarjian H. Application of successful but intensive, children’s AML protocol to adults. JCO 22:587, 2003. e-Pub 2003.
249. Wierda W, OBrien S, Ferrajoli A, Faderl S, Kornblau S, Andreeff M, Koller C, Garcia-Manero G, Thomas D, Kantarjian H, Keating M. Early analysis of combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab for relapsed and refractory patients with CLL. Blood 102(11):3606, 2003. e-Pub 2003.
250. Giles F, Tallman M, Garcia-Manero G, Cortes J, Thomas D, Wierda W, Verstovsek S, Hamilton M, Barrett E, Albitar M, Kantarjian H. Phase I and pharmacokinetic study of OSI-211, a liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor in patients with advanced leukemia. Blood 102(11):251b, 2003. e-Pub 2003.
251. Estey E, Faderl S, Giles F, Thomas D, Ferrajoli A, Wierda W, Verstovsek S, Garcia-Manero G, Kantarjian H. All-trans retinoic acid (ATRA) + arsenic trioxide (ATO) to minimize or eliminate chemotherapy in untreated APL. Blood 102(11):618a, 2003. e-Pub 2003.
252. Cortes J, Talpaz M, Garcia-Manero G, Giles F, OBrien S, Rios MB, Verstovsek S, Faderl S, Thomas D, Koller C, Wierda W, Andreeff M, Letvak L, Salvad A, Kantarjian H. High rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia (CML) in early chronic phase treated with high-dose imatinib 800 mg daily. Blood 102(11):30a, 2003. e-Pub 2003.
253. Thomas D, Wierda W, Faderl S, OBrien S, Kornblau S, Koller C, Bantia S, Kiltpatrick M, Bennett C, Kantarjian H, Gandhi V. Preliminary activity of intravenous BCX-1777 in aggressive T-Cell malignancies. Blood 102(11):261b, 2003. e-Pub 2003.
254. OBrien S, Gribben J, Thomas D, Albitar M, Wierda W, Ferrajoli A, Lerner S, Kantarjian H, Kipps T, Keatin M, the CLL Research Consortiumg M. Alemtuzumab for minimal residual disease in CLL. Blood 102(11):109a, 2003. e-Pub 2003.
255. Kipps T, Castro J, Wierda W, Keating M, Bole J, Meyer J, Roehrs H, Bouchard L, Yuan V, Chana H, Hami L, Bonyhadi M, Berenson R, Frohlich M. A Phase I/II trial of Xcellerated T Cells in patients with chronic lymphocytic leukemia (CLL). Blood 102(11):109a, 2003. e-Pub 2003.
256. Wierda W, OBrien S, Faderl S, Ferrajoli A, Lerner S, Wang X, Thomas D, Garcia-Manero G, Cortes J, Kantarjian H, Keating M. Improved survival in patients with relapsed refractory chronic lymphocytic leukemia (CLL) treated with fludarabine, cyclophosphamide, and rituximab (FCR) combination. Blood 102(11):110a, 2003. e-Pub 2003.
257. Castro J, Cantwell M, Prussak C, Bole J, Wierda W, Kipps T. Long-term follow-up of chronic lymphocytic leukemia patients treated wit CD40-Ligand (CD154) gene therapy. Blood 102(11):491a, 2003. e-Pub 2003.
258. Wierda W, Garcia-Manero G, OBrien S, Faderl S, Lerner S, Albitar M, Plunkett W, Giles F, Cortes J, Keating M. Molecular remissions in patients with relapsed or refractory CLL treated with combined fludarabine, cyclophosphamide, and rituximab. JCO 22:581, 2003. e-Pub 2003.
259. Keating MJ, Manshouri T, OBrien S, Wierda W, Kantarjian H, Lerner S, Albitar M. A high proportion of true complete remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukemia. J Clin Oncol 22:620a, 2003. e-Pub 2003.
260. Tsimberidou A, Estey E, Cortes J, Verstovsek S, Faderl S, Thomas D, Wierda W, Garcia-Manero G, Kantarjian H, Giles F. Randomized comparison of idarubicin and ara-C (IA)+- interleukin (IL11) in patients with newly diagnosed acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS). JCO 22:585, 2003. e-Pub 2003.
261. Liu N, Keating M, Albitar M, Wierda W, Ferrajoli A, Tran N, Lerner S, Kantarjian H, O'Brien S. Yttrium-90 ibritumomab tiuxetan for minimal residual disease in CLL, American Society of Clinical Oncology. Blood 102(11):674a, 2003. e-Pub 2003.
262. O'Brien S, Wierda W, Geisler D, Lerner S, Albitar M, Keating M. Yttrium-90 ibritumomab tiuxetan for minimal residual disease in CLL. JCO 22:631a, 2003. e-Pub 2003.
263. Faderl S, Albitar M, Wierda W, Ferrajoli A, Manshouri T, Garcia-Manero G, OBrien S, Thomas D, Kantarjian H, Browning M, Keating M. Continuous I.V. Infusion (C.I.) followed by subcutaneous (S.C.) alemtuzumab plus rituximab is active in patients with relapsed/refractory chronic lymphoproliferative disorders (LPD). Blood 102(11):676a, 2003. e-Pub 2003.
264. Cortes J, OBrien S, Talpaz M, Luthra R, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Ferrajoli A, Wierda W, Thomas D, Faderl S, Kantarjian H. Clinical Significance of molecular response in chronic myeloid leukemia (CML) after imatinib mesylate (Gleevec) therapy: low levels of residual disease predict for response duration. Blood 102(11):416a, 2003. e-Pub 2003.
265. Giles F, Kantarjian H, Cortes J, Tsimberidou A, Faderl S, Verstovsek S, Thomas D, Garcia-Manero G, Wierda W, Ferrajoli A, Kornblau S, Andreeff M, OBrien S, Beran M, Estey E. Adaptive randomized study of iarubicin and cytarabine (IA) alone or with interleukin 11 (IL-11) as induction therapy in patients aged 50 or above with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (HR-MDS). Blood 102(11):253b, 2003. e-Pub 2003.
266. Faderl S, Gandhi V, Cortes J, Wierda W, O’Brien S, Keating MJ, Craig A, Kwari M, Plunkett W, Kantarjian HM. Clofarabine is active as a single agent and in combination with ara-C in patients (pts) with relapsed/refractory acute leukemias and high-risk myelodsyplastic syndrome (MDS). JCO 22:638a, 2003. e-Pub 2003.
267. Faderl S, Thomas D, OBrien S, Wierda W, Kantarjian H, Garcia-Manero G, Giles F, Koller C, Beran M, Ferrajoli A, Lerner S, Merda K, William G. Combined use of alemtuzumab and rituximab in patients with relapsed and refractory chronic lymphoid malignancies – An update of the M.D. Anderson experience. Blood 100(11):206a, 2002. e-Pub 2002.
268. Keating M, Manshouri T, OBrien S, Wierda W, Kantarjian H, Washington L, Lerner S, Albitar M. High proportion of molecular remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in Chronic Lymphocytic Leukemia (CLL). Blood 100(11):205a, 2002. e-Pub 2002.
269. Sneed T, Kantarjian H, Talpaz M, OBrien S, Rios M, Wierda W, Thomas D, Cortes J. Significance of myelosuppression (MS) during the course of therapy with imatinib in patients with chronic myelogenous leukemia (CML) in chronic phase. Blood 100(11):787a, 2002. e-Pub 2002.
270. Cortes J, Ault P, Koller C, Tomas D, Ferrajoli A, Wierda W, Rios MB, Letvak L. Treatment of Hypereosinophilic Syndrome (HES) with imatinib mesylate. Blood 100(11):71a, 2002. e-Pub 2002.
271. Bonyhadi M, Leis J, Grosmaire L, Rasmussen A, Xu J, Roehrs H, Ferrand C, Markham E, Leshinsky N, Lindgre R, Wierda W, Kipps TJ, Maziarz RT, Tiberghien P, Berenson RJ, M: F. Autologous T cell therapy for B-CLL. Blood 100(11):206a, 2002. e-Pub 2002.
272. Huh Y, Lee J, Lerner S, Wierda W, Cy S, Keating. T cell subsets in B cell chronic lymphocytic leukemia. Blood 100(11):358a, 2002. e-Pub 2002.
273. Wierda W, Johnson M, Do K, Manshouri T, Dey A, OBrien S, Kantarjian H, Thomas D, Faderl S, Keating M, Albitar M. Plasma IL-8 level predicts for survival in chronic lymphocytic leukemia. Blood 98(11):288b (#4896), 2001. e-Pub 2001.
274. Thomas D, OBrien S, Cortes J, Faderl S, Fayad L, Garcia-Manero G, Wierda W, Verstovsek S, Kornblau S, Pierce S, Kantarjian H, Keating M. Treatment of splenic lymphoma with villous lymphocytes (SLVL) and marginal zone lymphomas (MZL) with single agent rituximab. Blood 98:134a(#563), 2001. e-Pub 2001.
275. McCarthy H, Wierda W, Barron L, Cromwell, Keating M, Abruzzo L. Chronic lymphocytic leukemia (CLL) patients with unmutated immunoglublin VH genes express high levels of activation-induced cytidine deaminase (AICD) mRNA and splice variants. Blood 100(11):99a, 2001. e-Pub 2001.
276. Wierda WG, OBrien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M Cortes J, Faderl S, Thomas D, Koller C, Kantarjian H, and Keating M. Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 98(11):771a (#3210), 2001. e-Pub 2001.
277. Wierda WG, Jacobs R, Barr PM, Allan JN, Siddiqi T, Tedeschi A, Kipps TJ, O'Brien SM, Badoux XC, Visentin A, Lasica M, Carney D, Camburn AE, Torroba JD, Szafer-Glusman E, Zhou C, Szoke A, Dean JP, Ghia P, Tam CS. Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): up to 5.5 years of follow-up in the phase 2 CAPTIVATE study. Journal of Clinical Oncology.

Book Chapters

1. Wierda, WG. Promising combinations of drugs targeting apoptosis. In: Volume 1 - Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies: From Concept to Practice. Wiley, 186-196, 2023.
2. Wierda W, O'Brien S. Chronic Lymphocytic Leukemia. In: Cancer: Principles and Practice of Oncology. 10th. Lipppincott Williams & Wilkins, 1654-1670, 2015.
3. Wierda W, O'Brien S. Chronic Lymphocytic Leukemia. In: Cancer: Principles and Practice of Oncology. 9th. Lipppincott Williams & Wilkins, 1973-1986, 2011.
4. Cortes JE, Kantarjian H, Wierda W. Chronic Leukemias. In: Conn's Current Therapy. W. B. Saunders Company Publications, 456-463, 2009.
5. Wierda WG, Keating MJ, O'Brien S. Chronic Lymphocytic Leukemia. In: Cancer: Principles and Practice of Oncology. 8th. Lipppincott Williams & Wilkins, 2278-2292, 2009.
6. Wierda WG. Gene Therapeutic Approaches for Chronic Lymphocytic Leukemia. In: Unknown, 201-215, 2008.
7. Wierda W, Weiss M. Chronic Lymphocytic Leukemia. In: Atlas of Cancer. 2nd Edition. Current Medicine, Chapter 4, 2008.
8. Wierda, WG. Gene Therapy, Vaccines and Immune Modulation. In: Chronic Lymphocytic Leukemia. Informa Healthcare, 2008.
9. Wierda William G, Joan A, Susan O. Clinical Features and Making the Diagnosis CLL. In: Clinical Malignant Hematology. McGraw-Hill Professional, Medical Publishing Division, Chapter 23, pp 225-233, 2007.
10. Wierda W, Lamanna N, Cortes J, Weiss M. Chronic Lymphocytic Leukemia. In: Cancer Management: A Multidisciplinary Approach. CMP Healthcare Media, CMP Media LLC, Chapter 34, 2006.
11. Wierda W, Lamanna N, Cortes J, Weiss M. Molecular Biology in CLL. In: Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis and Management,. Humana Press Inc, 77-94, 2004.

Letters to the Editor

1. Ravandi, F, Senapati, J, Jain, N, Short, NJ, Kadia, TM, Borthakur, G, Konopleva, M, Wierda, WG, Huang, X, Maiti, A, Issa, GC, Balkin, H, Garris, R, Ferrajoli, A, Garcia-Manero, G, Alvarado, Y, Kebriaei, P, Jabbour, EJ, Kantarjian, HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia 38: 2717-2721, 2024.
2. Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol 97: E201-E204, 2022.
3. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia. Leukemia 36: 1171-1175, 2022.
4. Jelloul FZ, Yang RK, Wang P, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL Jr, Wierda WG, Jain N, Thompson PA, Luthra R, Medeiros LJ, Patel KP. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol 97: E100-E102, 2022.
5. Sivina M, Kim E, Wierda WG, Ferrajoli A, Jain N, Thompson P, Kantarjian H, Keating M, Burger JA. Ibrutinib induces durable remissions in treatment-naive patients with CLL and 17p deletion and/or TP53 mutations. Blood 138: 2589-2592, 2021.
6. Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, Pemmaraju N, Borthakur G, Bose P, Issa GC, Short NJ, Yilmaz M, Montalban-Bravo G, Ferrajoli A, Jabbour EJ, Jain N, Ohanian M, Takahashi K, Thompson PA, Loghavi S, Montalbano KS, Pierce S, Wierda WG, Kantarjian HM, Konopleva MY. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J 11: 25, 2021.
7. Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135: 862-865, 2020.
8. Strati P, Schlette EJ, Solis Soto LM, Duenas DE, Sivina M, Kim E, Keating MJ, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA. Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood 135: 510-513, 2020.